ILLEGIBLE DOCUMENTS

THE FOLLOWING DOCUMENT(S) IS ILLEGIBLE OR OF POOR LEGIBILITY IN THE ORIGINAL. THIS IS THE BEST COPY AVAILABLE.

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/1

CANCER INCIDENCE AND MORTALITY IN THE UNITED STATES, 1973–77

John L. Young, Jr., Dr.P.H., Constance L. Percy, M.S., Ardyce J. Asire, M.S., John W. Berg, M.D.,[1] Mary M. Cusano, B.A., Lynn A. Gloeckler, M.S., John W. Horm, M.Sc., William I. Lourie, Jr., M.P.H., Earl S. Pollack, Sc.D., and Evelyn M. Shambaugh, M.A.

The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the Biometry Branch of the National Cancer Institute (NCI). The Program was initiated in 1972 as an outgrowth of 2 earlier NCI programs, i.e., the End Results Program (*1*) and the National Cancer Surveys (*2–4*). This Monograph reports detailed information on the incidence of and mortality from cancer in the United States during the initial 5 years of the Program, 1973–77. Data are classified according to sex, race, age, and residence of the patient; anatomic site; and histologic type of cancer. Cancer patient survival will be the subject of a subsequent monograph once enough time has elapsed for survival to be measured.

DESCRIPTION OF THE PROGRAM

Goals

The goals of the SEER Program are to:

1) Determine periodically incidence of cancer in selected geographic areas of the United States with respect to demographic and social characteristics of the population.

2) Estimate cancer incidence for the United States on an annual basis.

3) Monitor trends in incidence of specific forms of cancer with respect to geographic area and demographic and social characteristics of the population.

4) Determine periodically survival experience for cancer patients diagnosed among residents of selected geographic areas of the United States.

5) Monitor trends in cancer patient survival with respect to form of cancer, extent of disease, therapy, and demographic, socioeconomic, and other parameters of prognostic importance.

6) Identify cancer etiologic factors by conducting special studies which disclose groups of the population at high or low cancer risks. These groups may be defined by social, occupational, environmental, dietary, or other characteristics, and by drug history.

7) Identify factors related to patient survival through special studies of referral patterns, diagnostic procedures, treatment methods, and other aspects of medical care.

8) Promote specialty training in epidemiology, biostatistics, and tumor registry methodology, operation, and managemem..

[1] Department of Pathology, University of Colorado Medical School, Denver, Colorado 80262.

Participants

Participants in the SEER Program were selected on the basis of their ability to operate and maintain a population-based cancer reporting system and for the unique population subgroups that each of them offered. Thus participants were selected with forethought to subgroups within the defined populations which were epidemiologically interesting rather than on the basis of being representative with respect to various demographic characteristics of the United States population. Eight participants who were initially included in the program began collecting data for cases diagnosed in 1973, 2 others collected data beginning with 1974 diagnoses, and 1 began coverage with 1975 diagnoses. The 11 participants, their date of entry into the Program, and their respective reporting areas are:

Participant	Entry yr	Reporting area
Connecticut	1973	Entire State
Detroit, Michigan Metropolitan area	1973	Macomb, Oakland, and Wayne Counties
Iowa	1973	Entire State
Atlanta, Georgia Metropolitan area	1975	Clayton, Cobb, De Kalb, Fulton, and Gwinnett Counties
New Orleans, Louisiana Metropolitan area	1974	Jefferson, Orleans, and St. Bernard Parishes
New Mexico	1973	Entire State
Utah	1973	Entire State
Seattle-Puget Sound, Washington	1974	Clallam, Grays Harbor, Island, Jefferson, King, Kitsap, Mason, Pierce, San Juan, Skagit, Snohomish, Thurston, and Whatcom Counties
San Francisco-Oakland, California SMSA	1973	Alameda, Contra Costa, Marin, San Francisco, and San Mateo Counties
Hawaii	1973	Entire State
Puerto Rico	1973	Entire Commonwealth

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 2 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/2

These participants represent slightly more than 10% of the total population of the United States and are fairly representative with respect to age. Blacks are underrepresented, whereas other minority populations (Chinese, Japanese, Hawaiians, and American Indians) are overrepresented. Rural populations, especially rural blacks, are also underrepresented.

OPERATIONS

Collection of Incidence and Survival Data

The SEER Program is conducted in each geographic area under contract with local, nonprofit, medically oriented organizations. The statement of work for each contract requires the participant to:

Maintain a cancer information reporting system in the geographic area of coverage (as defined above). Utilize standardized abstracts of records for cancer patients seen in every hospital in and outside the area where area resident patients are diagnosed or treated for active cancer. Abstract all death certificates on which cancer is mentioned of residents dying within or outside the area and those for any case listed in the reporting system. Utilize records of private laboratories and radiotherapy units to ensure complete coverage of cases. Use records of nursing homes which provide the services of diagnostic physicians and/or laboratories to patients. Maintain reporting and data processing procedures so as to produce valid incidence rates within 11 months after the end of each calendar year.

Report all in situ and malignant neoplasms (a behavior code of "2" or "3," respectively) in the International Classification of Diseases for Oncology (ICD-O) (*5*) with the exception of papillary, squamous, basal cell, and carcinomas, not otherwise specified (NOS), of the skin.

Collect complete information regarding extent of disease, diagnostic procedures, and first course of cancer-directed therapy on all patients being diagnosed and residing in the area. With the use of all available methodologies, obtain active follow-up on all cases resident in the area. Maintain reporting and data processing procedures so as to provide current active follow-up on all living patients within 18 months of the date of diagnosis or the date of last contact, whichever is later.

Collect data in sufficient detail so that each cancer can be classified according to the variables described in the "Code Manual, the SEER Program" (*6*). Provide to the NCI computer tapes which contain data on the incidence of cancer, extent of disease at the time of diagnosis, diagnostic procedures used in determining cancer site and type, tumor-directed therapy, and patient survival information. Submit no information regarding patient name or name of the hospital at which diagnosis was made and/or treatment was given.

In conjunction with participation in the SEER Program, cooperate with the NCI field staff in its quality control activities by providing access to the Tumor Registry files, by arranging for the NCI staff to reabstract samples of hospital medical records, and by providing review of various sources of case identification, such as pathology logs, diagnostic indices, radiotherapy schedules, and autopsy reports, to ensure that all cancer cases are being reported.

Make arrangements to permit staff members to attend various workshops or meetings of the SEER Program to ensure that the staff can implement new codes or procedures and to allow the exchange of ideas and problems among the various participants.

Maintain a core staff of professional and technical people to do the following:

a) Conduct detailed analyses of data contained in the registry and prepare reports on these analyses, with presentation of the data on which they are based.

b) Respond to requests from the NCI to participate in collaborative epidemiologic studies within the SEER Program. Such response would include participation in aspects of study design that would facilitate arrangements for the study within the area and assessment of feasibility. These studies would be done under separate funding.

c) Based on analyses of the registry data and on research opportunities in the local area, develop specific etiologic hypotheses and formulate study plans to test these hypotheses, including design of questionnaires.

d) Conduct the administrative activities necessary to maintain the cooperation of physicians and hospitals in special studies.

Each contractor is responsible for consolidating all data concerning an individual cancer case into one record. The total file for each area is then submitted to the NCI via computer tape. Before submission, all information identifying the patient and any hospital involved in the patient's diagnosis and/or treatment is removed so that the NCI cannot identify any patient or hospital. Data are computer-edited for legitimate codes and for internal consistency by both the contractor and the NCI.

Contractors

The contractors for the various SEER participants are:

Area	Contractor
Connecticut	*Connecticut Tumor Registry* Connecticut Department of Health Services
	Connecticut Cancer Epidemiology Unit Yale University
Detroit, Michigan	*Michigan Cancer Foundation*
Iowa	*Iowa Tumor Registry* Department of Preventive Medicine and Environmental Health University of Iowa College of Medicine
Atlanta, Georgia	*Atlanta Cancer Surveillance Center* Emory University
New Orleans, Louisiana	*Louisiana Tumor Registry* Charity Hospital of New Orleans Louisiana Department of Health and Human Resources
New Mexico	*New Mexico Tumor Registry* University of New Mexico
Utah	*Utah Tumor Registry* University of Utah
Seattle-Puget Sound, Washington	*Fred Hutchinson Cancer Research Center*

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 3 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/3

Area	Contractor
San Francisco-Oakland, California	*Resource for Cancer Epidemiology* California Department of Health Services
Hawaii	*Research Corporation of Hawaii* *Hawaii Medical Association*
Puerto Rico	*Cancer Control Program* Commonwealth of Puerto Rico Department of Health

NCI Quality Control Program

The NCI field staff is responsible for conducting a regular program of quality control visits to each participant. During these visits, the staff routinely reabstracts and recodes samples of records. In addition, case-finding audits are conducted to ensure complete coverage of the area by the participant. Periodic training sessions and workshops are held to make certain that each participant is following uniform procedures and that the data submitted by each are compatible. The NCI is assisted in this effort through a contractual arrangement with the University of California at San Francisco.

Collection of Mortality Data

Annually, mortality tapes containing data on all deaths occurring within the United States are obtained from the National Center for Health Statistics. From these tapes, a file of all cancer deaths classifiable by age, sex, race, and cancer site is extracted so that cancer mortality for the entire United States and each SEER area can be determined. A file containing all cancer deaths occurring among residents of Puerto Rico has been obtained directly from the Commonwealth of Puerto Rico Department of Health.

Collection of Population Data

The computation of rates for both incidence and mortality requires population estimates by age, sex, and race for each geographic area included in the Program. Population estimates classified by sex and age for whites and other than whites are available for every county in the United States for 1973–75 from the U.S. Census Bureau. These estimates were used for 7 of the 11 participants. Estimates for 1976 and 1977 were obtained by a simple straight-line projection of the 1974–75 estimates within each race-sex-age group. Estimates of the populations of Hawaii and New Mexico, classified by age, sex, and race/ethnicity, were obtained from sources within the States of Hawaii and New Mexico, respectively. Estimates of the population of Puerto Rico, classified by age and sex, were obtained directly from the Commonwealth of Puerto Rico Department of Health. Finally, an estimate of the population of the State of Connecticut, classified by sex and age, was obtained from the Connecticut Department of Health Services.

Estimates of the black populations of Detroit, Atlanta, and New Orleans were obtained by application of the ratio of blacks to total other than white races from the 1970 Census to the 1973–77 other than white population estimates for each sex-age group for each of these 3 areas. Estimates for the black, Chinese, and Japanese populations of San Francisco-Oakland were obtained in a similar manner. Estimates of the white population of Connecticut were made with the use of the ratio of whites to the total population of Connecticut in the 1970 Census and the application of these ratios to the estimate of the total population of Connecticut for each year from 1973 to 1977. The populations used in calculations of incidence and mortality rates are presented in respective sections of this Monograph.

In tables 2–16 and in Appendix tables III and V, numbers and rates are shown for blacks for all SEER areas combined (excluding Puerto Rico). The rates are actually a composite of all 10 SEER areas, even though rates for blacks are presented separately only for Detroit, Atlanta, New Orleans, and San Francisco-Oakland. The black population of all SEER areas combined was estimated by the same procedure described above for the black populations of the 4 areas.

ORGANIZATION AND PRESENTATION OF DATA

Status of the File

The data in this volume represent data submitted to the NCI for the 5 years 1973–77. Data for 350,220 malignant and 28,992 in situ cases that occurred among residents of the 11 geographic areas as well as information on 170,375 cancer deaths among residents are available for analysis. These numbers include data for Puerto Rico. However, throughout this volume, *data for Puerto Rico are presented separately.*

Persons Versus Primaries

The 327,627 malignant cases reported for all SEER areas excluding Puerto Rico occurred among 317,297 individuals. During the first 5 years of the Program, 307,399 persons had 1 primary cancer, 9,486 had 2 independent primaries, 395 persons had 3, 15 persons had 4, 1 had 5, and 1 individual had 6 independent primary cancers. The 22,593 malignant cases reported by Puerto Rico occurred among 22,299 individuals; 22,013 persons had 1 primary cancer, 278 had 2, and 8 had 3 primary cancers diagnosed during 1973–77. The 28,531 in situ cancers reported by all areas excluding Puerto Rico occurred among 28,322 individuals; 199 persons had 2 distinct in situ lesions and 5 had 3. The most frequently occurring multiple in situ lesions were those reported in opposite breasts.

Coding of the Data

The grouping of codes which comprise individual site and type categories presented in this Monograph are shown in Appendix tables VII and IX, respectively. All lymphomas occurring in specific organ sites (the so-called extranodal lymphomas) have been grouped with the lymphomas. The distribution of these extranodal lymphomas is shown in table 8.

Mortality data were coded according to the "Eighth Revision: International Classification of Diseases, Adapted" (ICDA-8) (7) which primarily codes only the anatomic site. The grouping of mortality codes which comprise individual site categories is found in Appendix table VIII. Although every attempt was made to group data so that incidence and mortality categories would be comparable, there are 3 categories in which comparability is not possible: 1) Mortality data include deaths from basal cell and squamous cell skin cancers, whereas incidence data exclude these lesions. Therefore, throughout the Monograph, instances occur in which mortality for "other skin cancers" is greater than incidence. 2) Skin of the anus is included with the *anus* in incidence data but is

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 4 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/4

with cancers of the *skin* in mortality data. 3) Polycythemia vera and certain myeloproliferative diseases, previously considered as malignant under ICDA-8 and included in mortality data, are currently considered to be nonmalignant under ICD-O and are not reportable in the incidence system.

In Situ Carcinomas

Data for in situ carcinomas have been presented separately throughout the Monograph. However, due to space limitations, only the most common primary sites are shown in the tables. Rates for in situ carcinomas may be added directly to rates for malignant cancers to determine total incidence for a given site, e.g., cervix uteri.

Race/Ethnicity

Each contractor is responsible for classifying the race/ethnicity of each patient according to the categories defined in the SEER Code Manual (*6*). Two categories exist for Caucasians: Caucasians of Spanish/Mexican surname or origin and Caucasian, NOS; both are commonly referred to as Hispanic and Anglo, respectively. Throughout the Monograph, the term "white" has been used as a collective designation for Hispanics and Anglos. No data by race or ethnicity are available for Puerto Rico. Therefore, all data for Puerto Rico are considered to be in the Hispanic category.

At present, the only population data available for Anglos and Hispanics are from New Mexico, the only geographic area for which incidence data for Anglos and Hispanics are presented separately.

"Other than Caucasians" are classified into 7 categories: American Indian, black, Chinese, Filipino, Japanese, Hawaiian, and other. Data for these groups are shown separately only for those areas in which populations were sufficiently large to yield reliable rates.

Persons whose race was unknown have been included in the totals and the rates for all races combined. The percentage of cases with race unknown was 1.9 for malignant cases and 5.0 for in situ cases.

Age Adjustment

This Monograph presents rates which have been age adjusted by the direct method to the 1970 standard million population. Because rates for each sex and for each race/ethnic group have been age adjusted to the same standard, these rates may be directly compared with one another. The 1970 standard was chosen because this standard most closely reflects the age distribution of the United States population during 1973–77. For historical comparative purposes, rates which have been age adjusted to the 1950 standard population of the United States are shown in Appendix table V.

Cumulative Rates

In addition to age-adjusted incidence and mortality rates, a new measure of cancer risk is presented, i.e., the cumulative rate (*8*), a measure of the risk an individual has of developing (cumulative incidence) or dying from (cumulative mortality) cancer during a certain age range. Inasmuch as life expectancy in the United States is 69.3 years for males and 77.1 years for females (*9*), cumulative rates through age 74 are presented. The cumulative rate from birth to age 74 is five times the sum of the age-specific rates calculated for each 5-year age group through age 74 expressed as a rate per 100 or as a percentage. The cumulative rate can also be viewed as an age-adjusted rate with the same population size in each age group. The cumulative incidence rate for all races, both sexes, all areas combined and all sites was 30.8. This rate, which can be interpreted as the probability of developing cancer from birth to age 74, is approximately 31%.

Median Age

Each age-specific frequency table also displays the median age of patients who developed or died from cancer of each specific site. Medians were calculated even though 5 or fewer cases may have occurred in a category.

Reliability of Rates (Standard Errors)

One measure of the reliability of incidence and mortality rates is the standard error (SE) of the rate. As the alternative to presenting the SE for every rate in the tables, the following statement provides a simple method for computing the SE for a specific rate. If one considers the incidence or mortality rates to be binomial proportions, one can approximate the SE of any rate (r) presented in this Monograph by dividing that rate by the square root of the number of cases (c) upon which the rate has been based. This gives the SE of a rate per 100,000 population. For example, the average annual crude incidence rate, based on 327,627 cases, for all malignant cancers (1973–77) was 325.4/100,000 population. The square root of 327,627 is 572.39. Therefore, an estimate of the SE of the crude rate is 325.4 divided by 572.39 or 0.57. The 95% confidence interval for the crude rate would be 324.26–326.54 and the relative SE (SE/rate) would be 0.2%. For age-adjusted rates, the SE is more complex, but one can still obtain a rough estimate of it by multiplying the rate by the reciprocal of the square root of the number of cases on which the rate was based (*10*).

Arrangement of the Data

Data are presented in sections so that all data for each geographic area are grouped together. This section presents data primarily for all SEER areas combined (excluding Puerto Rico) arranged similarly to those data shown for each area separately but with more detailed data for primary site. Also presented are detailed data on histologic type for those cancers known to have been confirmed microscopically. This section contains data for the total number of blacks in all areas excluding Puerto Rico even though area-specific data for blacks are shown only for 4 areas: Detroit, Atlanta, New Orleans, and San Francisco-Oakland. The remaining sections are arranged according to Census geographic divisions as follows: New England: Connecticut; East North Central: Detroit; West North Central: Iowa; South Atlantic: Atlanta; West South Central: New Orleans; Mountain: New Mexico, Utah; Pacific: Seattle-Puget Sound, San Francisco-Oakland, Hawaii; and Other: Puerto Rico.

Tables are presented for each area as follows:

Age-adjusted (1970 standard) incidence and mortality rates

Age-specific incidence and mortality
- A - Number of cases - both sexes
- B - Number of cases - males
- C - Number of cases - females

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 5 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/5

D - Incidence rates - both sexes
E - Incidence rates - males
F - Incidence rates - females
G - Number of deaths - both sexes
H - Number of deaths - males
I - Number of deaths - females
J - Mortality rates - both sexes
K - Mortality rates - males
L - Mortality rates - females
Populations

Age-specific tables A–L are repeated for each specific race/ethnic group for which data are shown. Data for Connecticut, Iowa, Utah, and Seattle-Puget Sound are presented only for whites because the populations of other race/ethnic groups for these areas are too small to allow the calculation of stable incidence or mortality rates. Data for Puerto Rico will be shown for the total population only inasmuch as no racial classification is possible.

Finally, an Appendix includes mortality data for the entire United States (1973–77), 1977 age-adjusted (1970 standard) incidence and mortality rates for each area, average annual age-adjusted (1970 standard) incidence rates (1969–71) for each area included in the Third National Cancer Survey (TNCS), 1973–77 average annual age-adjusted (1950 standard) incidence and mortality rates for each SEER area, average annual age-adjusted (1950 standard) incidence rates for each TNCS area, and definitions of cancer sites and histologic types used throughout the Monograph.

SUMMARY RESULTS

Quality of the Data

Table 1 is a presentation of the quality of the data submitted to the SEER Program. Each participant is responsible for submitting quality data to the NCI. In addition, the NCI staff, assisted by staff from the General Tumor Registry of the University of California at San Francisco, annually visits each participant to provide quality control abstracting and coding of data and to audit case finding to ensure the complete reporting of cases. Each participant and the NCI staff perform computerized edits of all data. These edits include not only checking for legitimate codes in each data field but also interfield edits, such as site/sex, site/type, and type/extent of disease. Also, interrecord checks are performed for patients having more than 1 primary cancer so that race, sex, birthplace, birthdate, vital status, and date of last follow-up are the same on each record.

All death certificates of area residents that mention cancer are abstracted by each participant. For those persons who died of cancer and who were not diagnosed or treated in an area hospital or clinic, the physician who signed the death certificate is queried so that when and how a diagnosis of cancer was made can be ascertained. If the physician fails to respond or does not know the information, that case is then considered to be a "death certificate only" case, i.e., the only available data for that case is a death certificate which lists cancer as a cause of death. The date of diagnosis for "death certificate only" cases is the date of death.

One measure of completeness of data is the percentage of death certificate only cases. Table 1 shows this percentage for each participant by primary site of cancer. For all areas combined (excluding Puerto Rico), only 1.4% of the 327,627 malignant cases were reported by death certificate only, with a high of 3.0% in Utah and a low of 0.5% in Hawaii. In Puerto Rico, the death certificate only cases amounted to 6.6%. This higher percentage in the Commonwealth is undoubtedly due to the fact that nonmedical personnel (sometimes even family members) are permitted to report the cause of death on death certificates. Relatively high percentages of death certificate only diagnoses were found for nonspecific cancer sites such as large intestine, NOS and uterus, NOS. Conversely, relatively low percentages of death certificate only diagnoses were found for specific primary sites, such as the ascending colon and corpus uteri.

Another measure of the quality of the data is the percentage of cases known to have been confirmed microscopically; these data are also shown in table 1. For all SEER areas combined (excluding Puerto Rico), 92.2% of the malignant cases were microscopically confirmed. This percentage was 85.9 for Puerto Rico. During the TNCS (1969–71), 90.1% of the cases were microscopically confirmed. The percentages for the various SEER participants ranged from a low of 88.9 in Iowa to a high of 96.8 in Hawaii. Compared with other areas of the world, these percentages are high (*11*).

The percentages of microscopically confirmed cases tended to be lower for nonspecific cancer sites (large intestine, NOS; other digestive organs; uterus, NOS; unknown primary site), and for rapidly fatal cancers (liver, pancreas, lung).

Major Findings

Tables 2 and 3, respectively, present average annual age-adjusted incidence and mortality rates by primary site for each SEER area and for each major race/ethnic group represented in the Program.

The average annual age-adjusted incidence rate for all forms of malignant neoplasms for all races and both sexes combined for all SEER areas except Puerto Rico was 331.5, whereas the rate for Puerto Rico was 200.4. Among the other areas, rates ranged from a low of 279.8 in Utah to a high of 363.5 in San Francisco-Oakland.

The average annual rate of carcinoma in situ for all SEER areas excluding Puerto Rico was 26.7; the rate for Puerto Rico was 16.9. Among the other areas, these rates ranged from a low of 19.2 in Utah to a high of 41.8 in Atlanta.

The most common primary sites of cancer were colon/rectum, breast, and lung with age-adjusted rates of 48.5, 46.7, and 46.7, respectively. In fact, these 3 sites accounted for 42.7% of all malignant cancers. Seventy-eight percent of the in situ lesions occurred in the female genital system.

The average annual mortality rate due to malignant neoplasms for all SEER areas excluding Puerto Rico was 168.5 compared with a rate of 166.5 for the total United States. The comparable rate for Puerto Rico was 127.0. Rates ranged from a low of 123.6 in Utah to a high of 201.1 in New Orleans. The mortality rate for Puerto Rico was slightly higher than that for Utah, even though the incidence rate was considerably lower (200.4 vs. 279.8). This difference reflects the higher proportion among Puerto Rican patients with cancer at primary sites for which survival is poor (esophagus, stomach, liver) than in patients in Utah. Similarly, the high mortality rate in New Orleans is reflective of the high incidence of lung cancer in that area.

Of all cancer deaths, lung cancers accounted for 21.7%; colorectal, 13.6%; and breast cancers, 9.2%. These 3 sites accounted for over 40% of cancer cases and deaths, although proportionately more deaths were attributable to lung cancer.

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 6 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/6

Variation by Race/Ethnicity and Sex

Considerable variation is noted in both the incidence of and mortality from cancer among the various racial and ethnic groups for which data are available. The following list shows the variation in average annual age-adjusted incidence rates for all sites combined among the races for each sex:

Males

Hawaiian, Hawaii (465.0)
Black, all areas (454.3)
White, all areas (371.6)
Japanese, Hawaii (327.6)
Chinese, San Francisco-Oakland (325.6)
Chinese, Hawaii (262.9)
Filipino, Hawaii (249.5)
Hispanic, New Mexico (229.5)
Hispanic, Puerto Rico (229.2)
Japanese, San Francisco-Oakland (222.0)
American Indian, New Mexico (178.4)

Females

Hawaiian, Hawaii (408.5)
White, all areas (301.2)
Black, all areas (288.7)
Chinese, San Francisco-Oakland (283.6)
Chinese, Hawaii (263.0)
Hispanic, New Mexico (237.1)
Japanese, San Francisco-Oakland (224.0)
Japanese, Hawaii (220.9)
American Indian, New Mexico (191.6)
Filipino, Hawaii (191.5)
Hispanic, Puerto Rico (173.6)

In general, the highest rates occurred among Hawaiians, blacks, and whites. Among males, blacks had higher rates than whites, but the reverse was true among females. The contrast in rates among the Chinese and Japanese in Hawaii versus those in San Francisco-Oakland is striking. Both Chinese and Japanese females residing in these 2 areas experienced similar rates. However, wide disparity was noted among males; the Japanese in Hawaii had much higher rates than those in San Francisco-Oakland, whereas Chinese males residing in San Francisco-Oakland had much higher rates than those in Hawaii. Although Hispanic males in New Mexico had rates almost identical to those in Puerto Rico, Hispanic females residing in New Mexico had much higher rates than those in Puerto Rico.

Although, generally, males experienced higher rates than females, male and female Japanese residing in San Francisco-Oakland had equal rates; but Hispanic and American Indian males residing in New Mexico had lower rates than those experienced by females.

Variation by Primary Site

Striking differences occurred among the race-sex groups and geographic areas with respect to the incidence of cancer of various sites. Some of these differences are highlighted below:

Stomach: The incidence of stomach cancer was high among Japanese and Hispanics and among white populations with high percentages of foreign-born persons (Detroit, San Francisco-Oakland). The incidence was higher among blacks than among whites for both sexes.

Colon: Although the risk of colon cancer was similar between males and females for whites and blacks, males had slightly higher rates. The highest incidence was reported for Connecticut and the lowest in New Mexico, Utah, and Puerto Rico.

Rectum: The pattern for rectal cancer was similar to that of the colon although rates for blacks were lower than those for whites. Again, the highest incidence occurred in Connecticut and the lowest in New Mexico, Utah, and Puerto Rico.

Lung: Blacks and Hawaiians of both sexes experienced a higher incidence of lung cancer than did whites. Extremely high rates were reported for New Orleans, whereas those for Utah were the lowest. Rates among males almost quadrupled those for females.

Breast: Breast cancer was the most frequent female cancer in each race/ethnic group. The highest incidence was reported among Hawaiian and white females. Among whites, the highest incidence was reported in Hawaii, the lowest in Utah. Rates for Hispanic females were approximately one-half those for other whites.

Cervix: The risk of invasive cervical cancer was much higher among American Indians, blacks, Hawaiians, and Hispanics than among other whites. A similar disparity was noted for in situ carcinomas of the cervix among blacks and American Indians as compared with whites.

Corpus uteri: Both white and Hawaiian females experienced a high risk of cancer of the corpus uteri. A major exception occurred among the white females in New Orleans who had the lowest rates for whites among the geographic areas. Rates among whites residing in the Pacific region (Seattle-Puget Sound, San Francisco-Oakland, Hawaii) were much higher than those reported for other areas.

Prostate: The incidence of prostate cancer was much higher among blacks than among any other race/ethnic group. The highest rates for whites were reported for Hawaii, Utah, and Seattle-Puget Sound.

Bladder: The risk of bladder cancer was three to four times higher among males than among females. The highest rates for white males, who experienced rates almost double those for any other race/ethnic group, were reported by Hawaii and New Orleans; the lowest occurred in Utah.

These differences are of major importance in the targeting of cancer control programs and in the raising of issues for epidemiologic investigation. For example, is the exceptionally low rate of cancer of the corpus uteri among white females in New Orleans due to a lower level of risk factors or to a high prior hysterectomy rate among these women? Is the high incidence of male lung cancer in New Orleans due to occupational exposure? Are the lower cancer rates in Utah explained on the basis of personal behavior? To what extent do sexual and genetic factors influence the higher incidence of breast cancer and cancer of the corpus uteri in white females, of cancer of the cervix uteri in black females, and of cancer of the prostate gland in black males?

ALL SEER AREAS EXCLUDING PUERTO RICO

Tables 4–12 present data for all SEER areas combined (excluding Puerto Rico). The average annual age-adjusted incidence of cancer for all SEER areas during 1973–77 was

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 7 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/7

331.5/100,000 population for all malignant neoplasms and 26.7 for all in situ lesions. The average annual age-adjusted mortality rate for all SEER areas combined was 168.5 compared with a rate of 166.5 for the total United States. Because the mortality rates for all SEER areas are similar to mortality rates for the total United States, it is possible to hypothesize that incidence rates reported by the SEER Program reflect the incidence of cancer in the United States as a whole. However, when data are classfied by race, mortality rates for whites in the SEER program are similar to those for whites in the total United States, but those for blacks are higher: 217.4 for all SEER areas versus 205.0 for the total United States, all sites combined. The higher rates for blacks probably reflect the fact that rural blacks are underrepresented in the SEER Program. Therefore, if the incidence rates in this section are used to estimate numbers of cases occurring in other geographic areas, numbers for blacks may be overestimated.

Malignant Cases and Cancer Deaths

Tables 4–6 present data for all newly diagnosed malignant cases (incidence) and all cancer deaths (mortality) reported during 1973–77. These data have been classified into 77 primary site categories (defined in Appendix tables VII and VIII) arranged by organ systems. There are 327,627 malignant cases and 166,185 cancer deaths that yielded an incidence-to-mortality ratio of 1.97 or about 2:1.

Detailed Primary Site

In table 7, data have been classified according to the 304 specific anatomic sites included in the topography section of the ICD-O (*5*). The distribution of cases by these site categories is shown. Thus if one is interested in the frequency of cancers of the upper lip versus lower lip rather than lip as a whole, these data can be found in table 7. However, prior to 1977, anatomic site was coded according to the topography section of the Manual of Tumor Nomenclature and Coding (MOTNAC) (*12*). Later, these codes were converted to ICD-O (*13*). Few sites were affected by this conversion, although prior to 1977, no information was collected separately for certain categories, such as the hepatic and splenic flexures within the colon and quadrants within the breast. Consequently, the data presented in table 7 for the colonic flexures and the quadrants of the breast actually represent data for only 1 year rather than for 5. In table 7, all non-Hodgkin's lymphomas are combined, even though they may have arisen in a specific organ site.

The percentage distribution of each anatomic site within the 77 primary site categories is also shown. For example, 40% of all bone cancers occur in the long bones of the lower limbs, 30% of all melanomas of the skin occur on the trunk, etc.

Distribution of Non-Hodgkin's Lymphomas

The distribution of the 8,968 non-Hodgkin's lymphomas reported during 1973–77 by anatomic site of occurrence is shown in table 8. Almost 24% of these lymphomas occurred in anatomic sites other than lymph nodes; the most frequent sites were stomach (4.7%), skin (2.9%), and small intestine (2.1%). The average annual age-adjusted (1970 standard) incidence rates per 100,000 population for these 3 sites were 0.4, 0.3, and 0.2, respectively. If extranodal lymphomas had been included in the anatomic site of occurrence, the age-adjusted incidence of these 3 sites would have increased only slightly. The age-adjusted incidence of all other sites would have increased by only 0.1/100,000 or less. Further, lymphoma deaths could not have been distributed according to anatomic site. Thus the inclusion of all lymphomas together makes the comparison of incidence and mortality data possible.

The contrast between blacks and whites with respect to the distribution of the extranodal lymphomas is interesting. Among blacks, 6.9% of the extranodal lymphomas occurred on the skin versus only 2.7% for whites.

Distribution of In Situ Carcinomas

Throughout the Monograph, data are presented for an abbreviated list of in situ carcinomas. Table 9 gives a detailed breakdown of the 28,531 in situ tumors reported to the Program during 1973–77. Almost 72% of all in situ carcinomas occurred in the cervix uteri. In fact, 4 sites (cervix uteri, breast, colon/rectum, and corpus uteri) accounted for 90.2% of all in situ carcinomas. The large number of in situ lesions reported for vulva and penis probably reflect the fact that, for these particular anatomic sites, skin cancers are included. The majority of the lesions reported for vulva and penis are Bowen's disease.

Distribution by Age

In tables 10–12 incidence data are classified by the age of the patient at the time of diagnosis and mortality data are classified by the age of the patient at the time of death. Fifty-one percent of all malignant cancers were diagnosed at ages 65 and older compared with only 12% of in situ carcinomas. The median age at diagnosis for all cancer patients with malignant lesions was 65.4 years compared with 37.1 years for those with in situ lesions. When data are examined by primary site, the median age at diagnosis was less than 50 years for only 4 sites: acute lymphocytic leukemia (10.6 years), testis (31.4), bone and joint (32.3), and Hodgkin's disease (34.0). For in situ carcinomas, only patients with lesions of the cervix uteri had a median age of less than 50 years (32.3).

The median age at diagnosis for men was greater than that for women, 66.9 versus 63.5 years, respectively. Also, the median age at diagnosis was higher for whites than for blacks, 65.8 versus 62.2 years, respectively. The cumulative incidence rate for men was also higher than that for women for whites and blacks. Similar observations can be made for mortality data.

DATA BY HISTOLOGIC TYPE

Data for all areas combined (excluding Puerto Rico) are classified by histologic type in tables 13–15. The histologic typing of tumors is equally as important as the designation of anatomic site of the neoplasm because, in many instances, the prognosis for tumors of different histologic types within the same site varies greatly. Numbers presented for whites and blacks represent data for all 10 areas. Both numbers of cases and percent distribution within categories are included. Table 13 presents data for the primary site categories by the detailed histologic types listed in table 15. Histologic categories (defined in Appendix table IX) by primary site categories are shown in table 14. Data for the individual histologies, as defined below, are presented in table 15.

Only those cases which were known to have been confirmed microscopically have been included in these tables. Of the 327,627 malignant cases diagnosed during 1973–77, 92.2% or 301,972 cases were pathologically proved, either from an

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 8 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/8

autopsy, surgical specimen, biopsy, or by cytologic or hematologic findings.

Since it was published in late 1976, the ICD-O (*5*) has been used to code the anatomic site and histologic type of cancer. Prior to that, the MOTNAC (*12*) was used. All data in this Monograph have been converted (*13, 14*) to ICD-O classifications. There were few differences in the site codes from MOTNAC to ICD-O, so that data for anatomic site categories are comparable. For morphology, however, the 3-digit morphology code used in MOTNAC was expanded in ICD-O to a 4-digit code to allow for many new terms now being used to identify histologic entities. Inasmuch as only data for 1977 were originally coded by ICD-O, the histologic data in this section have been classified by only the first 3 digits of the ICD-O code, which corresponds in most cases to a MOTNAC code.

Although consistency is not 100% between the histologic coding schemes of MOTNAC and ICD-O, generally, the differences are minor and will have little effect on comparability of data. However, new terms introduced in ICD-O (e.g., adenocarcinoma, intestinal type; carcinoma, diffuse type; and superficial spreading melanoma) are now in common use among pathologists and will become more important as the data set grows. Two changes between MOTNAC and ICD-O that should be mentioned are: 1) Mesothelioma, NOS was not considered a malignant neoplasm in MOTNAC but is in ICD-O. Hence a case of "mesothelioma, NOS" could not have been reported until 1977 in the SEER Program. 2) Lentigo malignum or melanotic freckle was considered to be malignant in MOTNAC but is considered to be an in situ lesion in ICD-O.

Extensive edits were performed so that histologic type and anatomic site data would be compatible. Every unusual combination of anatomic site and histologic type submitted to the Program was flagged for review by the participant to assure that the pathologic diagnosis had been accurately recorded, but no slide review of tissue was undertaken. Those site and type combinations which were reviewed and whose accuracy of recording has been reconfirmed but which may represent highly unusual combinations of site and histology have been footnoted "*a*" in tables 13 and 14.

Over one-third (34.7%) of all neoplasms were classified as adenocarcinoma, NOS (table 15); another 12.4% were classified as squamous cell carcinoma; and 9.4% as duct adenocarcinoma. Thus these 3 histologic terms described over 56% of all malignant neoplasms; 7.1% were classified only as carcinoma, NOS.

Comparison With Previous Data

It is helpful in the understanding of current data to compare tables 13–15 with earlier data classified by both site and histology available from the TNCS, pages 394–447 (*4*). Comparison of SEER data by histologic type with data from the TNCS reveals the following:

1) A large increase has occurred in the relative frequency of malignant carcinoids of the small bowel and a minimal increase in carcinoids of the ascending colon.

2) The relative frequency of osteosarcomas has decreased from TNCS to SEER (44% vs. 34%, respectively) and has been offset to a certain extent by a rise in chondrosarcoma from 23 to 28% and to a lesser extent by a slight increase in the relative frequency of chordomas and giant cell tumors of the bone.

3) Malignant fibrous histiocytoma has become the third most frequent histologic type of soft tissue tumors. Because this exact term did not appear in MOTNAC, it is impossible to assess this increase.

4) The relative frequency of adenosquamous carcinomas of the cervix and corpus has increased considerably.

5) Endometrioid carcinoma" has emerged as an important type of ovarian cancer.

6) The relative frequency of mixed tumors of the salivary gland has decreased as has the incidence of salivary gland cancers as a whole. Perhaps pathologists are currently more conservative in diagnosing these tumors as malignant. Conversely, adenoid cystic carcinomas of the salivary gland increased in relative frequency from 13 to 18%.

Changes in the relative frequency of specific histologic types of cancer may be due to many factors, such as changes in pathologists' definitions and shifts to specific versus nonspecific diagnoses. Further, the specificity of the diagnosis and, in fact, microscopic confirmation are influenced by the age of the patient; older patients are less likely to have their cancers confirmed microscopically.

POPULATIONS

Table 16 shows the populations used in the calculations of all incidence and mortality rates presented in tables 6–12. The sources and derivations of these populations were discussed above.

FUTURE OF THE PROGRAM

The SEER Program was established to monitor the incidence of and survival from cancer on a continuing basis. Therefore, it is anticipated that such data will continue to be collected and available to the public into the foreseeable future.

Five-year follow-up data are now available for cases diagnosed during 1973–74, and 3-year follow-up data are available for cases diagnosed during 1973–76. A monograph presenting the survival experience of these patients is planned. Incidence data will be available on an annual basis but will not necessarily be published annually.

Computer tapes containing data found in this Monograph will be made available at cost to the public. Information concerning these tapes and/or any data contained in this Monograph may be obtained by writing to the:

Demographic Analysis Section
Biometry Branch
National Cancer Institute
Bethesda, Maryland 20205

ACKNOWLEDGMENTS

Special acknowledgement and appreciation are due to all of those who have served to bring together over the last 7 years the data presented in this Monograph. Several staff members served during the initial development and data collection phases of the Program and have now accepted positions elsewhere or have retired. These include Dr. William Haenszel, former chief of the Biometry Branch, Dr. Sidney J. Cutler, the first Director of the SEER Program, Lillian Axtell, Harvey Geller, and Dr. Russell Roegner. Throughout the development of this Monograph, secretarial and clerical assist-

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 9 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/9

ance have been provided by Carol B. Kalb, Mary E. Krause, and Barbara A. Lyles. Data processing and computer programming assistance have been provided by Bernard F. Huang, Joel R. Katz, Robert S. McConnell, Katherine McGlaughlin, Ruthann M. Piepenburg, Mary Ann Read, Thomas C. Ribson, Susan F. Steed, Bruce Miller Sutton, Michael D. Sutton, and Judith H. Walsh of GEOMET Technologies, Inc. Special mention should be made of the members of the NCI Computer Science Section who assisted various SEER participants in the development of viable data management systems. These include Altamease G. Barnaby, Calvin Hollingsworth, James E. Larson, J. Michael Stump, Valerie D. Van Holten, Theodore Weiss, and Ruth Wolfson. Members of the field staff who have labored to assure the quality of the data presented in this Monograph are B. Jean Cicero, Jack B. Cunningham, and Mary A. Kruse of the NCI and Dr. Calvin Zippin, Diana Lum, Julie Duerksen, Jennie Fong, and Susan Radovich of the University of California at San Francisco. Mention should be made of the efforts of Dr. Leonard Chiazze and Dr. Max H. Myers who served, respectively, as interim Branch Chief and interim SEER Director during the early years of the Program. Members of the Research Contracts Branch who have assisted both Program and Contract staff during the inception and development of the Program include Dorothy M. Coleman, Judi E. Cleaves, Charles Fafard, Sydney M. Jones, Teresa L. Voorhies, Karlene Wakefield, and Patrick J. Williams. Finally, the assistance of Dr. Wilna A. Woods, Executive Secretary of the Biometry and Epidemiology Contract Review Committee, as well as the assistance of the various committee members from 1972 to the present, is gratefully acknowledged.

REFERENCES

(1) CUTLER SJ, EDERER F (eds): End results and mortality trends in cancer: Part I. End results in cancer. Natl Cancer Inst Monogr 6:1–129, 1961

(2) DORN HF: Illness from cancer in the United States. Publ Health Rep 59:33–48, 65–77, 97–115, 1944

(3) DORN HF, CUTLER SJ: Morbidity from cancer in the United States. U.S. Department of Health, Education, and Welfare. Publ Health Serv Monogr No. 56. Washington, D.C.: U.S. Govt Print Off, 1959

(4) CUTLER SJ, YOUNG JL JR (eds): Third National Cancer Survey: Incidence data. Natl Cancer Inst Monogr 41:1–454, 1975

(5) World Health Organization: International Classification of Diseases for Oncology, 1976. Geneva: WHO, 1976

(6) Demographic Analysis Section, Biometry Branch, National Cancer Institute: Code Manual. The SEER Program. NIH Publ No. 79-1999. Bethesda, Md.: NCI/NIH, 1979, pp 1-30.1

(7) National Center for Health Statistics: Eighth revision: International Classification of Diseases, Adapted for Use in the United States, vol I, II. PHS Publ No. 1693. Washington, D.C.: U.S. Govt Print Off, 1967

(8) DAY NE: A new measure of age standardized incidence, the cumulative rate. *In*: Cancer Incidence in Five Continents, vol III (Waterhouse J, Muir C, Correa P, et al, eds). IARC Sci Publ No. 15. Lyon: IARC, 1976, pp 443–452

(9) National Center for Health Statistics: Vital Statistics of the United States, 1977: Life tables, vol II, Sect 5. DHEW Publ No. (PHS)80-1104. Hyattsville, Md.: NCHS, 1980, p 5-16

(10) KEYFITZ N: Sampling variance of standardized mortality rates. Hum Biol 38:309–317, 1966

(11) WATERHOUSE J, MUIR C, CORREA P, et al (eds): Cancer Incidence in Five Continents, vol III. IARC Sci Publ No. 15. Lyon: IARC, 1976, pp 45–69

(12) PERCY CL, BERG JW, THOMAS LB (eds): Manual of Tumor Nomenclature and Coding (1968 ed). New York: American Cancer Society, Inc., 1968

(13) PERCY CL (ed): Conversion table #3, conversion of topography section, Manual of Tumor Nomenclature and Coding (MOTNAC) to topography section, International Classification of Diseases for Oncology (ICD-O). Bethesda, Md.: Natl Cancer Inst, 1978

(14) ———: Conversion table #4, conversion of morphology sections (neoplasms) of 1968 Manual of Tumor Nomenclature and Coding (MOTNAC) and 1965 Systematized Nomenclature of Pathology (SNOP) to 1976 International Classification of Diseases for Oncology (ICD-O). Bethesda, Md.: Natl Cancer Inst, 1978

Cancer Incidence and Mortality in the United States, 1973-77 (1981)
ACL Doc 25458 · Page 10 of 50
Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/10

TABLE 1.—*Number of malignant cases diagnosed, percent microscopically confirmed (MC), and percent reported on death certificates only (DC) by primary site, geographic area, and period*

Primary site	All areas ex. Puerto Rico 1973-77			Connecticut 1973-77			Detroit 1973-77			Iowa 1973-77			Atlanta 1975-77			New Orleans 1974-77		
	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC
All sites	**327,627**	**92.2**	**1.4**	**55,918**	**92.1**	**1.3**	**64,131**	**92.2**	**1.2**	**51,483**	**88.9**	**1.0**	**12,410**	**93.3**	**1.6**	**12,787**	**90.2**	**1.5**
Buccal cavity and pharynx	**11,867**	**97.4**	**0.6**	**1,893**	**96.3**	**0.6**	**1,893**	**97.6**	**0.8**	**1,511**	**96.0**	**0.4**	**483**	**96.9**	**0.6**	**538**	**97.4**	**0.6**
Lip	1,875	98.6	0.3	175	98.9	0.6	175	100.0	.....	442	97.3	0.2	39	97.4	.....	48	100.0	.....
Tongue	1,987	97.4	0.9	399	96.2	0.8	399	97.7	0.8	295	96.4	1.0	86	97.7	.....	102	97.1	1.0
Major salivary gland	915	97.8	0.5	141	97.9	.....	171	98.2	1.8	143	95.1	0.7	32	100.0	.....	40	100.0	.....
Floor of mouth	1,253	98.3	0.2	249	96.4	0.8	232	98.7	.....	135	98.5	.....	44	93.2	.....	65	95.4	.....
Gum and other mouth	1,813	96.6	0.7	365	96.2	0.3	327	96.3	1.5	225	93.3	0.4	101	99.0	.....	103	98.1	.....
Nasopharynx	588	97.3	0.3	74	95.9	1.4	110	96.4	.....	54	92.6	1.9	25	100.0	.....	26	100.0	.....
Tonsil	1,080	97.6	0.4	208	96.2	0.5	203	97.5	.....	113	95.6	.....	60	96.7	1.7	58	100.0	.....
Oropharynx	286	98.6	.....	45	97.8	.....	45	100.0	.....	36	94.4	.....	12	100.0	.....	19	100.0	.....
Hypopharynx	968	97.6	0.4	170	95.3	0.6	177	97.7	0.6	129	98.4	.....	59	98.3	.....	53	98.1	.....
Pharynx and other buccal cavity	302	87.4	5.0	67	89.6	3.0	54	88.9	5.6	09	89.7	.....	25	80.0	8.0	24	79.2	8.3
Digestive system	**77,685**	**89.1**	**1.8**	**14,350**	**89.6**	**1.6**	**15,188**	**89.0**	**1.3**	**12,873**	**85.6**	**1.1**	**2,545**	**90.1**	**1.7**	**2,957**	**86.9**	**1.9**
Esophagus	3,567	90.9	1.6	676	90.7	1.5	933	92.0	1.3	391	83.9	1.5	155	92.9	2.6	156	94.9	1.3
Stomach	9,589	87.6	2.5	1,668	87.6	2.1	1,958	89.6	1.5	1,204	78.4	1.6	248	91.9	2.0	380	86.3	3.9
Small intestine	825	96.6	1.0	138	97.8	0.7	169	98.2	.....	145	93.8	0.7	30	93.3	3.3	31	96.8	.....
Colon excluding rectum	33,039	91.8	1.5	6,336	91.7	1.5	6,207	91.2	1.3	6,077	89.4	1.0	1,093	94.7	1.3	1,193	88.9	1.8
Cecum	6,744	94.0	0.4	1,229	93.8	0.5	1,247	92.9	0.6	1,293	92.2	0.2	239	98.3	.....	200	94.5	.....
Appendix	312	99.4	0.3	33	100.0	.....	43	100.0	.....	41	95.1	2.4	22	100.0	.....	13	100.0	.....
Ascending colon	4,007	93.2	0.2	748	91.7	0.1	774	94.2	.....	770	91.6	0.3	108	91.7	0.9	141	88.7	0.7
Hepatic flexure	905	91.8	0.3	159	91.8	.....	186	90.3	1.1	144	93.8	.....	45	95.6	.....	50	84.0	2.0
Transverse colon	3,918	93.7	0.2	789	92.4	0.3	703	91.2	.....	770	93.6	.....	131	99.2	.....	133	94.7	.....
Splenic flexure	993	92.8	.....	224	92.9	.....	203	92.1	.....	158	88.6	.....	43	90.7	.....	63	96.8	.....
Descending colon	2,743	93.2	0.2	495	93.7	.....	536	92.0	0.4	492	88.4	0.4	114	96.5	.....	118	90.7	.....
Sigmoid colon	11,579	94.7	0.3	2,352	94.8	0.2	2,124	94.4	0.3	2,059	91.6	0.0	341	96.2	.....	371	94.6	0.3
Large intestine, NOS	1,838	55.2	21.8	307	51.8	27.0	391	59.6	16.6	350	51.1	14.9	50	58.0	26.0	104	45.2	17.3
Rectum and rectosigmoid	14,630	95.6	0.7	2,911	95.7	0.6	2,780	96.0	0.7	2,585	93.2	0.6	412	97.3	.....	514	95.1	1.0
Rectosigmoid junction	4,642	95.6	0.2	1,008	96.6	0.1	864	96.3	.....	701	92.0	0.3	191	97.4	.....	162	93.2	0.6
Rectum	9,988	95.5	1.0	1,903	95.2	0.9	1,916	95.9	1.0	1,884	93.6	0.7	221	97.3	.....	352	96.0	1.1
Anus, anal canal, and anorectum	626	99.7	.....	93	100.0	.....	117	100.0	.....	74	98.6	.....	31	100.0	.....	33	100.0	.....
Liver	2,101	82.8	3.9	278	84.5	3.2	455	81.3	3.7	266	74.1	3.4	77	87.0	2.6	103	87.4	.....
Gallbladder	1,443	95.2	1.3	221	95.5	0.9	296	94.9	1.4	267	95.9	0.4	33	100.0	.....	52	90.4	1.9
Other biliary	1,338	87.2	1.3	226	89.4	0.9	239	85.4	0.8	185	82.7	1.1	50	86.0	2.0	34	85.3	2.9
Pancreas	9,662	70.9	3.1	1,682	72.2	3.2	1,860	69.5	1.6	1,564	63.7	1.5	385	67.0	3.1	424	67.5	2.1
Retroperitoneum	423	94.1	1.2	54	88.9	3.7	91	96.7	1.1	56	91.1	.....	18	88.9	.....	12	91.7	.....
Peritoneum	144	97.2	.....	21	95.2	.....	37	97.3	.....	27	92.6	.....	2	100.0	.....	7	100.0	.....
Other digestive organs	298	66.8	11.1	46	56.5	8.7	46	58.7	6.5	32	46.9	18.8	11	72.7	27.3	18	61.1	11.1
Respiratory system	**51,635**	**88.0**	**1.8**	**8,532**	**88.7**	**1.3**	**11,264**	**87.7**	**1.7**	**7,385**	**81.5**	**0.9**	**2,006**	**90.7**	**2.0**	**2,709**	**86.2**	**1.5**
Nasal cavity, sinuses, and ear	619	97.4	1.6	101	96.0	1.0	114	98.2	0.9	87	97.7	1.1	28	96.4	3.6	34	97.1	2.9
Larynx	4,507	97.5	0.8	844	97.9	0.2	1,054	96.9	1.3	617	96.3	0.8	164	97.6	1.2	240	98.8	0.4
Lung and bronchus	45,836	86.8	1.9	7,482	87.5	1.4	9,972	86.5	1.8	6,605	79.9	0.9	1,786	89.9	2.1	2,408	84.7	1.6
Trachea, pleura, mediastinum, and other	673	92.3	1.9	105	88.6	3.8	104	96.2	1.0	76	84.2	1.3	28	100.0	.....	27	96.3	.....
Bones and joints	**806**	**94.3**	**2.4**	**109**	**95.4**	**0.9**	**139**	**94.2**	**1.4**	**126**	**88.1**	**4.0**	**42**	**92.9**	**4.8**	**29**	**100.0**	.....
Soft tissues (including heart)	**1,946**	**98.2**	**0.4**	**290**	**97.6**	**0.3**	**336**	**99.4**	**0.3**	**282**	**95.4**	.....	**74**	**98.6**	.....	**75**	**98.7**	.....
Skin (excluding basal and squamous carcinoma)	**6,702**	**99.1**	**0.3**	**1,087**	**98.6**	**0.2**	**855**	**99.4**	**0.4**	**847**	**98.2**	**0.1**	**387**	**99.5**	.....	**218**	**100.0**	.....
Melanomas of the skin	6,114	99.1	0.3	1,015	98.6	0.2	725	99.4	0.4	800	98.3	0.1	367	99.5	.....	184	100.0	.....
Other skin cancers	588	99.1	0.2	72	98.6	.....	130	99.2	.....	47	97.9	.....	20	100.0	.....	34	100.0	.....
Breast	**46,171**	**97.6**	**0.9**	**8,250**	**96.8**	**1.0**	**8,979**	**97.2**	**0.8**	**7,080**	**96.0**	**0.8**	**1,879**	**97.3**	**1.1**	**1,651**	**97.2**	**0.5**
Female genital system	**31,540**	**97.9**	**0.7**	**4,624**	**97.6**	**0.7**	**6,425**	**97.9**	**0.6**	**4,683**	**96.3**	**0.6**	**1,218**	**97.9**	**1.3**	**865**	**97.0**	**0.6**
Cervix uteri	6,672	98.2	0.7	814	97.7	0.9	1,559	98.4	0.5	1,022	97.7	0.6	333	97.6	2.1	306	98.4	0.3
Corpus uteri	15,432	99.4	0.2	2,260	99.6	0.1	2,864	99.5	0.1	2,087	98.9	0.1	532	99.4	0.2	279	99.3	.....
Uterus, NOS	399	77.9	10.5	75	76.0	9.3	145	83.4	10.3	75	69.3	8.0	11	81.8	.....	8	75.0	12.5
Ovary	7,386	96.0	1.1	1,229	95.5	1.2	1,515	96.1	0.9	1,218	93.3	0.5	254	96.5	2.0	210	93.3	1.4
Vagina	374	94.4	1.3	44	97.7	.....	84	92.9	.....	64	89.1	1.6	34	94.1	5.9	15	93.3	.....
Vulva	901	97.2	1.0	147	94.6	0.7	201	97.5	1.0	173	96.5	1.2	28	96.4	3.6	34	100.0	.....
Other female genital organs	376	91.8	1.3	55	92.7	.....	57	98.2	.....	44	86.4	4.5	26	100.0	.....	13	84.6	.....

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/11

Prostatic gland	27,737	92.6	1.3	4,039	92.3	1.3	5,128	93.5	1.1	4,751	87.2	1.1	1,069	94.2	1.5	966	93.2	1.2
Testis	1,746	99.4	0.2	266	98.5	0.4	293	99.7	0.3	245	99.2	.....	79	100.0	.....	50	100.0	.....
Penis	382	96.9	1.0	60	96.7	1.7	76	98.7	.....	67	94.0	.....	18	100.0	.....	23	100.0	.....
Other male genital organs	95	91.6	3.2	21	95.2	.....	26	92.3	.....	13	76.9	15.4	2	100.0	.....	6	100.0	.....
Urinary system	**22,004**	**94.8**	**0.8**	**4,048**	**95.0**	**0.7**	**4,418**	**94.7**	**0.7**	**3,722**	**92.6**	**0.5**	**728**	**96.0**	**1.0**	**873**	**94.3**	**0.8**
Urinary bladder	14,759	97.6	0.7	2,767	97.8	0.7	2,930	97.5	0.8	2,528	96.6	0.4	455	97.6	1.1	583	95.7	1.0
Kidney and renal pelvis	6,441	88.2	1.1	1,127	88.2	0.8	1,365	88.3	0.7	1,056	82.8	0.7	236	93.2	0.8	258	90.3	0.4
Ureter	525	97.0	.....	113	95.6	.....	87	98.9	.....	102	95.1	.....	19	94.7	.....	22	100.0	.....
Other urinary organs	279	96.8	0.7	41	97.6	.....	56	98.2	.....	36	91.7	2.8	18	94.4	.....	10	100.0	.....
Eye	**750**	**91.9**	**1.5**	**84**	**89.3**	**1.2**	**137**	**94.9**	**0.7**	**158**	**91.1**	**0.6**	**40**	**87.5**	**2.5**	**32**	**96.9**	.....
Brain and other nervous system	**5,238**	**85.2**	**1.9**	**919**	**85.6**	**1.5**	**978**	**91.5**	**1.3**	**777**	**80.1**	**1.3**	**224**	**83.5**	**0.4**	**212**	**81.6**	**1.9**
Brain	4,939	85.1	1.9	864	85.1	1.6	930	91.4	1.4	737	80.1	1.2	209	83.7	.....	194	81.4	2.1
Other nervous system	299	88.3	1.0	55	94.5	.....	48	93.8	.....	40	80.0	2.5	15	80.0	6.7	18	83.3	.....
Endocrine system	**4,577**	**98.3**	**0.6**	**602**	**97.5**	**1.0**	**890**	**98.8**	**0.3**	**504**	**97.6**	**0.8**	**220**	**99.1**	.....	**159**	**96.9**	**1.3**
Thyroid gland	4,174	98.8	0.4	533	98.1	1.1	809	98.8	0.2	448	98.4	0.7	209	99.0	.....	142	97.9	0.7
Other endocrine (including thymus)	403	93.5	2.0	69	92.8	.....	81	98.8	1.2	56	91.1	1.8	11	100.0	.....	17	88.2	5.9
Lymphomas	**12,015**	**97.4**	**0.9**	**2,000**	**97.5**	**0.8**	**2,245**	**97.6**	**0.8**	**2,087**	**96.6**	**0.7**	**416**	**98.6**	**1.4**	**416**	**96.4**	**0.5**
Hodgkin's disease	3,047	98.4	0.7	575	98.8	0.5	592	98.1	0.7	457	97.6	0.7	110	100.0	.....	95	97.9	.....
Non-Hodgkin's lymphomas	8,968	97.1	1.0	1,425	97.0	0.8	1,653	97.4	0.8	1,630	96.3	0.7	306	98.0	2.0	321	96.0	0.6
Multiple myeloma	**3,815**	**91.6**	**1.7**	**656**	**88.1**	**2.4**	**800**	**93.8**	**1.1**	**642**	**90.5**	**1.4**	**134**	**88.1**	**2.2**	**165**	**87.9**	**0.6**
Leukemias	**9,714**	**95.0**	**2.1**	**1,626**	**94.6**	**2.4**	**1,889**	**95.8**	**1.3**	**1,904**	**95.3**	**1.2**	**374**	**94.1**	**2.1**	**314**	**94.3**	**1.0**
Lymphocytic	3,984	95.0	1.7	668	93.7	2.1	710	95.1	1.5	919	94.3	1.5	152	94.7	0.7	100	97.0	1.0
Acute lymphocytic	1,081	98.1	0.6	179	96.1	1.7	121	99.2	.....	212	97.2	0.9	47	95.7	.....	31	100.0	.....
Chronic lymphocytic	2,708	94.6	1.5	458	93.2	1.7	554	94.6	1.4	658	94.2	1.2	96	95.8	.....	66	98.5	1.5
Other lymphocytic	195	83.6	10.3	31	87.1	9.7	35	88.6	8.6	49	83.7	8.2	9	77.8	11.1	3	33.3	.....
Granulocytic	4,312	96.5	1.5	703	96.7	1.7	823	97.6	0.6	774	96.6	0.6	174	94.3	2.3	172	96.5	0.6
Acute granulocytic	2,559	97.5	1.3	448	98.0	1.1	425	99.1	0.5	427	97.7	0.7	109	93.6	2.8	105	96.2	1.0
Chronic granulocytic	1,401	95.5	1.4	204	94.6	2.9	314	96.2	.....	289	94.8	0.7	57	98.2	.....	54	98.1	.....
Other granulocytic	352	92.9	3.1	51	94.1	2.0	84	95.2	3.6	58	98.3	.....	8	75.0	12.5	13	92.3	.....
Monocytic	292	94.5	2.1	39	89.7	5.1	76	97.4	1.3	60	96.7	1.7	15	100.0	.....	18	83.3	.....
Acute monocytic	185	94.6	2.2	21	95.2	.....	44	95.5	2.3	39	97.4	2.6	13	100.0	.....	5	60.0	.....
Chronic monocytic	27	88.9	3.7	8	75.0	12.5	7	100.0	.....	7	85.7	.....	.....	.....	.....	.....	.....	.....
Other monocytic	80	96.3	1.3	10	90.0	10.0	25	100.0	.....	14	100.0	.....	2	100.0	.....	13	92.3	.....
Other	1,126	89.4	5.6	216	91.7	5.1	280	91.8	2.5	151	94.0	2.0	33	87.9	9.1	24	75.0	4.2
Other acute	442	93.7	4.1	71	90.1	8.5	145	98.6	1.4	31	93.5	3.2	11	90.9	9.1	12	75.0	8.3
Other chronic	30	73.3	20.0	3	100.0	.....	5	80.0	20.0	4	75.0	.....	.....	.....	.....	1	100.0	.....
Aleukemic, subleukemic, and NOS	654	87.3	6.0	142	92.3	3.5	130	84.6	3.1	116	94.8	1.7	22	86.4	9.1	11	72.7	.....
Other, ill-defined, and unknown sites	**12,002**	**72.8**	**4.8**	**2,462**	**75.7**	**4.2**	**2,192**	**71.2**	**5.0**	**1,826**	**63.9**	**3.1**	**472**	**74.2**	**8.3**	**529**	**63.7**	**9.1**

12 TABLE 1. *Number of malignant cases diagnosed, percent microscopically confirmed (MC), and percent reported on death certificates only (DC) by primary site, geographic area, and period—Continued*

Primary site	New Mexico 1973–77			Utah 1973–77			Seattle-Puget Sound 1974–77			San Francisco-Oakland 1973–77			Hawaii 1973–77			Puerto Rico 1973–77		
	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC	No. of cases	% MC	% DC
All sites	**13,381**	**91.2**	**1.7**	**13,403**	**92.2**	**3.0**	**33,598**	**93.9**	**1.3**	**60,181**	**93.7**	**1.9**	**10,335**	**96.8**	**0.5**	**22,593**	**85.9**	**6.6**
Buccal cavity and pharynx	**408**	**96.8**	**1.2**	**578**	**97.6**	**0.2**	**1,107**	**98.2**	**0.6**	**2,259**	**98.5**	**0.7**	**397**	**99.0**	**0.3**	**1,895**	**97.8**	**1.4**
Lip	145	96.6	0.7	306	99.3	.....	187	98.9	.....	332	99.1	0.6	26	100.0	.....	100	100.0	.....
Tongue	60	96.7	1.7	65	96.9	1.5	203	98.5	1.0	417	98.1	1.0	61	98.4	.....	514	98.8	0.4
Major salivary gland	38	97.4	2.6	57	94.7	.....	81	98.8	.....	174	99.4	.....	38	97.4	.....	66	97.0	1.5
Floor of mouth	30	100.0	.....	35	100.0	.....	121	100.0	.....	289	99.7	0.3	53	100.0	.....	154	100.0	.....
Gum and other mouth	46	95.7	2.2	44	93.2	.....	195	98.5	.....	347	97.7	1.2	60	96.7	1.7	411	99.0	1.0
Nasopharynx	21	100.0	.....	15	86.7	.....	55	98.2	.....	149	98.7	.....	59	100.0	.....	58	98.3	.....
Tonsil	25	100.0	.....	23	95.7	.....	97	96.9	2.1	254	99.2	.....	39	100.0	.....	221	98.6	0.9
Oropharynx	6	100.0	.....	8	100.0	.....	29	96.6	.....	68	100.0	.....	18	100.0	.....	37	97.3	.....
Hypopharynx	28	100.0	.....	19	100.0	.....	93	97.8	1.1	202	97.5	0.5	38	100.0	.....	271	98.2	0.7
Pharynx and other buccal cavity	9	66.7	11.1	6	83.3	.....	46	91.3	4.3	27	88.9	11.1	5	100.0	.....	63	68.3	23.8
Digestive system	**3,031**	**87.0**	**2.9**	**2,676**	**87.9**	**4.6**	**7,217**	**91.5**	**1.7**	**13,962**	**90.6**	**2.6**	**2,886**	**95.2**	**0.7**	**6,888**	**76.1**	**10.5**
Esophagus	89	84.3	3.4	77	87.0	2.6	265	90.2	3.0	683	93.0	1.5	142	96.5	0.7	1,286	80.9	8.7
Stomach	489	86.9	2.0	337	81.0	6.8	802	90.9	2.6	1,823	88.5	3.8	680	95.0	1.6	2,201	72.2	11.6
Small intestine	40	95.0	.....	47	100.0	.....	77	98.7	.....	123	95.9	2.4	25	92.0	8.0	92	88.0	4.3
Colon excluding rectum	1,079	91.7	1.3	1,143	92.0	3.5	3,161	94.1	1.2	5,882	93.3	2.1	868	96.7	0.3	1,110	84.2	7.6
Cecum	245	95.5	.....	219	94.5	0.5	702	94.9	.....	1,239	95.0	1.0	131	96.2	.....	199	89.4	2.0
Appendix	19	100.0	.....	12	100.0	.....	75	100.0	.....	50	100.0	.....	4	100.0	.....	7	100.0	.....
Ascending colon	111	93.7	.....	107	96.3	1.9	364	95.1	.....	786	94.1	0.3	98	98.0	.....	155	87.7	1.9
Hepatic flexure	46	87.0	.....	26	96.2	.....	114	92.1	.....	98	94.9	.....	37	91.9	.....	15	80.0	.....
Transverse colon	102	97.1	.....	91	94.5	.....	337	96.7	0.9	780	94.0	0.3	82	98.8	.....	115	89.6	.....
Splenic flexure	23	87.0	.....	18	100.0	.....	122	94.3	.....	105	97.1	.....	34	94.1	.....	14	92.9	.....
Descending colon	83	91.6	.....	89	97.8	.....	239	97.5	.....	490	94.9	0.4	87	98.9	.....	94	92.6	1.1
Sigmoid colon	370	94.1	0.8	422	95.5	1.4	1,077	96.6	0.2	2,094	95.8	0.7	369	98.1	.....	351	94.6	0.9
Large intestine, NOS	80	61.3	13.8	159	69.8	19.5	131	52.7	25.2	240	50.4	38.3	26	69.2	11.5	160	41.9	45.6
Rectum and rectosigmoid	449	93.5	2.0	496	96.6	1.6	1,440	95.6	0.3	2,523	96.9	1.0	520	97.9	0.2	745	93.6	1.7
Rectosigmoid junction	124	94.4	.....	126	96.8	0.8	472	94.7	0.2	768	96.9	0.4	226	98.2	.....	159	93.7	1.3
Rectum	325	93.2	2.8	370	96.5	1.9	968	96.0	0.4	1,755	96.9	1.3	294	97.6	0.3	586	93.5	1.9
Anus, anal canal, and anorectum	16	93.8	.....	23	100.0	.....	85	100.0	.....	137	100.0	.....	17	100.0	.....	76	98.7	1.3
Liver	113	84.1	4.4	54	63.0	13.0	152	83.6	5.9	417	85.1	5.5	186	91.4	.....	427	54.8	28.1
Gallbladder	142	94.4	2.1	62	95.2	3.2	116	94.8	.....	210	94.8	2.9	44	100.0	.....	182	89.0	5.5
Other biliary	69	81.2	1.4	46	89.1	4.3	121	89.3	.....	269	88.1	2.2	99	94.9	.....	123	74.0	11.4
Pancreas	504	70.4	3.0	346	68.2	10.7	858	76.5	4.3	1,765	74.1	4.7	274	88.7	0.7	570	51.9	16.1
Retroperitoneum	15	100.0	.....	34	97.1	.....	34	94.1	.....	89	95.5	2.2	20	95.0	.....	27	88.9	.....
Peritoneum	7	100.0	.....	3	100.0	.....	17	100.0	.....	21	100.0	.....	2	100.0	.....	11	100.0	.....
Other digestive organs	19	73.7	5.3	8	75.0	12.5	89	85.4	5.6	20	55.0	35.0	9	55.6	11.1	38	21.1	52.6
Respiratory system	**1,906**	**85.3**	**2.3**	**1,273**	**85.9**	**4.7**	**5,307**	**90.8**	**2.0**	**9,706**	**91.1**	**2.6**	**1,567**	**94.8**	**0.4**	**2,175**	**77.8**	**8.2**
Nasal cavity, sinuses, and ear	22	100.0	.....	25	92.0	8.0	76	97.4	1.3	105	98.1	1.9	27	100.0	.....	95	97.9	1.1
Larynx	157	97.5	1.3	121	95.0	1.7	392	98.2	0.5	804	98.3	0.7	114	98.2	.....	562	94.0	3.9
Lung and bronchus	1,694	83.8	2.5	1,091	84.7	5.0	4,744	89.1	2.1	8,645	90.4	2.8	1,409	94.4	0.5	1,495	70.4	10.2
Trachea, pleura, mediastinum, and other	33	93.9	.....	36	88.9	2.8	95	93.7	1.1	152	92.8	3.3	17	100.0	.....	23	78.3	8.7
Bones and joints	**43**	**100.0**	.....	**58**	**94.8**	**5.2**	**89**	**95.5**	**2.2**	**141**	**94.3**	**2.8**	**30**	**100.0**	.....	**92**	**85.9**	**9.8**
Soft tissues (including heart)	**122**	**100.0**	.....	**109**	**97.2**	**0.9**	**211**	**99.5**	**0.5**	**368**	**97.8**	**1.1**	**79**	**100.0**	.....	**167**	**98.2**	.....
Skin (excluding basal and squamous carcinoma)	**363**	**100.0**	.....	**457**	**98.7**	**0.7**	**756**	**99.9**	**0.1**	**1,567**	**99.0**	**0.6**	**165**	**100.0**	.....	**175**	**99.4**	.....
Melanomas of the skin	331	100.0	.....	418	98.6	0.7	691	99.9	0.1	1,438	99.1	0.6	145	100.0	.....	107	100.0	.....
Other skin cancers	32	100.0	.....	39	100.0	.....	65	100.0	.....	129	98.4	0.8	20	100.0	.....	68	98.5	.....
Breast	**1,838**	**96.9**	**0.7**	**1,887**	**96.7**	**2.0**	**4,599**	**97.6**	**0.7**	**8,696**	**97.3**	**1.1**	**1,312**	**99.4**	**0.2**	**2,021**	**96.8**	**1.8**
Female genital system	**1,356**	**97.9**	**1.0**	**1,295**	**97.5**	**1.2**	**3,601**	**98.8**	**0.4**	**6,516**	**98.4**	**0.8**	**957**	**99.6**	**0.1**	**2,314**	**95.9**	**2.8**
Cervix uteri	439	98.4	0.5	215	96.7	0.5	600	98.5	0.7	1,166	98.4	0.9	218	99.5	.....	1,252	98.5	1.0
Corpus uteri	500	99.8	0.2	636	98.9	0.3	2,105	99.7	0.1	3,630	99.3	0.5	539	99.4	0.2	424	98.1	0.7
Uterus, NOS	23	78.3	13.0	32	87.5	12.5	23	78.3	13.0	7	28.6	42.9	.....	.....	.....	73	47.9	42.5
Ovary	325	96.3	1.8	350	96.6	2.0	704	98.3	0.6	1,404	97.2	1.4	177	100.0	.....	353	94.6	3.4
Vagina	15	100.0	.....	13	84.6	7.7	35	100.0	.....	63	96.8	1.6	7	100.0	.....	50	92.0	6.0
Vulva	38	97.4	2.6	34	100.0	.....	77	97.4	.....	161	98.8	1.2	8	100.0	.....	141	97.2	2.1
Other female genital organs	16	87.5	.....	15	93.3	.....	57	87.7	3.5	85	90.6	1.2	8	100.0	.....	21	90.5	4.8

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/13

Male genital system	**1,404**	**93.1**	**1.5**	**1,749**	**94.0**	**2.3**	**3,578**	**94.9**	**1.0**	**5,155**	**94.5**	**1.6**	**876**	**97.7**	**0.5**	**2,188**	**86.2**	**7.4**[1]
Prostate gland	1,287	92.5	1.6	1,591	93.7	2.6	3,322	94.6	1.1	4,783	94.1	1.7	801	97.6	0.4	1,861	84.3	8.3
Testis	89	100.0	.....	141	97.9	.....	212	100.0	.....	309	99.7	0.3	62	100.0	.....	34	94.1	2.9
Penis	25	96.0	4.0	17	94.1	.....	33	100.0	.....	54	96.3	1.9	9	88.9	11.1	281	97.5	1.8
Other male genital organs	3	100.0	.....	.....	.....	.....	11	81.8	9.1	9	100.0	.....	4	100.0	.....	12	100.0	.....
Urinary system	**845**	**93.6**	**1.2**	**891**	**96.5**	**0.9**	**2,332**	**95.6**	**0.7**	**3,612**	**95.9**	**1.2**	**535**	**97.0**	**0.7**	**1,051**	**92.9**	**3.3**
Urinary bladder	503	98.0	0.6	605	98.2	0.5	1,585	98.0	0.6	2,487	98.2	0.8	336	98.8	0.9	820	93.3	3.7
Kidney and renal pelvis	308	86.4	2.3	257	92.6	1.9	650	89.7	1.1	1,005	89.8	2.1	179	93.3	0.6	204	90.2	2.5
Ureter	19	94.7	.....	21	95.2	.....	55	96.4	.....	71	100.0	.....	16	100.0	.....	12	100.0	.....
Other urinary organs	15	93.3	.....	8	100.0	.....	42	95.2	2.4	49	100.0	.....	4	100.0	.....	15	100.0	.....
Eye	**42**	**97.6**	.....	**68**	**86.8**	**1.5**	**65**	**89.2**	**6.2**	**109**	**92.7**	**1.8**	**15**	**100.0**	.....	**75**	**96.0**	**2.7**
Brain and other nervous system	**224**	**81.3**	**4.0**	**277**	**87.4**	**2.9**	**590**	**86.1**	**2.7**	**894**	**81.9**	**2.5**	**143**	**95.8**	.....	**281**	**93.6**	**2.8**
Brain	208	79.8	4.3	267	87.3	3.0	554	86.3	2.7	837	81.6	2.6	139	95.7	.....	260	93.5	3.1
Other nervous system	16	100.0	.....	10	90.0	.....	36	83.3	2.8	57	86.0	.....	4	100.0	.....	21	95.2	.....
Endocrine system	**277**	**97.5**	**0.7**	**258**	**97.3**	**1.2**	**375**	**98.7**	**0.5**	**938**	**98.6**	**0.4**	**354**	**99.7**	.....	**283**	**97.5**	**1.8**
Thyroid gland	259	97.7	0.4	240	98.8	0.8	334	99.1	0.3	867	99.1	0.2	333	100.0	.....	269	98.5	0.7
Other endocrine (including thymus)	18	94.4	5.6	18	77.8	5.6	41	95.1	2.4	71	93.0	2.8	21	95.2	.....	14	78.6	21.4
Lymphomas	**515**	**96.5**	**1.9**	**610**	**95.9**	**1.8**	**1,229**	**99.1**	**0.4**	**2,161**	**97.3**	**1.4**	**336**	**100.0**	.....	**774**	**99.7**	.....
Hodgkin's disease	146	97.9	2.1	173	98.3	.....	290	99.0	0.3	535	98.5	1.1	74	100.0	.....	249	100.0	.....
Non-Hodgkin's lymphomas	369	95.9	1.9	437	95.0	2.5	939	99.1	0.4	1,626	96.9	1.5	262	100.0	.....	525	99.6	.....
Multiple myeloma	**126**	**91.3**	.....	**153**	**90.8**	**2.6**	**394**	**93.1**	**1.5**	**644**	**94.1**	**2.0**	**101**	**94.1**	**2.0**	**301**	**96.0**	**1.3**
Leukemias	**430**	**94.4**	**1.6**	**462**	**88.7**	**6.9**	**911**	**95.9**	**2.2**	**1,525**	**95.3**	**2.8**	**279**	**97.8**	**0.7**	**689**	**94.8**	**3.5**
Lymphocytic	199	94.5	1.0	182	93.4	4.9	365	96.7	1.1	597	96.5	1.8	92	96.7	1.1	242	98.8	0.4
Acute lymphocytic	69	98.6	.....	84	98.8	1.2	102	100.0	.....	174	99.4	.....	62	98.4	1.6	168	99.4	0.6
Chronic lymphocytic	123	92.7	1.6	82	92.7	6.1	252	96.0	0.8	392	95.9	1.8	27	92.6	.....	66	97.0	.....
Other lymphocytic	7	85.7	.....	16	68.8	18.8	11	81.8	18.2	31	87.1	12.9	3	100.0	.....	8	100.0	.....
Granulocytic	174	97.1	0.6	203	89.2	5.9	410	97.3	1.5	726	96.3	2.2	153	98.7	0.7	329	97.3	2.4
Acute granulocytic	98	98.0	.....	121	90.9	5.0	255	98.4	1.2	469	97.4	2.1	102	99.0	.....	146	96.6	3.4
Chronic granulocytic	62	98.4	.....	70	84.3	8.6	119	95.8	1.7	188	96.8	1.6	44	100.0	.....	164	97.6	1.8
Other granulocytic	14	85.7	7.1	12	100.0	.....	36	94.4	2.8	69	87.0	4.3	7	85.7	14.3	19	100.0	.....
Monocytic	12	91.7	.....	12	91.7	8.3	18	94.4	.....	32	93.8	3.1	10	100.0	.....	8	100.0	.....
Acute monocytic	10	90.0	.....	8	87.5	12.5	10	100.0	.....	27	92.6	3.7	8	100.0	.....	7	100.0	.....
Chronic monocytic	1	100.0	.....	.....	.....	.....	1	100.0	.....	2	100.0	.....	1	100.0	.....	.....	.....	.....
Other monocytic	1	100.0	.....	4	100.0	.....	7	85.7	.....	3	100.0	.....	1	100.0	.....	1	100.0	.....
Other	45	84.4	8.9	65	73.8	15.4	118	89.0	8.5	170	87.6	8.2	24	95.8	.....	110	78.2	13.6
Other acute	16	87.5	6.3	14	85.7	7.1	56	92.9	3.6	78	93.6	3.8	8	100.0	.....	35	100.0	.....
Other chronic	3	66.7	33.3	6	50.0	50.0	4	100.0	.....	4	50.0	25.0	.....	.....	.....	3	100.0	.....
Aleukemic, subleukemic, and NOS	26	84.6	7.7	45	73.3	13.3	58	84.5	13.8	88	84.1	11.4	16	93.8	.....	72	66.7	20.8
Other, ill-defined, and unknown sites	**451**	**65.0**	**6.7**	**602**	**75.6**	**8.8**	**1,237**	**77.1**	**2.8**	**1,928**	**77.7**	**5.4**	**303**	**86.1**	**0.7**	**1,224**	**68.1**	**16.6**

TABLE 2A — *Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for all races, both sexes*

Primary site	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Puerto Rico 1973–77
MALIGNANT												
All sites	331.5	344.8	327.0	308.3	335.2	337.2	301.5	279.8	350.1	363.5	306.7	200.4
Buccal cavity and pharynx	11.2	11.6	9.5	9.3	13.2	14.1	9.0	12.1	11.6	13.6	11.5	17.1
Lip	1.9	1.1	0.9	2.6	1.1	1.3	3.2	6.5	2.0	2.0	0.7	0.9
Tongue	2.0	2.4	2.0	1.2	2.4	2.7	1.4	1.4	2.1	2.5	1.7	4.7
Major salivary gland	0.9	0.9	0.9	0.9	0.8	1.0	0.8	1.1	0.8	1.0	1.1	0.6
Floor of mouth	1.3	1.5	1.1	0.9	1.2	1.7	0.7	0.8	1.3	1.7	1.5	1.4
Gum and other mouth	1.8	2.2	1.6	1.3	2.8	2.7	1.0	0.9	2.0	2.1	1.9	3.7
Nasopharynx	0.6	0.5	0.5	0.4	0.6	0.7	0.4	0.3	0.6	0.9	1.6	0.5
Tonsil	1.1	1.3	1.0	0.7	1.6	1.5	0.5	0.5	1.0	1.5	1.1	2.0
Oropharynx	0.3	0.3	0.2	0.2	0.3	0.5	0.1	0.2	0.3	0.4	0.5	0.3
Hypopharynx	1.0	1.0	0.9	0.8	1.7	1.4	0.6	0.4	1.0	1.2	1.2	2.5
Pharynx and other buccal cavity	0.3	0.4	0.3	0.2	0.7	0.6	0.2	0.1	0.5	0.2	0.2	0.6
Digestive system	78.9	88.7	79.1	73.9	71.9	79.0	70.9	57.2	74.9	84.3	90.9	62.9
Esophagus	3.6	4.1	4.8	2.3	4.2	4.1	2.3	1.7	2.7	4.1	4.4	11.8
Stomach	9.7	10.3	10.3	6.7	7.0	10.2	11.5	7.2	8.3	11.0	21.9	20.3
Small intestine	0.8	0.9	0.8	0.9	0.8	0.8	0.9	1.0	0.8	0.7	0.7	0.8
Colon excluding rectum	33.6	39.3	32.5	34.7	31.0	32.0	25.1	24.5	32.7	35.4	27.3	10.1
Cecum	6.9	7.7	6.6	7.2	7.0	5.4	5.8	4.7	7.2	7.5	4.3	1.8
Appendix	0.3	0.2	0.2	0.3	0.5	0.3	0.3	0.2	0.7	0.3	0.1	0.1
Ascending colon	4.1	4.7	4.1	4.3	3.0	3.8	2.6	2.3	3.7	4.7	3.1	1.4
Hepatic flexure	0.9	1.0	1.0	0.8	1.3	1.4	1.1	0.6	1.2	0.6	1.2	0.1
Transverse colon	4.0	4.9	3.7	4.4	3.8	3.5	2.3	1.9	3.5	4.7	2.6	1.0
Splenic flexure	1.0	1.4	1.1	0.9	1.2	1.7	0.5	0.4	1.3	0.6	1.0	0.1
Descending colon	2.8	3.1	2.8	2.9	3.2	3.1	2.0	1.9	2.5	2.9	2.7	0.9
Sigmoid colon	11.8	14.5	11.1	12.0	9.5	9.9	8.5	9.0	11.3	12.7	11.4	3.2
Large intestine, NOS	1.8	1.9	2.1	1.9	1.4	2.8	1.9	3.4	1.3	1.4	0.8	1.4
Rectum and rectosigmoid	14.9	17.9	14.4	15.0	11.7	13.7	10.5	10.7	15.0	15.2	15.7	6.7
Rectosigmoid junction	4.7	6.2	4.5	4.0	5.4	4.3	2.9	2.7	4.9	4.7	6.8	1.4
Rectum	10.2	11.7	9.9	11.0	6.2	9.4	7.6	8.0	10.1	10.6	8.9	5.3
Anus, anal canal, and anorectum	0.6	0.6	0.6	0.4	0.9	0.9	0.4	0.5	0.9	0.8	0.5	0.7
Liver	2.1	1.7	2.3	1.5	2.2	2.7	2.6	1.1	1.6	2.5	5.7	3.9
Gallbladder	1.5	1.4	1.6	1.5	1.0	1.4	3.4	1.3	1.2	1.3	1.6	1.7
Other biliary	1.4	1.4	1.3	1.1	1.4	0.9	1.7	1.0	1.2	1.6	3.2	1.1
Pancreas	9.8	10.4	9.7	8.9	11.0	11.3	12.0	7.4	9.0	10.7	8.8	5.2
Retroperitoneum	0.4	0.3	0.5	0.4	0.5	0.3	0.3	0.7	0.3	0.6	0.5	0.2
Peritoneum	0.1	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.1
Other digestive organs	0.3	0.3	0.2	0.2	0.3	0.5	0.5	0.2	0.9	0.1	0.3	0.4
Respiratory system	52.6	52.3	57.2	45.5	54.9	71.1	43.6	27.3	56.0	59.1	47.4	19.8
Nasal cavity, sinuses, and ear	0.6	0.6	0.6	0.5	0.8	0.9	0.5	0.5	0.8	0.6	0.8	0.8
Larynx	4.6	5.1	5.3	3.9	4.5	6.2	3.5	2.6	4.1	4.9	3.4	5.1
Lung and bronchus	46.7	45.9	50.8	40.5	48.9	63.4	38.9	23.5	50.1	52.6	42.7	13.7
Trachea, pleura, mediastinum, and other	0.7	0.6	0.5	0.5	0.7	0.7	0.7	0.7	1.0	0.9	0.5	0.2
Bones and joints	0.8	0.7	0.7	0.8	1.0	0.7	0.8	1.0	0.9	0.9	0.8	0.6
Soft tissues (including heart)	1.9	1.8	1.7	1.3	1.8	1.9	2.5	2.0	2.2	2.2	2.1	1.3
Skin (excluding basal and squamous carcinoma)	6.6	6.7	4.1	5.5	8.7	5.5	7.6	8.8	7.7	9.2	3.9	1.5
Melanomas of the skin	6.0	6.2	3.5	5.2	8.2	4.7	6.7	8.1	7.1	8.4	3.5	0.9
Other skin cancers	0.6	0.4	0.6	0.3	0.4	0.9	0.7	0.7	0.7	0.8	0.4	0.6
Breast	46.7	50.8	44.7	44.1	49.3	43.5	48.0	48.1	48.2	52.5	35.0	17.4
Female genital system	31.7	28.2	31.8	29.9	31.5	22.4	29.1	27.0	37.6	39.1	25.4	20.1
Cervix uteri	6.6	4.9	7.6	6.8	7.9	7.7	9.0	4.3	6.1	6.8	5.6	10.7
Corpus uteri	15.6	13.7	14.2	13.3	14.3	7.4	11.0	13.6	22.1	21.9	14.7	3.8
Uterus, NOS	0.4	0.5	0.7	0.4	0.3	0.2	0.5	0.7	0.2	0.0	—	0.6
Ovary	7.4	7.5	7.6	7.7	6.7	5.4	7.0	7.2	7.4	8.5	4.6	3.0
Vagina	0.4	0.3	0.4	0.4	0.9	0.4	0.3	0.3	0.4	0.4	0.2	0.4
Vulva	0.9	0.9	1.0	1.0	0.8	0.9	0.9	0.7	0.8	1.0	0.2	1.3
Other female genital organs	0.4	0.3	0.3	0.3	0.7	0.3	0.3	0.2	0.6	0.5	0.2	0.2

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/15

Male genital system	**30.4**	**27.3**	**29.4**	**27.8**	**33.7**	**28.0**	**33.8**	**37.2**	**36.8**	**31.0**	**29.7**	**20.2**
Prostatic gland	28.3	25.2	27.5	25.7	31.7	26.1	31.6	34.6	34.3	29.0	28.1	17.4
Testis	1.6	1.6	1.3	1.7	1.5	1.1	1.6	2.2	2.0	1.7	1.2	0.2
Penis	0.4	0.4	0.4	0.4	0.5	0.6	0.6	0.4	0.3	0.3	0.3	2.5
Other male genital organs	0.1	0.1	0.1	0.1	0.1	0.2	0.1	.....	0.1	0.1	0.1	0.1
Urinary system	**22.4**	**25.0**	**22.8**	**21.8**	**20.4**	**23.3**	**19.6**	**18.9**	**24.3**	**21.9**	**16.8**	**9.5**
Urinary bladder	15.0	17.1	15.2	14.5	13.0	15.6	11.9	12.9	16.5	15.0	10.8	7.5
Kidney and renal pelvis	6.6	7.0	6.9	6.5	6.3	6.8	6.9	5.3	6.9	6.2	5.4	1.7
Ureter	0.5	0.7	0.5	0.6	0.6	0.6	0.5	0.5	0.6	0.4	0.5	0.1
Other urinary organs	0.3	0.3	0.3	0.2	0.5	0.3	0.4	0.2	0.4	0.3	0.1	0.1
Eye	**0.8**	**0.5**	**0.7**	**1.0**	**1.3**	**0.8**	**0.9**	**1.4**	**0.7**	**0.7**	**0.4**	**0.6**
Brain and other nervous system	**5.3**	**5.7**	**4.9**	**5.2**	**5.6**	**5.4**	**4.5**	**5.2**	**6.3**	**5.6**	**3.7**	**2.1**
Brain	5.0	5.4	4.6	5.0	5.2	5.0	4.2	5.0	5.9	5.3	3.6	1.9
Other nervous system	0.3	0.3	0.2	0.3	0.3	0.4	0.3	0.2	0.3	0.3	0.1	0.1
Endocrine system	**4.4**	**3.7**	**4.3**	**3.4**	**4.7**	**3.9**	**5.4**	**4.7**	**3.8**	**5.5**	**8.9**	**2.2**
Thyroid gland	4.0	3.2	3.9	3.0	4.4	3.5	5.1	4.3	3.3	5.0	8.2	2.1
Other endocrine (including thymus)	0.4	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.4	0.5	0.7	0.1
Lymphomas	**12.0**	**12.3**	**11.2**	**13.0**	**10.5**	**10.7**	**11.0**	**11.8**	**12.6**	**13.0**	**9.3**	**6.2**
Hodgkin's disease	3.0	3.5	2.9	3.0	2.5	2.3	2.8	2.9	2.9	3.1	1.7	1.8
Non-Hodgkin's lymphomas	9.0	8.8	8.3	10.0	8.1	8.5	8.3	8.9	9.7	9.9	7.6	4.4
Multiple myeloma	**3.9**	**4.1**	**4.1**	**3.7**	**3.8**	**4.4**	**3.0**	**3.3**	**4.1**	**3.9**	**3.1**	**2.8**
Leukemias	**9.8**	**10.2**	**9.7**	**11.2**	**10.0**	**8.2**	**9.3**	**8.9**	**9.5**	**9.5**	**8.0**	**5.3**
Lymphocytic	4.1	4.3	3.7	5.4	4.1	2.6	4.2	3.4	3.9	3.9	2.6	1.6
Acute lymphocytic	1.1	1.2	0.6	1.5	1.1	0.8	1.2	1.3	1.2	1.4	1.6	0.9
Chronic lymphocytic	2.7	2.8	2.9	3.7	2.7	1.8	2.9	1.8	2.6	2.4	0.9	0.6
Other lymphocytic	0.2	0.2	0.2	0.3	0.2	0.1	0.2	0.3	0.1	0.2	0.1	0.1
Granulocytic	4.3	4.4	4.1	4.6	4.6	4.4	3.8	4.0	4.2	4.3	4.4	2.7
Acute granulocytic	2.6	2.8	2.1	2.6	2.9	2.7	2.1	2.4	2.6	2.8	3.0	1.2
Chronic granulocytic	1.4	1.3	1.6	1.7	1.5	1.4	1.3	1.4	1.2	1.1	1.2	1.3
Other granulocytic	0.4	0.3	0.4	0.3	0.2	0.3	0.3	0.2	0.4	0.4	0.2	0.1
Monocytic	0.3	0.2	0.4	0.3	0.4	0.5	0.2	0.2	0.2	0.2	0.3	0.1
Acute monocytic	0.2	0.1	0.2	0.2	0.3	0.1	0.2	0.2	0.1	0.2	0.2	0.1
Chronic monocytic	0.0	0.1	0.0	0.0	.....	.....	0.0	.....	0.0	0.0	0.0	.....
Other monocytic	0.1	0.1	0.1	0.1	0.1	0.3	0.0	0.1	0.1	0.0	0.0	0.0
Other	1.1	1.4	1.4	0.9	0.9	0.6	1.0	1.3	1.2	1.1	0.7	0.9
Other acute	0.5	0.5	0.7	0.2	0.3	0.3	0.3	0.3	0.6	0.5	0.3	0.3
Other chronic	0.0	0.0	0.0	0.0	.....	0.0	0.1	0.1	0.0	0.0	.....	0.0
Aleukemic, subleukemic, and NOS	0.7	0.9	0.7	0.7	0.6	0.3	0.6	0.9	0.6	0.5	0.5	0.6
Other, ill-defined, and unknown sites	**12.1**	**15.3**	**11.4**	**10.6**	**13.3**	**14.1**	**10.7**	**12.8**	**12.8**	**11.6**	**9.6**	**10.9**
IN SITU												
All sites	**26.7**	**21.5**	**25.1**	**22.7**	**41.8**	**20.4**	**27.5**	**19.1**	**40.8**	**30.8**	**19.8**	**16.9**
Buccal cavity and pharynx	**0.2**	**0.3**	**0.1**	**0.1**	**0.4**	**0.2**	**0.3**	**0.4**	**0.4**	**0.3**	**0.3**	**0.3**
Digestive system	**1.9**	**1.9**	**1.3**	**1.5**	**2.3**	**3.5**	**0.9**	**1.1**	**2.9**	**2.5**	**3.3**	**0.4**
Stomach	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.4	0.1
Colon excluding rectum	1.0	0.9	0.7	0.7	1.4	2.0	0.3	0.6	1.6	1.4	1.2	0.1
Rectum and rectosigmoid	0.8	0.8	0.5	0.7	0.8	1.4	0.3	0.4	1.2	0.9	1.4	0.1
Anus, anal canal, and anorectum	0.1	0.0	0.0	0.0	0.1	0.1	0.1	.....	0.1	0.1	0.2	0.0
Respiratory system	**0.3**	**0.3**	**0.3**	**0.3**	**0.4**	**0.4**	**0.2**	**0.3**	**0.3**	**0.4**	**0.3**	**0.3**
Larynx	0.3	0.3	0.3	0.2	0.3	0.4	0.1	0.2	0.3	0.4	0.2	0.2
Lung and bronchus	0.0	0.0	0.1	0.1	0.1	0.0	.....	0.1	0.0	0.1	0.0	0.0
Melanomas of the skin	**0.3**	**0.3**	**0.1**	**0.1**	**0.6**	**0.1**	**0.3**	**0.8**	**0.6**	**0.6**	**0.5**	**0.0**
Breast	**2.3**	**1.8**	**2.0**	**1.7**	**4.5**	**1.7**	**1.7**	**3.1**	**2.6**	**3.0**	**4.1**	**1.0**
Female genital system	**20.8**	**16.4**	**20.6**	**18.6**	**32.6**	**13.9**	**23.7**	**12.9**	**33.5**	**22.5**	**11.0**	**14.2**
Cervix uteri	18.5	15.0	18.5	17.3	29.4	12.4	22.3	10.7	30.2	19.1	8.2	13.8
Corpus uteri	1.4	1.0	1.2	0.9	1.3	0.7	0.7	1.7	2.1	2.2	2.3	0.1
Vagina	0.2	0.1	0.2	0.1	0.6	0.2	0.3	0.1	0.2	0.2	0.1	0.1
Vulva	0.6	0.3	0.6	0.3	1.3	0.5	0.4	0.3	1.0	0.9	0.5	0.1
Male genital system	**0.2**	**0.2**	**0.1**	**0.1**	**0.5**	**0.2**	**0.2**	**0.3**	**0.2**	**0.3**	**0.1**	**0.5**
Prostatic gland	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.3	0.0	0.1	0.0	0.4
Penis	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.2	0.2	0.0	0.1
Urinary system	**0.5**	**0.3**	**0.4**	**0.4**	**0.4**	**0.2**	**0.1**	**0.1**	**0.3**	**1.2**	**0.3**	**0.0**
Urinary bladder	0.4	0.2	0.4	0.3	0.4	0.2	0.0	0.1	0.2	1.1	0.3	0.0

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/16

Primary site	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Puerto Rico 1973–77
MALIGNANT												
All sites	379.3	395.3	381.1	355.3	408.1	433.8	322.0	316.6	395.8	402.7	351.4	229.2
Buccal cavity and pharynx	17.4	19.1	14.4	15.9	20.9	25.7	13.8	19.8	16.6	20.1	16.1	27.1
Lip	3.9	2.2	1.8	5.9	2.1	2.9	6.0	12.4	3.9	4.1	1.5	1.5
Tongue	3.0	4.1	3.1	1.6	3.9	4.8	1.8	2.0	2.8	3.6	2.1	7.4
Major salivary gland	1.1	1.0	0.9	1.2	1.2	0.9	1.1	1.2	1.1	1.2	1.4	0.7
Floor of mouth	2.0	2.6	1.8	1.5	1.8	3.2	1.1	0.9	1.9	2.3	2.1	2.3
Gum and other mouth	2.4	3.5	2.0	1.9	1.4	3.9	1.3	1.1	2.2	2.6	1.9	5.2
Nasopharynx	0.9	0.6	0.8	0.6	0.9	1.2	0.5	0.3	0.7	1.4	2.5	0.7
Tonsil	1.6	2.1	1.6	1.0	2.7	2.2	0.8	0.7	1.3	2.1	1.1	3.3
Oropharynx	0.5	0.4	0.5	0.4	0.6	0.8	0.2	0.3	0.4	0.6	1.0	0.6
Hypopharynx	1.7	2.0	1.6	1.4	2.9	2.7	0.8	0.7	1.7	2.0	2.1	4.4
Pharynx and other buccal cavity	0.5	0.7	0.4	0.5	1.4	1.1	0.3	0.2	0.7	0.2	0.3	0.9
Digestive system	96.5	108.5	99.6	87.2	89.1	102.7	77.4	67.6	90.3	104.2	118.2	78.6
Esophagus	5.9	6.8	7.8	3.9	7.6	7.7	2.8	3.0	4.2	6.2	7.4	17.0
Stomach	14.1	14.7	15.1	10.1	9.8	15.0	15.9	10.4	12.1	15.7	30.2	28.4
Small intestine	0.9	1.0	1.0	1.0	0.8	1.2	0.7	1.0	1.0	0.8	0.6	0.9
Colon excluding rectum	36.9	44.2	37.6	35.5	33.3	36.7	24.0	26.8	35.5	39.9	32.6	9.8
Cecum	7.0	8.3	7.0	6.5	6.1	6.3	4.9	4.7	7.7	7.8	5.1	1.9
Appendix	0.3	0.3	0.2	0.2	0.6	0.3	0.3	0.2	0.4	0.3	0.1	0.1
Ascending colon	4.2	4.7	4.6	4.1	3.1	3.3	2.4	2.8	3.8	5.2	3.5	1.5
Hepatic flexure	1.0	1.1	1.1	0.9	1.9	1.2	0.8	0.5	1.4	0.7	1.3	0.2
Transverse colon	4.2	5.4	4.0	4.1	4.2	4.0	2.3	2.2	3.3	5.2	2.6	1.0
Splenic flexure	1.3	1.9	1.4	1.1	1.7	2.2	0.6	0.4	1.6	0.8	0.9	0.1
Descending colon	3.2	3.6	3.1	3.1	3.8	3.9	1.9	2.0	3.0	3.3	3.2	0.8
Sigmoid colon	13.8	16.8	13.9	13.5	10.5	12.6	8.5	10.1	12.7	14.8	14.8	3.0
Large intestine, NOS	2.0	2.1	2.1	2.0	1.5	2.8	2.1	3.9	1.5	1.8	1.0	1.3
Rectum and rectosigmoid	19.1	22.8	18.6	19.4	15.0	19.5	11.9	12.5	19.4	19.8	21.0	7.6
Rectosigmoid junction	5.7	7.7	5.4	4.7	6.2	6.5	3.0	2.5	6.2	5.8	8.7	1.7
Rectum	13.4	15.1	13.2	14.8	8.8	13.1	8.9	10.0	13.2	14.1	12.3	5.9
Anus, anal canal, and anorectum	0.5	0.6	0.5	0.4	0.8	0.8	0.3	0.5	0.7	0.7	0.3	0.4
Liver	3.2	2.4	3.4	2.2	3.6	4.3	2.9	1.2	2.3	4.2	8.5	5.1
Gallbladder	1.0	1.0	1.1	1.0	0.7	1.0	1.8	1.0	0.8	0.9	3.5	1.1
Other biliary	1.7	1.6	1.6	1.3	2.1	0.9	2.0	0.9	1.6	2.0	3.8	1.2
Pancreas	12.2	12.6	12.0	11.6	15.1	14.3	13.9	9.3	11.3	13.1	10.9	6.4
Retroperitoneum	0.5	0.5	0.5	0.5	0.3	0.4	0.5	0.6	0.3	0.6	0.8	0.2
Peritoneum	0.1	0.1	0.2	0.1	.....	0.3	0.2	0.1	0.1	0.1	0.1	0.1
Other digestive organs	0.3	0.3	0.2	0.2	0.2	0.6	0.5	0.1	1.0	0.2	0.5	0.4
Respiratory system	88.7	89.7	98.0	82.6	99.4	128.1	67.2	48.2	90.5	94.5	76.2	30.5
Nasal cavity, sinuses, and ear	0.8	0.7	0.8	0.7	0.9	1.4	0.6	0.5	1.0	0.9	1.0	1.1
Larynx	8.5	9.8	9.8	7.6	9.2	12.1	6.6	4.9	7.4	8.9	5.9	8.5
Lung and bronchus	78.3	78.1	86.6	73.5	88.1	113.2	58.8	41.8	80.3	83.2	62.4	20.6
Trachea, pleura, mediastinum, and other	1.1	1.0	0.8	0.7	1.3	1.4	1.2	0.9	1.7	1.5	1.0	0.3
Bones and joints	1.0	0.8	0.8	0.9	1.3	0.9	1.0	1.0	1.2	1.1	1.2	0.8
Soft tissues (including heart)	2.4	2.3	2.1	2.3	1.9	2.6	2.9	2.3	2.4	2.9	2.7	1.5
Skin (excluding basal and squamous carcinoma)	7.0	7.5	4.6	5.5	8.9	7.2	7.1	8.3	8.2	10.0	4.9	1.6
Melanomas of the skin	6.3	7.0	3.8	5.2	8.6	6.0	6.3	7.7	7.4	8.8	4.4	0.9
Other skin cancers	0.7	0.5	0.7	0.3	0.4	1.2	0.8	0.6	0.8	1.2	0.5	0.7
Breast	0.8	0.9	1.1	0.6	0.7	1.1	0.7	0.7	0.6	1.0	0.5	0.4

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/17

Male genital system	73.5	66.8	70.4	68.0	90.6	73.1	73.6	86.4	88.2	76.1	64.5	42.7
Prostate gland	69.2	62.4	66.4	63.5	86.2	68.9	69.0	81.0	83.1	71.9	61.2	36.4
Testis	3.3	3.3	2.8	3.4	3.1	2.4	3.1	4.6	4.0	3.4	2.5	0.5
Penis	0.9	0.9	0.9	0.9	1.2	1.4	1.2	0.8	0.8	0.8	0.5	5.2
Other male genital organs	0.2	0.3	0.3	0.2	0.1	0.4	0.1	.....	0.3	0.1	0.3	0.2
Urinary system	36.3	40.8	36.3	36.1	35.4	39.3	29.0	29.6	39.9	35.9	25.6	14.1
Urinary bladder	25.8	29.6	26.0	25.7	23.6	27.7	18.9	21.7	28.4	25.7	16.9	11.7
Kidney and renal pelvis	9.2	9.7	9.3	9.0	9.8	10.1	9.3	7.4	10.0	9.1	7.7	2.2
Ureter	0.8	1.1	0.5	1.1	1.0	0.9	0.6	0.4	0.9	0.6	0.8	0.2
Other urinary organs	0.4	0.4	0.4	0.3	1.0	0.6	0.3	0.2	0.6	0.5	0.2	0.1
Eye	0.9	0.6	0.8	1.2	1.3	0.9	1.1	1.5	0.6	0.9	0.6	0.6
Brain and other nervous system	6.3	7.2	5.8	6.4	7.2	6.6	6.0	5.5	7.3	6.3	4.3	2.4
Brain	6.0	6.8	5.6	6.2	6.6	6.1	5.6	5.3	6.7	6.0	4.3	2.2
Other nervous system	0.3	0.5	0.3	0.2	0.6	0.6	0.4	0.2	0.6	0.4	0.1	0.1
Endocrine system	3.0	2.6	2.8	2.2	2.8	3.0	4.0	2.6	2.6	3.6	7.3	1.1
Thyroid gland	2.5	2.0	2.3	1.7	2.3	2.2	3.5	2.1	2.1	3.1	6.2	1.0
Other endocrine (including thymus)	0.5	0.4	0.5	0.5	0.5	0.8	0.5	0.5	0.6	0.5	1.1	0.1
Lymphomas	14.0	13.8	13.2	14.9	13.6	12.8	12.3	13.3	14.8	15.6	10.8	7.4
Hodgkin's disease	3.5	4.2	3.5	3.6	2.8	2.6	3.4	3.8	3.6	3.6	2.1	2.2
Non Hodgkin's lymphomas	10.4	9.7	9.8	11.2	10.7	10.3	9.0	9.4	11.2	12.1	8.7	5.3
Multiple myeloma	4.7	4.7	5.1	4.4	4.1	5.4	3.3	4.2	5.3	5.0	3.5	3.2
Leukemias	12.8	13.1	12.7	15.2	14.2	10.9	11.7	11.4	12.5	12.0	9.4	6.2
Lymphocytic	5.5	5.7	5.2	7.5	6.0	3.6	5.3	4.6	5.3	4.9	3.0	1.8
Acute lymphocytic	1.4	1.5	0.7	2.0	1.1	1.1	1.5	1.6	1.3	1.6	1.7	0.9
Chronic lymphocytic	3.8	4.0	4.2	5.2	4.6	2.4	3.6	2.4	3.8	3.0	1.1	0.8
Other lymphocytic	0.3	0.2	0.3	0.4	0.3	0.1	0.2	0.5	0.1	0.2	0.1	0.1
Granulocytic	5.4	5.4	5.2	5.7	6.1	5.6	5.0	4.8	5.1	5.3	5.4	3.2
Acute granulocytic	3.1	3.2	2.5	3.0	3.6	3.5	3.0	3.2	2.9	3.3	3.4	1.3
Chronic granulocytic	1.8	1.7	2.1	2.2	2.1	1.6	1.7	1.4	1.8	1.4	1.8	1.7
Other granulocytic	0.5	0.4	0.6	0.4	0.4	0.5	0.3	0.3	0.4	0.5	0.2	0.2
Monocytic	0.4	0.3	0.5	0.5	0.6	0.5	0.3	0.2	0.4	0.3	0.3	0.1
Acute monocytic	0.2	0.1	0.3	0.3	0.5	0.2	0.2	0.1	0.2	0.2	0.2	0.1
Chronic monocytic	0.0	0.1	0.0	0.1	.....	.....	0.0	.....	.....	0.0	0.1	.....
Other monocytic	0.1	0.0	0.2	0.2	0.1	0.3	.....	0.1	0.1	0.0	.....	.....
Other	1.6	1.8	1.8	1.4	1.5	1.2	1.2	1.8	1.8	1.5	0.7	1.1
Other acute	0.6	0.5	0.9	0.3	0.4	0.5	0.4	0.3	0.7	0.7	0.2	0.3
Other chronic	0.0	0.0	0.0	0.0	.....	.....	0.1	0.2	0.0	0.0	.....	0.0
Aleukemic, subleukemic, and NOS	1.0	1.2	0.9	1.1	1.1	0.7	0.7	1.3	1.0	0.8	0.6	0.8
Other, ill-defined, and unknown sites	14.0	16.9	13.6	11.9	16.9	15.4	10.8	14.2	14.8	13.6	11.6	11.6
IN SITU												
All sites	5.1	4.7	3.8	3.7	7.2	5.8	2.6	4.8	6.9	7.6	6.1	2.8
Buccal cavity and pharynx	0.4	0.3	0.2	0.2	0.6	0.1	0.5	0.6	0.7	0.5	0.6	0.4
Digestive system	2.4	2.4	1.8	1.8	2.7	3.8	0.8	1.5	3.8	3.1	3.5	0.4
Stomach	0.1	0.1	0.1	.....	.....	0.2	0.0	.....	0.1	0.1	0.6	0.1
Colon excluding rectum	1.3	1.2	0.9	0.9	1.6	2.0	0.2	0.9	2.1	1.8	1.5	0.1
Rectum and rectosigmoid	1.0	1.1	0.7	0.8	1.1	1.6	0.3	0.5	1.5	1.0	1.3	0.1
Anus, anal canal, and anorectum	0.1	0.0	0.0	.....	.....	0.1	0.1	.....	0.1	0.1	0.1	.....
Respiratory system	0.6	0.6	0.5	0.6	0.8	0.6	0.2	0.5	0.6	0.8	0.4	0.5
Larynx	0.5	0.5	0.4	0.5	0.6	0.6	0.2	0.3	0.5	0.7	0.4	0.4
Lung and bronchus	0.1	0.1	0.1	0.1	0.1	.....	.....	0.1	0.1	0.1	0.1	0.0
Melanomas of the skin	0.4	0.3	0.1	0.1	0.7	0.1	0.3	1.0	0.6	0.6	0.8	0.0
Breast	0.1	0.0	0.1	0.0	0.1	0.1	.....	0.1	0.1	0.0	.....	0.0
Male genital system	0.5	0.5	0.3	0.3	1.2	0.6	0.4	0.8	0.5	0.6	0.2	1.0
Prostate gland	0.2	0.4	0.1	0.2	0.4	0.3	0.1	0.6	0.1	0.2	0.1	0.8
Penis	0.2	0.1	0.1	0.2	0.8	0.3	0.3	0.2	0.4	0.4	0.1	0.2
Urinary system	0.8	0.5	0.7	0.6	1.0	0.4	0.1	0.3	0.5	1.8	0.5	0.1
Urinary bladder	0.7	0.4	0.6	0.6	0.8	0.2	.....	0.2	0.3	1.7	0.5	0.0

TABLE 2C — *Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for all races, females*

Primary site	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Puerto Rico 1973–77
MALIGNANT												
All sites	**304.1**	**315.1**	**293.3**	**280.8**	**299.5**	**277.6**	**286.3**	**257.8**	**327.2**	**347.0**	**278.1**	**173.6**
Buccal cavity and pharynx	**6.2**	**5.7**	**5.5**	**4.0**	**7.8**	**7.0**	**4.8**	**5.5**	**7.5**	**8.7**	**7.4**	**7.5**
Lip	0.3	0.3	0.2	0.1	0.4	0.1	0.7	1.3	0.4	0.4	0.2	0.4
Tongue	1.2	1.1	1.1	0.9	1.2	1.2	1.0	0.9	1.6	1.7	1.4	2.1
Major salivary gland	0.8	0.8	0.8	0.7	0.6	1.2	0.5	1.1	0.7	0.9	0.9	0.4
Floor of mouth	0.7	0.7	0.6	0.4	0.9	0.6	0.3	0.6	0.7	1.2	0.9	0.4
Gum and other mouth	1.4	1.3	1.3	0.9	2.2	1.9	0.8	0.8	1.9	1.7	1.9	2.3
Nasopharynx	0.3	0.3	0.3	0.2	0.4	0.3	0.4	0.2	0.5	0.5	0.6	0.3
Tonsil	0.7	0.6	0.6	0.5	0.9	0.9	0.3	0.3	0.8	1.1	1.0	0.7
Oropharynx	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.0	0.3	0.2	0.2	0.1
Hypopharynx	0.4	0.3	0.3	0.3	0.9	0.4	0.5	0.2	0.4	0.7	0.3	0.6
Pharynx and other buccal cavity	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.3	0.1	0.1	0.3
Digestive system	**65.8**	**74.0**	**63.7**	**64.1**	**60.3**	**62.9**	**65.0**	**49.2**	**63.6**	**70.0**	**67.4**	**47.9**
Esophagus	1.9	2.2	2.3	1.1	1.7	1.5	1.4	0.5	1.6	2.6	1.6	6.8
Stomach	6.4	7.0	6.5	4.2	5.1	6.8	7.6	4.8	5.3	7.5	14.8	12.6
Small intestine	0.8	0.8	0.7	0.7	1.0	0.5	1.1	1.0	0.7	0.7	0.8	0.8
Colon excluding rectum	31.3	35.8	29.0	34.5	29.6	29.1	26.0	22.8	31.2	32.6	23.0	10.2
Cecum	6.7	7.2	6.3	7.6	7.3	4.9	6.5	4.6	6.9	7.2	3.7	1.8
Appendix	0.3	0.2	0.2	0.3	0.6	0.3	0.4	0.3	1.0	0.3	0.0	0.1
Ascending colon	4.0	4.6	3.7	4.5	3.0	4.1	2.7	1.9	3.7	4.5	2.8	1.3
Hepatic flexure	0.9	0.9	0.9	0.8	0.8	1.5	1.3	0.6	1.0	0.5	1.2	0.1
Transverse colon	3.9	4.6	3.5	4.7	3.6	3.2	2.3	1.8	3.6	4.4	2.6	1.1
Splenic flexure	0.8	1.1	0.8	0.8	0.9	1.4	0.4	0.4	1.0	0.5	1.1	0.1
Descending colon	2.6	2.7	2.5	2.8	2.8	2.6	2.0	1.9	2.2	2.7	2.3	0.9
Sigmoid colon	10.5	13.0	9.1	11.2	9.1	8.2	8.5	8.4	10.5	11.3	8.5	3.3
Large intestine, NOS	1.7	1.7	2.0	1.7	1.5	2.8	1.8	3.0	1.2	1.2	0.7	1.5
Rectum and rectosigmoid	11.7	14.2	11.3	11.7	9.5	9.9	9.2	9.2	11.6	11.9	11.0	5.9
Rectosigmoid junction	4.0	5.1	3.9	3.6	4.8	2.8	2.7	2.9	3.9	3.9	5.1	1.2
Rectum	7.7	9.2	7.4	8.1	4.6	7.1	6.5	6.2	7.7	8.0	5.9	4.7
Anus, anal canal, and anorectum	0.7	0.6	0.7	0.5	1.0	1.0	0.4	0.5	1.0	1.0	0.8	0.9
Liver	1.3	1.2	1.5	1.1	1.1	1.4	2.2	1.1	1.0	1.3	3.2	2.7
Gallbladder	1.8	1.6	1.9	1.8	1.1	1.7	4.7	1.6	1.5	1.5	1.6	2.2
Other biliary	1.1	1.3	1.0	0.9	0.9	0.9	1.3	1.0	1.0	1.3	2.9	1.1
Pancreas	8.0	8.7	7.8	6.9	8.2	9.3	10.3	5.9	7.2	8.9	7.0	4.0
Retroperitoneum	0.4	0.2	0.4	0.3	0.7	0.3	0.2	0.7	0.4	0.5	0.3	0.3
Peritoneum	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.0	0.3	0.1	0.0	0.1
Other digestive organs	0.3	0.2	0.2	0.2	0.4	0.4	0.4	0.2	0.9	0.0	0.1	0.3
Respiratory system	**24.4**	**24.1**	**25.0**	**16.3**	**23.5**	**30.0**	**22.8**	**10.1**	**28.9**	**32.5**	**26.8**	**9.6**
Nasal cavity, sinuses, and ear	0.5	0.5	0.4	0.4	0.7	0.6	0.4	0.5	0.6	0.4	0.8	0.5
Larynx	1.3	1.4	1.6	0.9	1.1	1.8	0.8	0.7	1.4	1.8	0.9	1.9
Lung and bronchus	22.2	21.8	22.7	14.6	21.5	27.5	21.3	8.5	26.5	29.8	25.1	7.1
Trachea, pleura, mediastinum, and other	0.3	0.4	0.3	0.3	0.3	0.1	0.3	0.4	0.4	0.5	.....	0.1
Bones and joints	**0.6**	**0.6**	**0.5**	**0.7**	**0.8**	**0.6**	**0.6**	**0.9**	**0.7**	**0.6**	**0.6**	**0.5**
Soft tissues (including heart)	**1.6**	**1.4**	**1.4**	**1.3**	**1.8**	**1.4**	**2.1**	**1.8**	**2.1**	**1.8**	**1.6**	**1.1**
Skin (excluding basal and squamous carcinoma)	**6.3**	**6.0**	**3.8**	**5.4**	**8.5**	**4.6**	**7.7**	**9.4**	**7.4**	**8.8**	**3.1**	**1.4**
Melanomas of the skin	5.8	5.6	3.2	5.1	8.0	3.8	7.1	8.5	6.9	8.2	2.7	0.9
Other skin cancers	0.5	0.4	0.6	0.3	0.5	0.6	0.6	0.9	0.5	0.6	0.4	0.5
Breast	**85.4**	**91.8**	**81.7**	**80.6**	**87.3**	**76.2**	**75.6**	**74.7**	**89.3**	**96.0**	**70.6**	**33.6**
Female genital system	**58.9**	**51.7**	**59.0**	**55.6**	**56.7**	**39.8**	**55.6**	**51.1**	**71.2**	**72.4**	**51.9**	**39.2**
Cervix uteri	12.4	9.2	14.2	12.8	14.4	14.1	17.3	8.2	11.8	12.9	11.1	21.0
Corpus uteri	29.0	25.2	26.4	24.7	25.7	12.9	21.1	25.6	41.9	40.6	30.3	7.4
Uterus, NOS	0.7	0.8	1.3	0.8	0.5	0.4	1.0	1.2	0.4	0.1	.....	1.2
Ovary	13.8	13.8	14.0	14.3	11.9	9.6	13.4	13.7	13.9	15.7	9.3	5.9
Vagina	0.7	0.5	0.8	0.6	1.6	0.7	0.6	0.5	0.7	0.7	0.4	0.8
Vulva	1.6	1.6	1.8	1.8	1.3	1.6	1.6	1.3	1.5	1.7	0.5	2.5
Other female genital organs	0.7	0.6	0.5	0.5	1.2	0.6	0.6	0.5	1.1	0.9	0.3	0.4

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/19

Urinary system	**11.9**	**13.3**	**12.6**	**11.2**	**10.5**	**12.7**	**11.3**	**10.1**	**12.4**	**11.6**	**8.7**	**5.2**
Urinary bladder	7.0	7.9	7.0	6.2	6.1	7.8	5.8	5.9	7.5	7.3	5.1	3.7
Kidney and renal pelvis	4.4	4.8	5.0	4.6	3.9	4.5	4.7	3.5	4.3	3.8	3.4	1.2
Ureter	0.3	0.4	0.4	0.2	0.2	0.4	0.4	0.5	0.3	0.3	0.2	0.1
Other urinary organs	0.2	0.2	0.2	0.1	0.2	0.1	0.4	0.2	0.3	0.2	0.1	0.1
Eye	**0.7**	**0.5**	**0.6**	**0.9**	**0.8**	**0.8**	**0.6**	**1.2**	**0.8**	**0.6**	**0.3**	**0.5**
Brain and other nervous system	**4.4**	**4.4**	**4.0**	**4.2**	**4.5**	**4.5**	**3.1**	**4.8**	**5.5**	**5.0**	**3.0**	**1.8**
Brain	4.1	4.2	3.8	3.8	4.3	4.1	2.8	4.7	5.2	4.6	2.9	1.6
Other nervous system	0.2	0.2	0.2	0.4	0.3	0.4	0.2	0.2	0.2	0.3	0.1	0.1
Endocrine system	**5.8**	**4.8**	**5.6**	**4.5**	**6.4**	**4.8**	**6.9**	**6.7**	**4.9**	**7.3**	**10.8**	**3.2**
Thyroid gland	5.5	4.4	5.3	4.2	6.3	4.6	6.6	6.5	4.6	6.9	10.5	3.1
Other endocrine (including thymus)	0.3	0.4	0.3	0.3	0.1	0.1	0.2	0.2	0.3	0.4	0.3	0.1
Lymphomas	**10.3**	**11.1**	**9.4**	**11.5**	**8.4**	**9.0**	**9.8**	**10.6**	**10.8**	**10.7**	**7.9**	**5.0**
Hodgkin's disease	2.4	2.9	2.2	2.5	2.2	1.9	2.2	2.1	2.3	2.6	1.3	1.5
Non-Hodgkin's lymphomas	7.9	8.1	7.1	9.0	6.2	7.1	7.6	8.5	8.5	8.0	6.6	3.5
Multiple myeloma	**3.3**	**3.6**	**3.4**	**3.2**	**3.7**	**3.8**	**2.7**	**2.7**	**3.3**	**3.3**	**3.0**	**2.4**
Leukemias	**7.7**	**8.1**	**7.4**	**8.4**	**7.4**	**6.4**	**7.3**	**7.0**	**7.3**	**7.8**	**6.8**	**4.4**
Lymphocytic	3.0	3.2	2.5	3.9	2.9	1.9	3.3	2.4	2.9	3.2	2.2	1.4
Acute lymphocytic	0.9	1.0	0.5	1.0	1.0	0.5	0.9	1.0	1.1	1.2	1.4	0.9
Chronic lymphocytic	2.0	2.0	1.9	2.6	1.7	1.4	2.2	1.3	1.7	1.9	0.7	0.4
Other lymphocytic	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1
Granulocytic	3.6	3.6	3.4	3.8	3.6	3.8	2.7	3.4	3.6	3.8	3.6	2.2
Acute granulocytic	2.2	2.5	1.8	2.2	2.4	2.3	1.4	1.8	2.5	2.5	2.6	1.1
Chronic granulocytic	1.1	0.9	1.2	1.3	1.1	1.3	1.0	1.5	0.7	0.8	0.8	1.0
Other granulocytic	0.3	0.2	0.4	0.3	0.1	0.2	0.3	0.2	0.4	0.4	0.3	0.1
Monocytic	0.2	0.2	0.3	0.2	0.3	0.5	0.2	0.3	0.1	0.1	0.3	0.1
Acute monocytic	0.2	0.1	0.2	0.2	0.2	0.1	0.2	0.2	0.0	0.1	0.2	0.0
Chronic monocytic	0.0	0.0	0.0	0.0	.....	.....	.....	.....	0.0	.....	.....	.....
Other monocytic	0.1	0.1	0.1	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.1	0.0
Other	0.8	1.0	1.1	0.5	0.6	0.3	0.9	0.9	0.8	0.7	0.7	0.7
Other acute	0.4	0.4	0.6	0.1	0.3	0.2	0.3	0.2	0.4	0.4	0.3	0.2
Other chronic	0.0	0.0	0.0	0.0	.....	0.0	0.1	0.1	0.0	0.0	.....	0.0
Aleukemic, subleukemic, and NOS	0.4	0.6	0.5	0.4	0.3	0.1	0.5	0.6	0.3	0.3	0.4	0.5
Other, ill-defined, and unknown sites	**10.8**	**14.0**	**9.8**	**9.0**	**11.0**	**13.1**	**10.7**	**11.8**	**11.3**	**10.2**	**8.5**	**10.3**
IN SITU												
All sites	**47.5**	**37.5**	**44.9**	**41.1**	**74.6**	**33.4**	**50.8**	**33.3**	**75.1**	**53.9**	**34.2**	**29.8**
Buccal cavity and pharynx	**0.1**	**0.2**	**0.1**	**0.1**	**0.2**	**0.2**	**0.0**	**0.2**	**0.2**	**0.2**	**0.1**	**0.2**
Digestive system	**1.6**	**1.5**	**1.0**	**1.2**	**1.9**	**3.2**	**1.0**	**0.8**	**2.2**	**2.0**	**3.0**	**0.3**
Stomach	0.0	0.1	0.0	0.0	0.1	.....	.....	0.0	.....	0.0	0.3	0.0
Colon excluding rectum	0.8	0.7	0.5	0.5	1.2	2.0	0.4	0.5	1.2	1.1	1.0	0.1
Rectum and rectosigmoid	0.6	0.6	0.3	0.5	0.6	1.1	0.3	0.3	0.9	0.7	1.4	0.0
Anus, anal canal, and anorectum	0.1	0.0	0.1	0.0	0.1	0.0	0.1	.....	0.1	0.1	0.2	0.1
Respiratory system	**0.1**	**0.1**	**0.1**	**0.1**	**0.2**	**0.3**	**0.1**	**0.2**	**0.1**	**0.2**	**0.1**	**0.0**
Larynx	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.0
Lung and bronchus	0.0	.....	.....	.....	0.0	0.0	.....	0.0	.....	0.0	.....	0.0
Melanomas of the skin	**0.3**	**0.4**	**0.1**	**0.1**	**0.5**	**0.0**	**0.3**	**0.7**	**0.6**	**0.6**	**0.3**	**0.0**
Breast	**4.4**	**3.3**	**3.7**	**3.0**	**8.0**	**3.0**	**3.2**	**5.8**	**4.8**	**5.7**	**8.3**	**1.9**
Female genital system	**40.7**	**32.0**	**39.8**	**36.5**	**63.6**	**26.3**	**46.0**	**25.7**	**67.1**	**44.6**	**22.3**	**27.3**
Cervix uteri	36.5	29.2	35.7	34.1	57.5	23.6	43.3	21.3	60.7	38.1	16.5	26.5
Corpus uteri	2.7	1.9	2.4	1.7	2.4	1.3	1.3	3.3	4.0	4.3	4.7	0.3
Vagina	0.3	0.2	0.4	0.2	1.1	0.3	0.5	0.2	0.4	0.4	0.2	0.2
Vulva	1.1	0.6	1.2	0.6	2.3	1.0	0.8	0.5	1.9	1.7	0.9	0.3
Urinary system	**0.2**	**0.1**	**0.2**	**0.1**	**0.1**	**0.1**	**0.2**	**0.0**	**0.1**	**0.7**	**0.0**	.....
Urinary bladder	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.1	0.6	0.0	.....

MALIGNANT														
All sites	**325.7**	**337.7**	**321.1**	**305.5**	**327.4**	**322.0**	**308.3**	**271.9**	**333.3**	**358.4**	**362.0**	**345.3**	**233.2**	**200.4**
Buccal cavity and pharynx	**10.7**	**10.9**	**9.2**	**9.1**	**12.5**	**13.1**	**9.5**	**10.2**	**10.9**	**13.3**	**18.6**	**11.6**	**5.2**	**17.1**
Lip	1.9	1.0	1.0	2.5	1.3	1.5	3.4	4.8	1.7	2.0	2.4	4.6	1.1	0.9
Tongue	2.0	2.4	1.9	1.2	2.1	2.4	1.5	1.3	2.0	2.6	2.2	1.9	0.6	4.7
Major salivary gland	0.9	0.8	0.8	0.9	0.8	1.1	0.9	1.1	0.8	1.0	1.9	0.9	0.9	0.6
Floor of mouth	1.2	1.4	1.1	0.9	1.2	1.6	0.7	0.7	1.3	1.8	2.3	0.8	0.4	1.4
Gum and other mouth	1.7	2.1	1.6	1.1	2.7	2.3	1.1	0.9	1.9	2.0	3.1	1.3	0.7	3.7
Nasopharynx	0.4	0.4	0.5	0.4	0.6	0.7	0.4	0.3	0.5	0.5	0.6	0.4	0.4	0.5
Tonsil	1.0	1.1	0.9	0.7	1.3	1.4	0.6	0.5	1.0	1.5	2.4	0.8	0.2	2.0
Oropharynx	0.3	0.3	0.2	0.2	0.3	0.5	0.1	0.2	0.3	0.5	1.3	0.1	0.2	0.3
Hypopharynx	0.9	1.0	0.8	0.8	1.4	1.1	0.6	0.4	1.0	1.2	1.8	0.6	0.7	2.5
Pharynx and other buccal cavity	0.3	0.4	0.3	0.2	0.7	0.4	0.2	0.1	0.5	0.2	0.5	0.3	0.1	0.6
Digestive system	**75.9**	**86.9**	**76.4**	**73.2**	**66.8**	**71.5**	**70.9**	**55.9**	**70.3**	**80.9**	**74.1**	**70.9**	**73.1**	**62.9**
Esophagus	3.0	3.7	3.7	2.3	2.5	2.3	2.1	1.6	2.6	3.6	2.7	2.2	2.0	1.8
Stomach	8.6	10.0	9.5	6.7	5.3	6.8	10.9	6.9	7.6	10.0	11.2	7.4	18.4	20.3
Small intestine	0.8	0.8	0.8	0.9	0.8	0.7	0.9	1.0	0.8	0.7	0.6	1.1	0.5	0.8
Colon excluding rectum	33.2	38.8	32.2	34.4	30.6	30.9	26.1	24.0	30.7	35.1	28.7	31.0	16.1	10.1
Cecum	6.8	7.6	6.5	7.1	7.1	5.4	6.0	4.7	6.8	7.4	5.8	7.4	3.1	1.8
Appendix	0.3	0.2	0.2	0.3	0.6	0.3	0.4	0.2	0.7	0.3	0.1	0.5	0.3	0.1
Ascending colon	4.1	4.6	4.2	4.3	3.0	3.4	2.7	2.3	3.5	4.8	3.5	3.1	1.8	1.4
Hepatic flexure	0.9	1.0	0.9	0.8	1.1	1.4	1.1	0.5	1.1	0.6	2.0	1.4	0.5	0.1
Transverse colon	3.9	4.8	3.5	4.4	3.8	3.6	2.5	2.0	3.4	4.7	2.9	2.8	1.7	1.0
Splenic flexure	1.0	1.4	1.0	0.9	1.1	1.5	0.6	0.4	1.1	0.6	0.7	0.8	0.2	0.1
Descending colon	2.7	3.0	2.7	2.9	2.9	2.6	2.0	1.9	2.2	2.8	3.3	2.3	1.4	0.9
Sigmoid colon	11.8	14.4	11.3	11.9	9.8	10.1	8.8	8.9	10.5	12.5	9.7	10.4	5.7	3.2
Large intestine, NOS	1.8	1.9	2.0	1.8	1.1	2.7	2.0	3.1	1.3	1.4	0.6	2.3	1.3	1.4
Rectum and rectosigmoid	14.7	17.7	14.8	14.9	11.1	13.7	10.8	10.3	14.0	14.9	13.5	12.2	8.0	6.7
Rectosigmoid junction	4.7	6.2	4.7	4.0	5.1	4.6	3.0	2.7	4.5	4.7	5.4	3.3	2.5	1.4
Rectum	10.0	11.5	10.1	10.9	6.0	9.2	7.8	7.6	9.5	10.2	8.1	8.9	5.5	5.3
Anus, anal canal, and anorectum	0.6	0.5	0.6	0.4	0.9	0.6	0.3	0.5	0.8	0.9	0.9	0.4	0.2	0.7
Liver	1.8	1.7	2.1	1.5	1.7	2.2	2.5	1.1	1.4	2.1	2.4	2.2	3.0	3.9
Gallbladder	1.4	1.4	1.7	1.5	1.0	1.2	2.9	1.3	1.2	1.2	0.6	1.5	5.9	1.7
Other biliary	1.3	1.4	1.3	1.1	1.5	1.1	1.5	1.0	1.2	1.6	2.6	1.4	1.7	1.1
Pancreas	9.5	10.1	9.0	8.9	10.6	10.8	11.9	7.4	8.6	10.1	9.9	10.7	14.5	5.2
Retroperitoneum	0.4	0.3	0.4	0.4	0.4	0.4	0.3	0.7	0.4	0.6	0.6	0.4	0.3	0.2
Peritoneum	0.2	0.1	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.1	—	0.1	0.2	0.1
Other digestive organs	0.3	0.3	0.2	0.2	0.2	0.4	0.5	0.2	0.9	0.1	0.2	0.5	0.3	0.4
Respiratory system	**51.1**	**50.9**	**54.2**	**45.1**	**55.5**	**67.5**	**45.2**	**27.0**	**54.3**	**57.8**	**59.7**	**54.9**	**25.3**	**19.8**
Nasal cavity, sinuses, and ear	0.6	0.6	0.6	0.5	0.9	0.9	0.5	0.5	0.8	0.6	0.3	0.4	0.5	0.8
Larynx	4.4	4.9	5.0	3.9	4.2	5.6	3.7	2.6	4.1	4.8	5.5	4.6	1.9	5.1
Lung and bronchus	45.4	44.9	48.0	40.2	49.7	60.1	40.3	23.3	48.5	51.4	53.4	49.0	22.3	13.7
Trachea, pleura, mediastinum, and other	0.7	0.6	0.6	0.5	0.7	0.9	0.8	0.7	1.0	1.0	0.5	0.8	0.5	0.2
Bones and joints	**0.8**	**0.7**	**0.6**	**0.8**	**1.0**	**0.7**	**0.8**	**1.0**	**0.9**	**0.9**	**0.8**	**0.9**	**0.6**	**0.6**
Soft tissues (including heart)	**1.9**	**1.7**	**1.6**	**1.8**	**1.7**	**1.9**	**2.6**	**2.0**	**2.1**	**2.1**	**3.5**	**3.0**	**1.6**	**1.3**
Skin (excluding basal and squamous carcinoma)	**6.8**	**6.5**	**4.7**	**5.3**	**9.5**	**6.9**	**8.0**	**7.4**	**7.2**	**9.6**	**10.1**	**10.9**	**2.6**	**1.5**
Melanomas of the skin	6.3	6.1	4.1	5.0	9.2	6.2	7.2	6.8	6.7	8.8	10.0	10.2	1.9	0.9
Other skin cancers	0.5	0.4	0.6	0.3	0.3	0.6	0.7	0.6	0.5	0.7	0.1	0.7	0.7	0.6
Breast	**46.9**	**50.1**	**45.4**	**43.7**	**50.1**	**44.3**	**41.8**	**39.5**	**45.2**	**53.4**	**51.7**	**50.2**	**24.7**	**17.4**
Female genital system	**31.5**	**27.6**	**31.8**	**29.6**	**30.1**	**20.0**	**29.6**	**26.3**	**36.1**	**40.0**	**31.9**	**32.2**	**24.1**	**20.1**
Cervix uteri	5.8	4.5	6.1	6.6	5.4	5.3	8.9	4.1	5.6	6.0	4.9	7.3	12.1	10.7
Corpus uteri	16.1	13.7	15.4	13.3	15.1	7.1	11.6	13.3	21.3	23.4	20.8	14.9	4.7	3.8
Uterus, NOS	0.4	0.4	0.7	0.4	0.1	0.2	0.6	0.6	0.2	0.0	—	0.6	0.5	0.6
Ovary	7.7	7.5	7.9	7.7	7.2	5.9	7.1	7.2	7.2	8.8	5.2	7.7	5.9	3.0
Vagina	0.3	0.2	0.4	0.3	0.8	0.3	0.3	0.3	0.4	0.3	0.1	0.4	0.1	0.4
Vulva	0.9	0.9	1.1	1.0	0.6	0.9	0.9	0.7	0.8	0.9	0.4	1.0	0.5	1.3
Other female genital organs	0.4	0.3	0.2	0.3	0.8	0.4	0.3	0.2	0.6	0.5	0.3	0.4	0.1	0.2

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/21

Male genital system	**28.9**	**26.4**	**26.6**	**27.6**	**29.0**	**22.3**	**34.1**	**36.9**	**34.7**	**28.9**	**38.7**	**36.0**	**30.1**	**20.2**
Prostate gland	26.7	24.3	24.5	25.4	26.9	20.4	31.8	34.3	32.4	26.6	35.6	33.6	27.9	17.4
Testis	1.8	1.7	1.6	1.7	1.8	1.5	1.7	2.2	1.9	1.9	2.5	2.0	1.3	0.2
Penis	0.4	0.4	0.4	0.4	0.3	0.3	0.6	0.4	0.3	0.3	0.4	0.4	0.8	2.5
Other male genital organs	0.1	0.1	0.2	0.1	.....	0.1	0.1	.....	0.1	0.0	0.2	0.1	0.1	0.1
Urinary system	**22.9**	**24.9**	**24.0**	**21.7**	**21.9**	**26.2**	**20.4**	**18.8**	**23.4**	**22.3**	**24.7**	**24.2**	**12.4**	**9.5**
Urinary bladder	15.5	17.1	16.2	14.4	14.1	17.9	12.5	12.9	15.8	15.4	16.7	15.7	5.9	7.5
Kidney and renal pelvis	6.6	6.9	6.9	6.5	6.6	7.3	7.0	5.3	6.6	6.1	7.3	7.6	5.8	1.7
Ureter	0.6	0.7	0.5	0.6	0.7	0.8	0.5	0.4	0.5	0.5	0.5	0.5	0.4	0.1
Other urinary organs	0.3	0.2	0.3	0.2	0.5	0.3	0.3	0.1	0.4	0.3	0.2	0.4	0.3	0.1
Eye	**0.8**	**0.5**	**0.7**	**1.0**	**1.2**	**0.9**	**0.9**	**1.3**	**0.7**	**0.7**	**0.7**	**1.0**	**0.7**	**0.6**
Brain and other nervous system	**5.6**	**5.8**	**5.2**	**5.3**	**6.4**	**6.0**	**4.6**	**5.2**	**6.4**	**6.0**	**5.7**	**5.6**	**2.9**	**2.1**
Brain	5.3	5.4	5.0	5.0	5.9	5.6	4.3	5.1	6.0	5.7	5.5	5.2	2.7	1.9
Other nervous system	0.3	0.3	0.2	0.3	0.4	0.4	0.3	0.1	0.4	0.3	0.2	0.4	0.2	0.1
Endocrine system	**4.3**	**3.6**	**4.5**	**3.3**	**4.9**	**4.4**	**5.6**	**4.6**	**3.5**	**5.3**	**5.9**	**5.5**	**5.9**	**2.2**
Thyroid gland	3.9	3.2	4.0	3.0	4.7	3.8	5.3	4.3	3.1	4.8	5.2	5.1	5.7	2.1
Other endocrine (including thymus)	0.4	0.4	0.4	0.4	0.2	0.5	0.4	0.3	0.4	0.4	0.7	0.4	0.2	0.1
Lymphomas	**12.3**	**12.3**	**11.8**	**13.0**	**11.8**	**12.0**	**11.6**	**11.6**	**12.3**	**13.2**	**10.8**	**13.3**	**8.3**	**6.2**
Hodgkin's disease	3.1	3.6	2.9	3.0	2.7	2.8	3.0	2.9	2.9	3.3	2.2	3.3	2.5	1.8
Non-Hodgkin's lymphomas	9.3	8.8	8.8	10.0	9.0	9.3	8.6	8.6	9.5	9.9	8.6	10.0	5.9	4.4
Multiple myeloma	**3.5**	**3.8**	**3.5**	**3.7**	**3.3**	**3.2**	**2.8**	**3.1**	**3.7**	**3.4**	**2.8**	**3.1**	**2.3**	**2.8**
Leukemias	**9.9**	**10.1**	**9.8**	**11.2**	**10.2**	**8.4**	**9.5**	**8.9**	**9.3**	**9.5**	**9.4**	**10.9**	**6.3**	**5.3**
Lymphocytic	4.2	4.2	3.7	5.4	3.9	2.6	4.3	3.4	3.8	4.0	3.8	5.0	2.7	1.6
Acute lymphocytic	1.2	1.3	0.7	1.5	1.2	0.8	1.2	1.3	1.1	1.5	1.3	1.2	1.0	0.9
Chronic lymphocytic	2.8	2.8	2.8	3.7	2.5	1.8	3.0	1.7	2.6	2.4	2.2	3.7	1.4	0.6
Other lymphocytic	0.2	0.2	0.2	0.3	0.2	0.0	0.1	0.3	0.1	0.2	0.3	0.0	0.3	0.1
Granulocytic	4.3	4.3	4.2	4.6	4.9	4.6	3.9	4.0	4.1	4.3	4.5	4.5	2.6	2.7
Acute granulocytic	2.6	2.8	2.3	2.6	3.1	2.8	2.2	2.4	2.6	2.8	3.6	2.7	1.3	1.2
Chronic granulocytic	1.4	1.2	1.5	1.7	1.6	1.4	1.3	1.4	1.1	1.1	0.8	1.4	1.2	1.3
Other granulocytic	0.4	0.3	0.4	0.3	0.2	0.4	0.3	0.2	0.4	0.4	.....	0.4	0.2	0.1
Monocytic	0.3	0.3	0.4	0.4	0.4	0.5	0.2	0.2	0.2	0.2	0.1	0.3	0.1	0.1
Acute monocytic	0.2	0.1	0.2	0.2	0.4	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.1
Chronic monocytic	0.0	0.1	0.0	0.0	.....	.....	0.0	.....	0.0	0.0	.....	0.0	.....	.....
Other monocytic	0.1	0.1	0.1	0.1	0.0	0.3	0.0	0.1	0.1	0.0	.....	0.0	.....	0.0
Other	1.2	1.3	1.5	0.9	0.9	0.7	1.1	1.3	1.1	1.0	1.0	1.2	0.8	0.9
Other acute	0.5	0.5	0.8	0.2	0.2	0.4	0.4	0.3	0.5	0.5	0.2	0.4	0.2	0.3
Other chronic	0.0	0.0	0.0	0.0	.....	0.0	0.1	0.1	0.0	0.0	.....	0.1	0.1	0.0
Aleukemic, subleukemic, and NOS	0.7	0.9	0.7	0.7	0.7	0.3	0.6	0.9	0.6	0.6	0.8	0.7	0.5	0.6
Other, ill-defined, and unknown sites	**11.8**	**14.8**	**11.1**	**10.3**	**11.6**	**12.8**	**10.4**	**12.3**	**12.2**	**11.1**	**12.9**	**11.1**	**9.3**	**10.9**
IN SITU														
All sites	**24.3**	**19.8**	**20.7**	**22.2**	**33.7**	**19.6**	**27.1**	**17.9**	**35.5**	**28.7**	**26.9**	**28.8**	**24.3**	**16.9**
Buccal cavity and pharynx	**0.2**	**0.2**	**0.1**	**0.1**	**0.4**	**0.2**	**0.3**	**0.3**	**0.3**	**0.4**	**0.6**	**0.4**	**0.2**	**0.3**
Digestive system	**1.8**	**1.8**	**1.2**	**1.4**	**1.9**	**3.7**	**0.9**	**1.0**	**2.5**	**2.4**	**4.6**	**1.1**	**0.4**	**0.4**
Stomach	0.0	0.1	0.0	0.0	.....	0.0	0.0	0.0	0.0	0.1	0.2	.....	0.1	0.1
Colon excluding rectum	1.0	0.9	0.6	0.7	1.0	2.2	0.3	0.6	1.4	1.4	2.2	0.4	.....	0.1
Rectum and rectosigmoid	0.7	0.8	0.5	0.6	0.8	1.4	0.4	0.3	1.0	0.8	2.1	0.5	0.1	0.1
Anus, anal canal, and anorectum	0.0	0.0	0.0	0.0	0.0	0.1	0.1	.....	0.1	0.1	0.2	0.1	.....	0.0
Respiratory system	**0.3**	**0.3**	**0.3**	**0.3**	**0.4**	**0.4**	**0.2**	**0.3**	**0.3**	**0.4**	**0.2**	**0.2**	**0.1**	**0.3**
Larynx	0.3	0.3	0.3	0.2	0.3	0.4	0.2	0.2	0.3	0.4	0.2	0.2	0.1	0.2
Lung and bronchus	0.0	0.0	0.0	0.1	0.0	0.0	.....	0.0	0.0	0.1	.....	.....	.....	0.0
Melanomas of the skin	**0.3**	**0.3**	**0.1**	**0.1**	**0.7**	**0.1**	**0.3**	**0.4**	**0.5**	**0.6**	**1.7**	**0.4**	**0.1**	**0.0**
Breast	**2.3**	**1.8**	**2.0**	**1.6**	**4.9**	**1.7**	**1.7**	**3.0**	**2.3**	**3.2**	**4.3**	**2.2**	**0.8**	**1.0**
Female genital system	**18.6**	**14.8**	**16.3**	**18.1**	**24.5**	**12.7**	**23.2**	**12.4**	**29.1**	**20.2**	**14.8**	**24.1**	**22.1**	**14.2**
Cervix uteri	16.4	13.4	14.0	16.9	21.1	11.2	21.8	10.2	25.9	16.8	10.2	22.3	21.4	13.8
Corpus uteri	1.4	1.0	1.4	0.9	1.5	0.7	0.7	1.6	2.0	2.4	3.4	0.9	0.4	0.1
Vagina	0.2	0.1	0.2	0.1	0.6	0.1	0.3	0.1	0.2	0.2	0.3	0.3	0.2	0.1
Vulva	0.6	0.3	0.6	0.3	1.3	0.6	0.4	0.2	0.9	0.9	1.0	0.6	0.1	0.1
Male genital system	**0.2**	**0.2**	**0.1**	**0.1**	**0.4**	**0.3**	**0.2**	**0.3**	**0.2**	**0.2**	**0.2**	**0.1**	**0.4**	**0.5**
Prostate gland	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.1	.....	0.0	0.1	0.4
Penis	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.3	0.1
Urinary system	**0.5**	**0.3**	**0.5**	**0.4**	**0.6**	**0.3**	**0.2**	**0.2**	**0.3**	**1.3**	**0.4**	**0.2**	**0.2**	**0.0**
Urinary bladder	0.4	0.2	0.5	0.3	0.5	0.3	0.0	0.1	0.2	1.1	0.4	0.0	0.1	0.0

TABLE 21. *Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for white,[1] Anglo, and Hispanic males*

Primary site	White											Anglo	Hispanic	
	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	New Mexico 1973–77	New Mexico 1973–77	Puerto Rico 1973–77
MALIGNANT														
All sites	371.6	386.7	371.1	352.6	388.8	412.4	331.1	308.4	377.9	395.0	431.7	384.8	229.5	229.2
Buccal cavity and pharynx	16.8	18.2	14.1	15.5	19.5	22.3	14.6	16.6	15.4	19.6	25.9	18.5	7.3	27.1
Lip	3.9	2.1	2.1	5.7	2.5	3.6	6.4	9.3	3.4	4.1	4.9	8.9	1.9	1.5
Tongue	2.9	4.0	3.0	1.6	3.3	4.6	1.9	2.0	2.7	3.6	2.2	2.6	0.6	7.4
Major salivary gland	1.1	1.0	0.8	1.2	1.2	0.9	1.1	1.1	1.0	1.2	3.0	1.1	1.2	0.7
Floor of mouth	1.9	2.5	1.7	1.5	1.4	2.9	1.1	0.9	1.9	2.4	3.4	1.3	0.8	2.3
Gum and other mouth	2.3	3.3	2.0	1.9	3.1	3.6	1.4	1.0	2.0	2.4	3.3	1.6	1.0	5.2
Nasopharynx	0.7	0.6	0.7	0.5	1.0	1.3	0.5	0.3	0.6	0.8	1.1	0.4	0.5	0.7
Tonsil	1.5	1.9	1.5	1.0	2.2	1.9	0.8	0.8	1.2	2.0	2.4	1.1	0.3	3.3
Oropharynx	0.5	0.4	0.4	0.4	0.5	0.7	0.2	0.3	0.3	0.7	2.3	0.3	—	0.6
Hypopharynx	1.6	1.8	1.5	1.4	2.9	1.9	0.8	0.7	1.6	1.9	2.5	0.7	0.9	4.4
Pharynx and other buccal cavity	0.5	0.6	0.4	0.4	1.4	0.8	0.3	0.2	0.7	0.2	0.9	0.5	—	0.9
Digestive system	92.6	106.3	97.1	86.5	81.3	93.8	78.1	66.3	85.1	100.2	90.2	80.4	73.6	78.6
Esophagus	4.8	6.0	6.1	3.8	4.0	4.6	2.8	3.0	3.9	5.2	3.1	3.2	2.2	17.0
Stomach	12.7	14.3	14.1	10.1	7.4	9.8	15.0	10.1	11.4	14.7	15.6	10.0	24.2	28.4
Small intestine	0.9	1.0	1.0	1.1	0.9	1.1	0.7	1.0	0.9	0.8	1.4	0.9	0.3	0.9
Colon excluding rectum	36.7	43.7	37.7	35.2	33.1	37.1	25.1	26.4	33.2	39.7	33.8	31.0	14.3	9.8
Cecum	7.0	8.3	6.9	6.5	6.3	6.1	5.1	4.7	7.1	7.8	6.2	6.2	3.2	1.9
Appendix	0.3	0.3	0.2	0.2	0.4	0.2	0.3	0.2	0.4	0.3	0.1	0.4	0.4	0.1
Ascending colon	4.2	4.6	4.7	4.0	3.5	3.2	2.6	2.8	3.6	5.3	4.4	2.9	2.1	1.5
Hepatic flexure	1.0	1.1	1.0	0.8	1.7	1.1	0.8	0.5	1.3	0.7	1.9	1.0	0.6	0.2
Transverse colon	4.1	5.4	3.7	4.1	4.3	4.0	2.4	2.2	3.2	5.2	4.0	3.0	1.5	1.0
Splenic flexure	1.2	1.7	1.4	1.0	1.5	1.9	0.7	0.5	1.5	0.7	0.6	1.0	0.2	0.1
Descending colon	3.1	3.6	3.2	3.1	3.6	3.6	1.9	2.0	2.6	3.2	4.0	2.4	1.0	0.8
Sigmoid colon	13.8	16.8	14.5	13.5	10.8	14.2	8.9	9.9	11.9	14.6	12.5	11.6	4.0	3.0
Large intestine, NOS	2.0	2.1	2.1	1.9	0.9	2.6	2.2	3.6	1.5	1.8	0.2	2.6	1.5	1.3
Rectum and rectosigmoid	19.1	22.5	19.7	19.2	14.1	20.4	12.4	12.0	18.5	19.8	17.6	14.7	7.9	7.6
Rectosigmoid junction	5.7	7.7	5.9	4.6	5.8	6.9	3.2	2.5	5.9	5.9	6.9	3.7	2.2	1.7
Rectum	13.3	14.8	13.9	14.6	8.3	13.6	9.2	9.5	12.6	13.8	10.7	11.0	5.7	5.9
Anus, anal canal, and anorectum	0.5	0.5	0.4	0.4	0.8	0.7	0.2	0.5	0.6	0.7	0.4	0.2	0.3	0.4
Liver	2.6	2.4	3.0	2.1	3.0	4.0	2.8	1.2	2.0	3.3	2.9	2.9	2.9	5.1
Gallbladder	1.0	1.0	1.1	1.0	0.7	0.7	1.6	0.9	0.8	0.8	—	1.1	2.5	1.1
Other biliary	1.6	1.6	1.7	1.3	2.3	1.2	2.0	1.0	1.6	2.0	3.5	2.1	1.7	1.2
Pancreas	11.9	12.3	11.5	11.6	14.9	12.9	14.3	9.3	10.7	12.4	11.4	13.1	16.4	6.4
Retroperitoneum	0.5	0.5	0.5	0.5	0.2	0.5	0.4	0.6	0.3	0.7	0.5	0.5	0.4	0.2
Peritoneum	0.1	0.1	0.2	0.1	—	0.4	0.2	0.1	0.1	0.1	—	0.2	0.2	0.1
Other digestive organs	0.3	0.3	0.2	0.2	0.1	0.5	0.5	0.1	1.0	0.2	0.1	0.6	0.3	0.4
Respiratory system	86.5	87.2	93.0	81.8	97.6	121.5	70.0	47.6	87.8	93.2	96.6	90.1	31.6	30.5
Nasal cavity, sinuses, and ear	0.7	0.6	0.7	0.7	1.1	1.2	0.6	0.4	0.9	0.8	0.7	0.5	0.7	1.1
Larynx	8.3	9.3	9.4	7.4	8.6	10.7	7.1	4.8	7.3	8.8	10.0	9.1	3.1	8.5
Lung and bronchus	76.4	76.3	82.0	72.9	86.8	107.6	61.0	41.4	77.9	82.0	84.8	78.9	27.0	20.6
Trachea, pleura, mediastinum, and other	1.1	1.0	0.9	0.7	1.2	1.9	1.3	0.9	1.7	1.5	1.1	1.5	0.8	0.3
Bones and joints	1.0	0.8	0.8	0.9	1.4	1.0	1.0	1.0	1.1	1.3	1.3	1.3	0.5	0.8
Soft tissues (including heart)	2.4	2.2	2.0	2.3	1.9	2.7	3.1	2.3	2.3	2.7	5.2	3.6	1.9	1.5
Skin (excluding basal and squamous carcinoma)	7.3	7.4	5.2	5.4	9.9	9.0	7.6	7.0	7.7	10.4	12.7	10.6	2.4	1.6
Melanomas of the skin	6.7	6.9	4.5	5.1	9.7	7.9	6.8	6.5	7.0	9.3	12.5	9.9	1.4	0.9
Other skin cancers	0.6	0.5	0.7	0.3	0.2	1.1	0.8	0.4	0.7	1.1	0.1	0.7	1.1	0.7
Breast	0.8	0.8	0.9	0.6	0.8	1.0	0.8	0.7	0.6	1.0	1.3	1.0	0.3	0.4

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/23

Male genital system	**70.8**	**65.1**	**64.4**	**67.5**	**78.4**	**59.6**	**74.9**	**85.9**	**83.8**	**72.7**	**92.6**	**82.1**	**61.2**	**42.2**
Prostatic gland	66.2	60.5	60.0	63.0	74.1	55.7	70.0	80.5	79.0	68.2	86.7	77.0	56.8	36.4
Testis	3.6	3.4	3.2	3.4	3.6	3.0	3.5	4.6	3.9	3.8	4.6	4.0	2.7	0.5
Penis	0.8	0.9	0.9	0.9	0.7	0.6	1.2	0.8	0.7	0.7	0.8	1.0	1.7	5.2
Other male genital organs	0.2	0.3	0.4	0.2	—	0.3	0.2	—	0.3	0.1	0.4	0.2	0.1	0.2
Urinary system	**37.7**	**40.8**	**38.9**	**36.1**	**38.4**	**45.4**	**30.5**	**29.4**	**38.4**	**37.2**	**45.9**	**38.1**	**15.9**	**14.1**
Urinary bladder	27.0	29.7	28.3	25.7	26.3	32.9	20.0	21.6	27.4	26.8	31.3	26.2	8.4	11.7
Kidney and renal pelvis	9.4	9.6	9.5	9.0	9.6	10.9	9.6	7.3	9.6	9.2	13.5	10.9	7.1	2.2
Ureter	0.8	1.1	0.6	1.1	1.3	1.1	0.5	0.3	0.8	0.7	0.7	0.7	0.2	0.2
Other urinary organs	0.4	0.4	0.4	0.3	1.2	0.6	0.3	0.2	0.6	0.5	0.3	0.3	0.3	0.1
Eye	**0.9**	**0.6**	**0.9**	**1.2**	**1.4**	**1.1**	**1.2**	**1.3**	**0.6**	**0.9**	**1.2**	**1.4**	**0.8**	**0.6**
Brain and other nervous system	**6.7**	**7.3**	**6.2**	**6.5**	**8.3**	**7.6**	**6.2**	**5.6**	**7.4**	**6.8**	**8.0**	**7.6**	**3.8**	**2.4**
Brain	6.3	6.8	5.9	6.3	7.6	7.0	5.8	5.4	6.9	6.4	7.8	7.1	3.6	2.2
Other nervous system	0.3	0.5	0.3	0.2	0.7	0.5	0.4	0.2	0.5	0.4	0.2	0.6	0.2	0.1
Endocrine system	**2.8**	**2.4**	**2.9**	**2.1**	**3.1**	**3.7**	**4.1**	**2.7**	**2.4**	**3.6**	**5.1**	**4.4**	**3.5**	**1.1**
Thyroid gland	2.4	2.0	2.5	1.7	2.6	2.7	3.6	2.2	1.8	3.1	3.7	3.9	3.3	1.0
Other endocrine (including thymus)	0.5	0.4	0.5	0.4	0.5	1.0	0.5	0.5	0.6	0.5	1.3	0.6	0.3	0.1
Lymphomas	**14.3**	**13.8**	**13.8**	**14.8**	**14.7**	**14.2**	**13.0**	**13.1**	**14.3**	**15.9**	**13.5**	**15.5**	**8.7**	**7.4**
Hodgkin's disease	3.6	4.1	3.5	3.6	2.8	2.8	3.6	3.9	3.5	3.7	3.0	4.2	2.6	2.2
Non-Hodgkin's lymphomas	10.7	9.6	10.3	11.1	11.9	11.3	9.4	9.2	10.9	12.1	10.5	11.3	6.1	5.3
Multiple myeloma	**4.3**	**4.4**	**4.3**	**4.4**	**3.5**	**4.0**	**3.2**	**3.9**	**4.8**	**4.5**	**2.3**	**3.7**	**2.3**	**3.2**
Leukemias	**13.0**	**13.1**	**13.0**	**15.2**	**14.2**	**11.6**	**12.1**	**11.4**	**12.1**	**12.1**	**11.6**	**14.2**	**7.9**	**6.2**
Lymphocytic	5.6	5.7	5.2	7.5	5.5	3.8	5.4	4.5	5.3	5.0	4.7	6.3	3.4	1.8
Acute lymphocytic	1.4	1.6	0.8	2.0	1.1	1.3	1.5	1.6	1.3	1.7	0.7	1.3	1.4	0.9
Chronic lymphocytic	3.9	3.8	4.1	5.2	4.1	2.5	3.7	2.4	3.9	3.0	3.4	4.9	1.6	0.8
Other lymphocytic	0.3	0.2	0.3	0.4	0.2	—	0.2	0.5	0.1	0.2	0.7	0.1	0.3	0.1
Granulocytic	5.4	5.4	5.4	5.7	6.8	6.2	5.2	4.9	4.9	5.3	6.0	6.2	3.3	3.2
Acute granulocytic	3.1	3.3	2.8	3.1	3.9	3.8	3.1	3.2	2.9	3.3	4.5	3.9	1.7	1.3
Chronic granulocytic	1.8	1.7	2.0	2.2	2.5	1.8	1.7	1.3	1.6	1.5	1.5	1.8	1.5	1.7
Other granulocytic	0.5	0.4	0.6	0.4	0.3	0.6	0.3	0.3	0.4	0.6	—	0.4	0.1	0.2
Monocytic	0.4	0.3	0.5	0.5	0.5	0.4	0.3	0.2	0.3	0.2	—	0.3	0.3	0.1
Acute monocytic	0.2	0.1	0.3	0.3	0.5	0.2	0.2	0.1	0.2	0.2	—	0.2	0.3	0.1
Chronic monocytic	0.0	0.1	0.1	0.1	—	—	0.1	—	—	0.0	—	0.1	—	—
Other monocytic	0.1	0.0	0.2	0.2	—	0.2	—	0.1	0.1	0.0	—	—	—	—
Other	1.6	1.7	1.9	1.4	1.5	1.2	1.3	1.8	1.6	1.6	0.9	1.4	0.9	1.1
Other acute	0.6	0.5	1.0	0.3	0.4	0.7	0.4	0.3	0.7	0.6	—	0.5	0.2	0.3
Other chronic	0.0	0.0	0.0	0.0	—	—	0.1	0.2	0.0	0.0	—	—	0.2	0.0
Aleukemic, subleukemic, and NOS	1.0	1.2	0.9	1.1	1.1	0.5	0.8	1.3	0.9	0.9	0.9	0.9	0.5	0.8
Other, ill-defined, and unknown sites	**13.6**	**16.3**	**13.4**	**11.8**	**14.3**	**14.0**	**10.6**	**13.8**	**14.0**	**13.0**	**18.4**	**12.1**	**7.8**	**11.6**
IN SITU														
All sites	**4.9**	**4.6**	**3.8**	**3.6**	**6.9**	**6.4**	**2.8**	**3.9**	**6.0**	**7.6**	**9.7**	**3.1**	**2.1**	**2.8**
Buccal cavity and pharynx	**0.4**	**0.3**	**0.2**	**0.2**	**0.7**	**0.1**	**0.6**	**0.5**	**0.6**	**0.5**	**1.1**	**0.7**	**0.3**	**0.4**
Digestive system	**2.3**	**2.3**	**1.6**	**1.7**	**2.3**	**4.1**	**0.8**	**1.3**	**3.3**	**3.1**	**4.3**	**0.9**	**0.6**	**0.4**
Stomach	0.0	0.1	0.1	—	—	0.1	0.0	—	0.1	0.1	—	—	0.1	0.1
Colon excluding rectum	1.2	1.1	0.8	0.9	1.3	2.3	0.2	0.8	1.9	1.9	1.9	0.3	—	0.1
Rectum and rectosigmoid	0.9	1.0	0.7	0.8	1.0	1.7	0.4	0.4	1.3	1.0	2.1	0.6	—	0.1
Anus, anal canal, and anorectum	0.0	0.0	0.0	—	—	0.1	0.1	—	0.1	0.1	0.4	0.1	—	—
Respiratory system	**0.6**	**0.6**	**0.5**	**0.6**	**0.7**	**0.6**	**0.2**	**0.5**	**0.5**	**0.8**	**0.3**	**0.3**	**0.1**	**0.5**
Larynx	0.5	0.5	0.4	0.5	0.6	0.6	0.2	0.3	0.4	0.7	0.3	0.2	0.1	0.4
Lung and bronchus	0.1	0.1	0.1	0.1	0.1	—	—	0.1	0.1	0.1	—	—	—	0.0
Melanomas of the skin	**0.3**	**0.3**	**0.1**	**0.1**	**0.7**	**0.2**	**0.3**	**0.5**	**0.4**	**0.6**	**2.9**	**0.4**	—	**0.0**
Breast	**0.1**	**0.0**	**0.1**	**0.0**	**0.2**	**0.1**	—	**0.1**	**0.1**	**0.0**	—	—	—	**0.0**
Male genital system	**0.5**	**0.5**	**0.3**	**0.3**	**1.0**	**0.7**	**0.5**	**0.7**	**0.5**	**0.5**	**0.3**	**0.3**	**0.7**	**1.0**
Prostatic gland	0.2	0.4	0.1	0.2	0.3	0.4	0.1	0.5	0.1	0.2	—	0.1	0.1	0.8
Penis	0.2	0.1	0.2	0.2	0.7	0.3	0.3	0.2	0.4	0.2	0.3	0.2	0.6	0.2
Urinary system	**0.8**	**0.5**	**0.8**	**0.6**	**1.2**	**0.4**	**0.1**	**0.3**	**0.5**	**2.0**	**0.8**	**0.2**	—	**0.1**
Urinary bladder	0.7	0.4	0.8	0.6	1.0	0.3	—	0.2	0.4	1.8	0.8	—	—	0.0

TABLE 21. *Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for white, Anglo, and Hispanic females*

Primary site	White											Anglo	Hispanic	
	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	New Mexico 1973–77	New Mexico 1973–77	Puerto Rico 1973–77
MALIGNANT														
All sites	301.2	309.4	292.5	277.9	301.3	270.8	292.1	250.3	311.2	346.9	326.6	318.8	237.1	173.6
Buccal cavity and pharynx	6.0	5.4	5.3	3.9	7.8	6.6	5.0	4.7	7.2	8.6	13.2	5.9	3.3	7.5
Lip	0.3	0.3	0.2	0.2	0.5	0.1	0.8	0.9	0.3	0.4	0.6	0.9	0.4	0.4
Tongue	1.2	1.1	1.1	0.8	1.3	1.0	1.0	0.7	1.5	1.8	2.1	1.3	0.6	2.1
Major salivary gland	0.8	0.7	0.8	0.6	0.6	1.4	0.6	1.0	0.7	0.9	1.0	0.7	0.5	0.4
Floor of mouth	0.7	0.6	0.6	0.3	1.2	0.6	0.3	0.5	0.7	1.4	1.6	0.4	.....	0.4
Gum and other mouth	1.3	1.2	1.3	0.8	2.2	1.5	0.9	0.8	1.8	1.7	3.1	1.1	0.4	2.3
Nasopharynx	0.3	0.3	0.3	0.2	0.3	0.2	0.4	0.2	0.4	0.3	0.2	0.4	0.4	0.3
Tonsil	0.7	0.5	0.5	0.5	0.8	0.9	0.3	0.3	0.7	1.1	2.5	0.5	.....	0.7
Oropharynx	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.0	0.3	0.3	0.6	.....	0.3	0.1
Hypopharynx	0.4	0.3	0.3	0.3	0.5	0.5	0.5	0.2	0.4	0.7	1.2	0.5	0.5	0.6
Pharynx and other buccal cavity	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.0	0.3	0.1	0.2	0.1	0.1	0.3
Digestive system	63.7	72.6	61.3	63.5	57.1	57.2	64.5	48.0	59.7	67.8	60.0	63.0	68.5	47.9
Esophagus	1.6	1.9	1.8	1.1	1.4	0.7	1.5	0.4	1.6	2.4	2.4	1.4	1.9	6.8
Stomach	5.6	6.8	6.1	4.2	3.9	4.8	7.4	4.4	4.7	6.7	7.0	5.2	12.7	12.6
Small intestine	0.7	0.8	0.7	0.8	0.9	0.4	1.0	1.0	0.8	0.7	0.2	1.2	0.6	0.8
Colon excluding rectum	31.0	35.4	28.5	34.1	29.1	27.3	26.7	22.3	29.4	32.4	24.4	30.8	17.8	10.2
Cecum	6.7	7.1	6.2	7.5	7.3	4.9	6.6	4.6	6.6	7.1	5.6	8.2	3.0	1.8
Appendix	0.3	0.2	0.2	0.3	0.7	0.4	0.4	0.3	0.9	0.3	0.1	0.6	0.2	0.1
Ascending colon	4.0	4.5	3.9	4.4	2.8	3.4	2.8	1.9	3.5	4.6	2.6	3.3	1.6	1.3
Hepatic flexure	0.8	0.9	0.8	0.8	0.8	1.6	1.4	0.5	1.0	0.5	1.9	1.8	0.5	0.1
Transverse colon	3.8	4.4	3.3	4.6	3.6	3.4	2.4	1.8	3.5	4.3	2.1	2.7	1.8	1.1
Splenic flexure	0.8	1.1	0.7	0.8	0.8	1.1	0.5	0.4	0.8	0.5	0.8	0.6	0.2	0.1
Descending colon	2.4	2.7	2.3	2.8	2.4	2.0	2.1	1.9	2.0	2.6	3.0	2.2	1.8	0.9
Sigmoid colon	10.4	12.8	9.1	11.0	9.4	7.7	8.7	8.4	9.8	11.3	7.4	9.4	7.4	3.3
Large intestine, NOS	1.7	1.7	1.9	1.7	1.3	2.8	1.8	2.6	1.1	1.2	0.9	2.1	1.2	1.5
Rectum and rectosigmoid	11.5	14.0	11.3	11.6	9.0	9.6	9.4	9.0	10.7	11.5	10.2	10.0	8.1	5.9
Rectosigmoid junction	3.9	5.0	3.9	3.6	4.5	3.2	2.9	3.0	3.5	3.9	3.6	3.0	2.7	1.2
Rectum	7.6	9.0	7.4	8.1	4.5	6.5	6.6	6.0	7.2	7.6	6.6	7.1	5.3	4.7
Anus, anal canal, and anorectum	0.7	0.6	0.7	0.5	1.0	0.6	0.5	0.5	0.9	1.0	1.3	0.7	.....	0.9
Liver	1.2	1.2	1.3	1.1	0.8	0.9	2.1	1.1	0.9	1.1	1.9	1.7	3.2	2.7
Gallbladder	1.8	1.6	2.0	1.8	1.2	1.5	4.0	1.6	1.4	1.5	0.9	1.7	9.2	2.2
Other biliary	1.1	1.3	1.0	0.9	1.0	1.0	1.1	1.0	0.9	1.3	2.0	0.8	1.7	1.1
Pancreas	7.7	8.4	7.1	6.9	7.7	9.6	9.9	5.9	7.0	8.4	8.7	8.8	12.7	4.0
Retroperitoneum	0.4	0.2	0.4	0.3	0.6	0.3	0.2	0.7	0.4	0.5	0.7	0.3	0.1	0.3
Peritoneum	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.0	0.3	0.1	.....	.....	0.2	0.1
Other digestive organs	0.3	0.2	0.2	0.2	0.2	0.4	0.4	0.1	0.8	0.1	0.2	0.5	0.3	0.3
Respiratory system	23.9	23.7	24.2	16.1	26.2	30.0	23.6	10.0	28.2	32.4	30.1	26.0	19.0	9.6
Nasal cavity, sinuses, and ear	0.5	0.5	0.4	0.4	0.7	0.7	0.3	0.5	0.6	0.4	.....	0.3	0.3	0.5
Larynx	1.3	1.3	1.5	0.9	1.1	1.7	0.8	0.7	1.4	1.7	1.5	0.8	0.7	1.9
Lung and bronchus	21.8	21.5	22.1	14.5	24.0	27.4	22.3	8.4	25.9	29.7	28.6	24.6	17.7	7.1
Trachea, pleura, mediastinum, and other	0.3	0.3	0.2	0.2	0.4	0.2	0.3	0.4	0.4	0.5	.....	0.3	0.3	0.1
Bones and joints	0.6	0.6	0.5	0.7	0.8	0.6	0.7	1.0	0.6	0.6	0.5	0.6	0.7	0.5
Soft tissues (including heart)	1.5	1.3	1.3	1.3	1.7	1.3	2.1	1.7	2.1	1.6	2.3	2.5	1.3	1.1
Skin (excluding basal and squamous carcinoma)	6.5	5.8	4.3	5.1	9.2	5.5	8.2	7.9	6.8	9.3	7.7	11.1	2.8	1.4
Melanomas of the skin	6.0	5.5	3.8	4.9	8.8	5.3	7.6	7.2	6.4	8.7	7.7	10.5	2.4	0.9
Other skin cancers	0.4	0.4	0.6	0.3	0.4	0.2	0.6	0.7	0.4	0.5	.....	0.7	0.5	0.5
Breast	85.6	90.5	82.9	79.7	89.4	78.1	78.7	73.7	83.7	97.0	99.9	92.7	48.5	33.6
Female genital system	58.5	50.6	59.0	55.0	54.7	35.7	56.5	49.7	68.2	73.7	63.9	60.6	47.3	39.2
Cervix uteri	10.9	8.3	11.4	12.5	10.1	9.8	17.1	7.8	10.8	11.4	10.0	13.9	23.8	21.0
Corpus uteri	29.9	25.1	28.8	24.6	27.6	12.5	22.1	25.1	40.2	43.0	41.5	28.0	9.3	7.4
Uterus, NOS	0.7	0.8	1.3	0.8	0.2	0.3	1.0	1.2	0.4	0.1	.....	1.1	1.0	1.2
Ovary	14.2	13.8	14.6	14.3	13.0	10.4	13.5	13.5	13.5	16.2	10.7	14.3	11.6	5.9
Vagina	0.6	0.4	0.7	0.6	1.3	0.5	0.6	0.5	0.6	0.6	0.2	0.7	0.2	0.8
Vulva	1.6	1.5	1.9	1.8	1.0	1.6	1.6	1.2	1.5	1.6	0.8	1.9	1.1	2.5
Other female genital organs	0.7	0.6	0.4	0.5	1.4	0.7	0.5	0.5	1.0	0.9	0.7	0.7	0.2	0.4


Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/25

Urinary system	12.0	13.2	12.8	11.1	11.1	13.9	11.6	10.1	11.9	11.6	8.6	12.8	9.0	5.2
Urinary bladder	7.1	7.9	7.3	6.1	6.3	8.6	6.1	5.9	7.3	7.4	5.2	7.3	3.5	3.7
Kidney and renal pelvis	4.4	4.7	4.9	4.6	4.4	4.8	4.7	3.6	4.0	3.8	3.0	4.7	4.5	1.2
Ureter	0.4	0.4	0.4	0.2	0.3	0.5	0.4	0.5	0.3	0.3	0.2	0.3	0.7	0.1
Other urinary organs	0.2	0.1	0.2	0.1	0.2	0.1	0.4	0.1	0.3	0.2	0.2	0.4	0.3	0.1
Eye	0.7	0.5	0.6	0.9	1.0	0.8	0.6	1.2	0.8	0.6	0.2	0.7	0.5	0.5
Brain and other nervous system	4.6	4.5	4.4	4.2	5.2	4.6	3.2	4.8	5.6	5.3	3.4	3.9	2.0	1.8
Brain	4.3	4.2	4.2	3.8	4.9	4.4	3.0	4.7	5.3	5.0	3.3	3.5	1.9	1.6
Other nervous system	0.2	0.2	0.2	0.4	0.3	0.2	0.3	0.1	0.3	0.3	0.1	0.3	0.1	0.1
Endocrine system	5.6	4.8	5.9	4.5	6.6	5.1	7.1	6.6	4.6	7.0	7.0	6.6	8.1	3.2
Thyroid gland	5.3	4.4	5.5	4.2	6.6	5.0	6.8	6.4	4.3	6.6	6.8	6.3	7.9	3.1
Other endocrine (including thymus)	0.3	0.4	0.4	0.3	0.0	0.2	0.2	0.2	0.3	0.4	0.2	0.3	0.2	0.1
Lymphomas	10.7	11.1	10.1	11.4	9.8	10.4	10.2	10.3	10.7	11.1	8.6	11.4	8.0	5.0
Hodgkin's disease	2.5	3.0	2.4	2.4	2.7	2.5	2.4	2.1	2.4	2.9	1.7	2.4	2.4	1.5
Non-Hodgkin's lymphomas	8.2	8.1	7.7	9.0	7.0	7.9	7.9	8.2	8.3	8.2	6.9	8.9	5.6	3.5
Multiple myeloma	3.0	3.4	2.9	3.1	3.2	2.7	2.5	2.6	2.9	2.7	3.1	2.6	2.3	2.4
Leukemias	7.7	7.9	7.4	8.3	7.7	6.4	7.2	7.0	7.2	7.8	7.8	8.4	4.9	4.4
Lymphocytic	3.1	3.1	2.5	3.9	3.0	1.8	3.3	2.4	2.8	3.3	3.0	3.9	2.1	1.4
Acute lymphocytic	0.9	0.9	0.5	1.1	1.2	0.4	0.9	1.0	1.0	1.2	1.9	1.1	0.6	0.9
Chronic lymphocytic	2.0	2.0	1.9	2.6	1.7	1.3	2.3	1.3	1.7	2.0	1.1	2.8	1.2	0.4
Other lymphocytic	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.1	.....	.....	0.3	0.1
Granulocytic	3.6	3.6	3.4	3.7	3.7	3.7	2.8	3.4	3.6	3.7	3.6	3.2	2.0	2.2
Acute granulocytic	2.2	2.4	1.9	2.2	2.6	2.2	1.4	1.8	2.5	2.5	3.1	1.7	0.8	1.1
Chronic granulocytic	1.0	0.9	1.2	1.2	1.0	1.2	1.0	1.5	0.7	0.8	0.4	1.1	0.9	1.0
Other granulocytic	0.3	0.2	0.4	0.3	0.1	0.3	0.4	0.2	0.4	0.4	.....	0.4	0.2	0.1
Monocytic	0.2	0.2	0.3	0.2	0.4	0.5	0.2	0.3	0.1	0.1	0.2	0.3	.....	0.1
Acute monocytic	0.1	0.1	0.2	0.2	0.3	0.2	0.1	0.2	0.0	0.1	0.2	0.2	.....	0.0
Chronic monocytic	0.0	0.0	0.0	0.0	.....	.....	.....	.....	0.0	.....	.....	.....	.....	.....
Other monocytic	0.1	0.1	0.1	0.0	0.1	0.3	0.0	0.1	0.0	0.0	.....	0.1	.....	0.0
Other	0.8	1.0	1.1	0.5	0.6	0.4	0.9	0.9	0.7	0.7	1.0	1.0	0.7	0.7
Other acute	0.3	0.4	0.6	0.1	0.2	0.2	0.3	0.2	0.4	0.4	0.3	0.3	0.3	0.2
Other chronic	0.0	0.0	0.0	0.0	.....	0.1	0.1	0.1	0.0	0.0	.....	0.1	.....	0.0
Aleukemic, subleukemic, and NOS	0.4	0.6	0.5	0.4	0.4	0.1	0.5	0.6	0.3	0.3	0.7	0.6	0.4	0.5
Other, ill-defined, and unknown sites	10.5	13.7	9.5	9.0	9.9	11.9	10.3	11.1	10.8	9.8	10.3	10.2	10.9	10.3
IN SITU														
All sites	43.3	34.4	37.1	40.3	60.2	32.4	50.2	31.6	65.3	50.0	46.8	53.8	44.6	29.8
Buccal cavity and pharynx	0.1	0.2	0.1	0.1	0.2	0.3	0.0	0.1	0.1	0.2	0.2	0.1	.....	0.2
Digestive system	1.5	1.4	0.9	1.2	1.6	3.4	0.9	0.7	2.0	1.9	4.7	1.2	0.3	0.3
Stomach	0.0	0.1	0.0	0.0	.....	.....	.....	0.0	.....	0.0	0.3	.....	.....	0.0
Colon excluding rectum	0.8	0.7	0.4	0.5	0.9	2.2	0.4	0.5	1.0	1.0	2.5	0.6	.....	0.1
Rectum and rectosigmoid	0.6	0.6	0.4	0.5	0.6	1.2	0.4	0.2	0.8	0.7	2.0	0.5	0.2	0.0
Anus, anal canal, and anorectum	0.0	0.0	0.0	0.0	0.1	0.1	0.1	.....	0.1	0.1	.....	0.1	.....	0.1
Respiratory system	0.1	0.1	0.2	0.0	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.2	0.0
Larynx	0.1	0.1	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0
Lung and bronchus	0.0	.....	.....	.....	.....	0.1	.....	.....	.....	0.0	.....	.....	.....	0.0
Melanomas of the skin	0.3	0.4	0.1	0.1	0.6	0.1	0.3	0.4	0.5	0.6	1.0	0.5	0.1	0.0
Breast	4.3	3.3	3.8	3.0	8.9	3.1	3.3	5.7	4.3	5.9	8.9	4.2	1.5	1.9
Female genital system	36.7	28.9	31.8	35.7	48.6	25.1	45.2	24.5	58.2	40.4	31.8	47.5	42.3	27.3
Cervix uteri	32.5	26.2	27.6	33.4	42.0	22.3	42.5	20.4	52.2	33.8	21.9	44.0	41.0	26.5
Corpus uteri	2.7	1.9	2.7	1.6	2.9	1.3	1.4	3.2	3.8	4.5	7.2	1.7	0.7	0.3
Vagina	0.3	0.2	0.3	0.1	1.1	0.3	0.5	0.2	0.4	0.3	0.6	0.6	0.3	0.2
Vulva	1.1	0.6	1.1	0.6	2.4	1.1	0.8	0.4	1.7	1.7	2.1	1.2	0.3	0.3
Urinary system	0.2	0.1	0.3	0.1	0.2	0.2	0.2	0.0	0.1	0.7	.....	0.2	0.2	.....
Urinary bladder	0.2	0.1	0.2	0.1	0.1	0.2	0.1	0.0	0.0	0.6	.....	0.1	0.2	.....

TABLE 26 *Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for races other than white, both sexes*

Primary site	Black					Chinese		Japanese		Hawaiian	Filipino	Am Indian
	All areas ex. Puerto Rico 1973-77	Detroit 1973-77	Atlanta 1975-77	New Orleans 1974-77	San Francisco-Oakland 1973-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	Hawaii 1973-77	Hawaii 1973-77	New Mexico 1973-77
MALIGNANT												
All sites	359.4	354.7	343.4	365.4	366.9	306.0	259.3	218.2	260.0	422.7	234.1	185.4
Buccal cavity and pharynx	12.5	10.6	14.3	16.3	12.3	17.6	7.3	3.1	5.3	15.6	10.8	0.5
Lip	0.2	0.2	.....	0.4	0.3	.....	.....	0.6	.....	.....	.....	.....
Tongue	2.5	2.3	3.0	3.0	2.4	1.1	0.7	0.7	1.1	3.3	1.2	.....
Major salivary gland	0.9	0.9	0.6	0.8	0.8	0.8	.....	1.1	0.5	1.7	1.3	.....
Floor of mouth	1.6	1.5	1.3	2.1	1.1	0.4	.....	.....	0.4	2.6	2.2	0.5
Gum and other mouth	2.5	1.8	2.7	3.6	3.1	1.7	0.7	0.3	0.9	1.9	2.3	.....
Nasopharynx	0.6	0.6	0.6	0.5	0.6	12.1	4.1	.....	0.9	3.0	2.1	.....
Tonsil	1.8	1.4	2.2	1.9	2.2	0.5	0.3	0.3	0.2	1.3	0.6	.....
Oropharynx	0.4	0.4	0.4	0.6	0.2	.....	0.5	.....	0.1	0.5	0.5	.....
Hypopharynx	1.6	1.2	2.5	2.2	1.5	0.6	0.5	.....	1.2	1.3	0.5	.....
Pharynx and other buccal cavity	0.5	0.3	0.9	1.1	0.1	0.4	0.5	.....	.....	.....	.....	.....
Digestive system	92.9	91.2	88.3	95.6	92.1	97.4	88.0	91.3	102.7	109.4	74.8	71.9
Esophagus	10.0	10.3	11.3	9.1	8.7	5.9	4.2	5.5	3.1	11.8	6.9	1.0
Stomach	15.4	14.2	12.5	20.0	16.2	15.0	12.0	31.7	31.4	35.5	11.4	21.6
Small intestine	0.9	1.1	0.9	0.9	0.8	0.5	0.3	0.6	0.7	2.4	0.1	0.8
Colon excluding rectum	33.0	33.7	30.8	31.1	31.4	32.3	33.5	31.9	29.1	18.2	21.2	8.6
Cecum	6.8	7.2	5.8	4.8	7.4	5.0	5.0	6.4	4.4	3.3	1.3	1.9
Appendix	0.3	0.2	0.4	0.4	0.3	0.4	.....	1.0	0.1	0.2	.....	.....
Ascending colon	3.5	3.2	2.6	4.3	3.7	2.2	2.7	1.6	3.5	2.4	2.0	1.0
Hepatic flexure	1.3	1.3	1.8	1.4	0.8	0.4	0.7	0.4	1.1	0.8	0.6	0.5
Transverse colon	4.3	4.8	3.6	3.0	4.5	2.5	3.2	3.4	2.3	0.8	3.2	0.7
Splenic flexure	1.5	1.4	1.9	2.3	0.7	0.6	2.2	0.8	1.1	1.8	0.2	.....
Descending colon	3.7	3.3	4.0	4.5	3.5	4.1	3.8	1.8	2.2	1.2	3.6	0.5
Sigmoid colon	9.3	9.7	8.0	8.5	9.1	14.9	14.5	16.6	13.7	6.0	9.7	3.1
Large intestine, NOS	2.2	2.6	2.7	2.0	1.4	2.2	1.3	.....	0.8	1.8	0.6	0.9
Rectum and rectosigmoid	11.7	11.3	13.4	12.5	10.8	18.0	15.7	11.0	18.4	12.2	14.1	6.2
Rectosigmoid junction	3.6	3.4	6.4	3.5	2.2	3.8	6.3	2.4	8.3	5.3	5.6	0.5
Rectum	8.1	7.9	7.0	9.0	8.6	14.1	9.4	8.5	10.0	6.9	8.4	5.7
Anus, anal canal, and anorectum	0.8	0.7	0.7	1.6	0.5	0.4	.....	.....	0.3	0.6	0.4	0.9
Liver	3.5	3.7	3.6	3.6	3.0	12.9	7.0	2.2	4.8	11.1	9.3	3.3
Gallbladder	1.2	1.0	0.7	1.9	1.0	1.2	2.6	0.9	1.8	1.8	2.0	13.8
Other biliary	0.9	0.9	0.9	0.4	1.5	2.3	2.7	1.0	3.9	2.6	3.1	4.7
Pancreas	14.4	13.2	12.0	13.2	17.4	8.4	9.3	5.9	8.5	10.8	6.1	10.8
Retroperitoneum	0.5	0.6	0.8	0.2	0.6	0.2	0.5	0.7	0.5	1.2	.....	.....
Peritoneum	0.1	0.1	.....	0.2	0.1	.....	0.3	.....	.....	.....	.....	.....
Other digestive organs	0.4	0.4	0.8	0.7	0.1	0.4	.....	.....	0.2	1.1	0.2	0.4
Respiratory system	70.2	71.9	49.5	80.1	68.5	56.9	39.4	21.7	34.1	87.8	32.0	9.5
Nasal cavity, sinuses, and ear	0.7	0.6	0.1	0.8	1.0	0.8	2.0	0.4	0.9	0.6	0.7	1.4
Larynx	6.5	6.3	4.9	7.5	6.5	2.2	1.1	1.0	2.2	4.3	2.2	0.9
Lung and bronchus	62.5	64.6	43.8	71.8	60.4	53.5	35.9	20.3	30.4	81.4	29.1	7.3
Trachea, pleura, mediastinum, and other	0.5	0.4	0.7	0.1	0.6	0.4	0.3	.....	0.6	1.4	.....	.....
Bones and joints	0.6	0.7	0.8	0.7	0.4	1.0	0.4	.....	0.4	2.4	0.2	0.5
Soft tissues (including heart)	1.9	1.7	1.9	2.0	2.7	2.9	1.5	1.1	1.3	2.5	1.3	0.9
Skin (excluding basal and squamous carcinoma)	1.5	1.3	1.2	1.7	2.0	0.6	0.6	0.7	0.6	4.5	1.1	1.2
Melanomas of the skin	0.7	0.6	0.6	0.4	1.1	0.6	.....	0.7	0.1	3.0	0.9	0.6
Other skin cancers	0.8	0.7	0.6	1.3	0.9	.....	0.6	.....	0.4	1.4	0.2	0.6
Breast	40.2	39.7	41.8	39.1	40.8	30.7	31.8	35.2	27.1	55.6	11.9	10.8
Female genital system	30.3	31.8	35.0	26.8	28.2	24.2	25.5	20.7	20.7	37.8	12.3	19.5
Cervix uteri	14.1	15.1	16.8	13.9	11.8	7.2	4.5	3.0	4.1	10.6	3.0	10.0
Corpus uteri	8.1	7.8	10.1	7.7	8.0	10.0	15.8	9.7	11.7	21.0	7.0	1.9
Uterus, NOS	0.7	0.9	0.9	0.3	.....	.....	.....	.....	.....	.....	.....	.....
Ovary	5.2	5.9	4.3	3.6	5.6	5.4	4.1	7.7	4.3	6.0	1.8	5.8
Vagina	0.8	0.7	1.3	0.5	0.8	0.4	1.1	.....	0.2	.....	0.3	0.6
Vulva	1.0	0.9	1.3	0.7	1.3	0.6	.....	.....	0.3	.....	.....	.....
Other female genital organs	0.5	0.5	0.2	0.1	0.8	0.5	.....	0.3	0.1	0.3	0.2	1.1

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/27



Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/28

TABLE 21.—*Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for races other than white, males*

Primary site	Black					Chinese		Japanese		Hawaiian	Filipino	Am. Indian
	All areas ex Puerto Rico 1973–77	Detroit 1973–77	Atlanta 1975–77	New Orleans 1974–77	San Francisco-Oakland 1973–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Hawaii 1973–77	Hawaii 1973–77	New Mexico 1973–77
MALIGNANT												
All sites	454.3	433.0	464.2	480.8	474.9	325.6	262.9	222.0	327.6	465.0	249.5	178.4
Buccal cavity and pharynx	19.3	15.7	23.6	26.8	19.0	23.1	11.8	2.7	8.1	22.7	12.5	0.9
Lip	0.3	0.3	.....	0.9	0.6	.....	.....	.....	.....	.....	.....	.....
Tongue	3.9	3.7	5.4	4.9	3.9	2.0	0.8	0.9	1.4	5.9	1.4	.....
Major salivary gland	1.0	1.0	1.0	0.8	0.7	0.5	.....	0.9	0.6	1.0	1.3	.....
Floor of mouth	2.8	2.5	3.2	3.9	1.9	0.7	.....	.....	0.6	3.4	3.2	0.9
Gum and other mouth	3.3	2.1	3.9	4.5	4.6	1.5	0.6	.....	0.8	1.2	2.1	.....
Nasopharynx	0.8	0.8	0.8	0.5	0.9	15.3	6.2	.....	1.7	5.4	2.3	.....
Tonsil	2.7	2.1	3.6	3.3	3.1	1.0	0.6	0.9	.....	1.3	0.6	.....
Oropharynx	0.8	0.8	1.0	1.1	0.3	.....	1.3	.....	0.2	1.0	0.8	.....
Hypopharynx	2.8	2.0	2.8	4.8	2.8	1.3	1.0	.....	2.8	3.5	0.8	.....
Pharynx and other buccal cavity	0.9	0.4	1.9	2.1	0.3	0.8	1.3	.....	.....	.....	.....	.....
Digestive system	116.7	110.5	117.9	123.2	118.8	123.8	110.9	111.2	145.6	143.7	92.3	68.5
Esophagus	16.9	16.5	22.9	16.6	14.7	8.7	8.1	12.3	6.1	23.0	9.5	1.9
Stomach	22.4	20.5	18.0	29.0	24.9	19.3	14.6	33.0	47.3	51.4	13.3	30.9
Small intestine	1.1	1.1	0.6	1.4	0.8	0.9	.....	1.6	0.5	0.8	0.2	0.7
Colon excluding rectum	36.3	36.9	33.5	31.5	35.3	36.3	39.3	34.3	36.5	20.2	24.3	7.8
Cecum	7.2	7.7	4.8	5.7	6.7	4.7	5.8	4.3	6.0	5.2	1.6	1.6
Appendix	0.4	0.4	0.9	0.4	0.6	0.4	.....	.....	0.1	0.3	.....	.....
Ascending colon	4.1	4.1	1.7	3.5	4.3	2.8	3.2	1.8	3.8	1.0	2.9	0.6
Hepatic flexure	1.4	1.4	2.6	1.6	0.9	0.4	0.6	.....	1.1	0.9	0.9	0.9
Transverse colon	4.6	5.4	3.5	3.4	4.5	2.1	1.5	3.9	1.7	.....	3.9	1.4
Splenic flexure	2.1	1.5	2.8	2.8	1.6	0.4	1.9	.....	1.2	.....	0.2	.....
Descending colon	4.0	2.9	4.6	4.6	4.3	4.1	5.4	.....	2.3	1.5	4.2	.....
Sigmoid colon	10.2	10.8	8.7	7.7	10.6	17.9	19.0	24.4	19.4	8.2	9.8	2.3
Large intestine, NOS	2.3	2.6	3.8	1.8	1.7	3.6	1.9	.....	1.0	3.0	0.6	0.9
Rectum and rectosigmoid	13.3	11.4	18.1	17.0	10.6	23.6	20.6	17.7	28.2	15.9	16.5	5.0
Rectosigmoid junction	3.8	2.9	7.8	5.6	1.6	6.6	6.9	5.4	12.0	5.5	6.8	.....
Rectum	9.5	8.5	10.3	11.4	9.0	17.0	13.7	12.3	16.1	10.4	9.7	5.0
Anus, anal canal, and anorectum	0.7	0.7	0.7	1.3	0.3	0.4	.....	.....	0.2	.....	0.2	2.0
Liver	5.2	5.3	6.1	4.8	4.6	20.9	10.3	5.0	7.5	12.6	13.3	3.0
Gallbladder	1.1	1.0	0.6	1.6	0.8	2.2	3.3	.....	1.4	2.3	2.4	5.9
Other biliary	1.1	1.1	1.2	0.2	2.4	1.6	2.5	2.3	4.9	0.7	3.6	3.4
Pancreas	17.5	14.7	14.7	18.7	23.6	8.8	11.5	5.0	11.7	12.9	8.6	7.8
Retroperitoneum	0.5	0.6	0.7	0.3	0.5	0.4	0.9	.....	1.0	1.2	.....	.....
Peritoneum	0.1	0.2	.....	.....	0.2	.....	.....	.....	.....	.....	.....	.....
Other digestive organs	0.5	0.5	0.7	0.8	0.1	0.8	.....	.....	0.2	2.6	0.3	.....
Respiratory system	123.9	123.0	102.3	146.3	118.7	76.6	49.7	39.6	57.9	128.1	34.9	13.5
Nasal cavity, sinuses, and ear	1.1	0.7	.....	1.8	1.5	0.4	3.5	.....	0.7	0.9	0.3	0.9
Larynx	12.1	11.1	10.6	14.7	12.2	3.8	2.1	2.3	4.1	7.2	2.7	1.9
Lung and bronchus	110.0	110.7	90.0	129.6	103.9	71.7	43.5	37.3	52.0	116.9	31.9	10.8
Trachea, pleura, mediastinum, and other	0.7	0.4	1.6	0.2	1.1	0.7	0.6	.....	1.2	3.1	.....	.....
Bones and joints	0.6	0.8	0.7	0.7	0.4	1.2	0.8	.....	0.5	4.6	0.4	0.7
Soft tissues (including heart)	2.1	2.0	1.2	2.3	3.1	2.7	1.3	2.8	1.6	4.5	0.6	0.5
Skin (excluding basal and squamous carcinoma)	1.5	1.0	1.1	2.0	2.1	0.7	.....	.....	0.4	7.8	1.4	1.9
Melanomas of the skin	0.6	0.5	0.6	0.7	0.9	0.7	.....	.....	0.1	6.1	1.1	0.7
Other skin cancers	0.9	0.6	0.5	1.3	1.1	.....	.....	.....	0.3	1.7	0.3	1.2
Breast	1.4	1.7	0.3	1.7	0.4	1.2	.....	.....	0.6	.....	.....	.....

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/29

Male genital system	111.3	104.2	136.8	105.6	128.9	32.5	40.6	19.8	55.7	74.8	47.2	50.6
Prostatic gland	108.9	102.7	132.5	100.8	126.4	29.4	40.0	17.5	54.1	66.3	46.9	47.0
Testis	0.8	0.7	1.0	0.5	1.1	2.1	0.6	2.3	0.8	3.5	0.2	1.6
Penis	1.3	0.8	2.5	3.6	1.1	1.0	...	...	0.7	0.7	...	1.6
Other male genital organs	0.3	...	0.8	0.7	0.5	...	...	...	...	0.2	...	...
Urinary system	22.8	22.8	22.5	19.9	23.6	18.1	12.9	15.2	21.0	13.1	16.7	11.9
Urinary bladder	13.6	13.7	12.1	11.8	14.1	14.3	9.9	8.3	13.7	6.8	10.8	3.1
Kidney and renal pelvis	8.7	8.7	10.0	7.5	8.9	3.8	2.9	5.9	6.1	5.8	4.7	7.9
Ureter	0.0	...	...	...	...	...	...	...	1.1	...	0.8	0.9
Other urinary organs	0.4	0.5	0.4	0.7	0.6	...	...	0.9	...	0.5	0.5	...
Eye	0.3	0.3	0.3	0.3	0.3	...	1.2	...	0.3	0.2	...	0.3
Brain and other nervous system	4.2	3.9	2.6	4.3	5.1	2.6	2.1	2.7	2.0	5.0	3.0	3.9
Brain	3.9	3.7	2.6	3.7	4.8	1.9	2.1	2.7	2.0	5.0	3.0	3.9
Other nervous system	0.2	0.2	...	0.6	0.3	0.7	...	...	...	...	...	...
Endocrine system	2.0	1.8	1.3	1.2	2.8	4.7	10.7	1.6	7.1	9.0	8.5	2.7
Thyroid gland	1.3	1.4	0.7	0.8	1.9	3.8	9.9	1.6	6.0	7.5	7.9	2.7
Other endocrine (including thymus)	0.6	0.5	0.5	0.4	0.9	0.9	0.8	...	1.1	1.5	0.6	...
Lymphomas	10.3	10.2	8.0	8.4	13.3	10.4	5.9	10.4	8.2	12.9	10.8	4.2
Hodgkin's disease	3.0	3.2	3.4	1.7	3.6	1.5	0.6	...	1.4	1.3	3.1	0.5
Non-Hodgkin's lymphomas	7.2	7.1	4.6	6.7	9.8	8.9	5.2	10.3	6.8	11.7	7.7	3.7
Multiple myeloma	9.6	9.3	6.4	9.4	11.2	1.4	1.5	...	1.9	11.0	5.1	2.1
Leukemias	11.1	11.4	12.1	9.1	12.5	8.9	4.7	3.9	8.3	15.5	8.2	4.7
Lymphocytic	5.0	5.4	6.4	3.2	4.7	2.3	4.0	...	1.4	1.8	3.5	1.7
Acute lymphocytic	0.7	0.4	1.0	1.0	1.1	1.6	2.8	...	1.4	1.8	2.8	1.7
Chronic lymphocytic	3.9	4.7	4.4	2.1	2.9	0.7	1.3	...	...	...	0.6	...
Other lymphocytic	0.4	0.3	1.0	0.2	0.7	...	...	...	...	...	...	...
Granulocytic	4.4	4.1	3.3	4.1	6.3	5.2	0.6	2.6	5.8	12.9	3.3	3.0
Acute granulocytic	2.2	1.4	2.5	2.7	4.2	3.8	0.6	2.6	2.9	8.2	2.2	1.5
Chronic granulocytic	1.8	2.2	0.3	1.2	1.9	1.4	...	...	2.5	4.7	1.0	1.6
Other granulocytic	0.4	0.6	0.5	0.2	0.2	...	...	...	0.4	...	0.2	...
Monocytic	0.5	0.4	1.3	0.5	0.4	0.7	...	...	0.2	0.8	0.7	...
Acute monocytic	0.3	0.4	0.8	...	0.2	0.7	...	...	0.2	0.8	0.3	...
Chronic monocytic	...	...	...	...	...	...	...	...	...	...	0.4	...
Other monocytic	0.2	0.1	0.5	0.5	0.2	...	...	...	...	...	...	...
Other	1.2	1.4	1.1	1.3	1.2	0.7	...	1.3	0.9	...	0.7	...
Other acute	0.5	0.6	0.4	0.2	1.2	...	...	1.3	0.2	...	0.3	...
Other chronic	0.0	0.1	...	...	...	...	...	...	...	...	...	...
Aleukemic, subleukemic, and NOS	0.7	0.8	0.7	1.2	...	0.7	...	...	0.7	...	0.4	...
Other, ill-defined, and unknown sites	17.4	14.2	27.2	19.5	14.6	17.8	8.9	12.2	8.6	15.1	8.0	12.2
IN SITU												
All sites	4.2	3.8	6.5	3.2	4.1	2.0	1.6	4.2	5.8	4.5	2.8	1.3
Buccal cavity and pharynx	0.3	0.2	0.3	...	0.3	...	0.8	...	0.3	...	0.6	...
Digestive system	2.4	2.8	3.5	2.3	1.7	1.5	0.8	3.3	4.0	2.3	2.1	1.3
Stomach	0.1	0.2	...	0.5	...	...	...	1.7	1.3	1.4	...	...
Colon excluding rectum	1.3	1.6	2.3	0.9	0.7	0.8	0.8	...	2.2	0.4	0.6	0.6
Rectum and rectosigmoid	0.9	0.8	1.3	1.0	0.8	0.7	...	1.6	0.4	0.5	1.6	...
Anus, anal canal, and anorectum	0.0	0.1	...	...	...	...	...	...	...	...	...	...
Respiratory system	0.8	0.7	0.9	0.3	1.0	...	...	0.9	0.6	1.3	...	...
Larynx	0.6	0.5	0.3	0.3	0.9	...	...	0.9	0.6	0.6	...	...
Lung and bronchus	0.2	0.2	0.3	...	0.1	...	...	...	...	0.7	...	...
Melanomas of the skin	...	...	...	...	...	...	...	...	...	...	...	...
Breast	0.0	...	...	...	...	...	...	...	...	...	...	...
Male genital system	0.4	0.1	1.7	0.3	0.5	...	...	...	0.3	...	...	...
Prostatic gland	0.1	0.1	0.7	...	...	...	...	...	0.3	...	...	...
Penis	0.3	...	1.0	0.3	0.5	...	...	...	...	...	...	...
Urinary system	0.2	0.1	...	0.2	0.5	0.4	...	...	0.6	0.9	...	...
Urinary bladder	0.1	0.1	...	...	0.5	0.4	...	...	0.6	0.9	...	...

TABLE 21 *Average annual age-adjusted (1970 standard) incidence rates per 100,000 population by primary site, geographic area, and period for races other than white, females*

Primary site	Black					Chinese		Japanese		Hawaiian	Filipino	Am. Indian
	All areas ex. Puerto Rico 1973-77	Detroit 1973-77	Atlanta 1975-77	New Orleans 1974-77	San Francisco-Oakland 1973-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	Hawaii 1973-77	Hawaii 1973-77	New Mexico 1973-77
MALIGNANT												
All sites	288.7	292.1	270.1	282.3	290.7	283.6	263.0	224.0	220.9	408.5	191.5	191.6
Buccal cavity and pharynx	7.0	6.3	7.4	8.2	6.8	11.4	3.5	3.3	2.9	10.1	6.6	
Lip	0.1	0.1			0.1			0.8				
Tongue	1.3	1.3	1.1	1.6	1.3		0.7	0.5	0.9	1.6	0.4	
Major salivary gland	0.8	0.9	0.4	0.8	0.8	1.1		1.4	0.5	2.2	0.9	
Floor of mouth	0.6	0.6		0.7	0.4				0.1	1.9	0.6	
Gum and other mouth	1.8	1.4	1.8	2.9	1.9	1.8	0.8	0.5	1.0	2.4	3.1	
Nasopharynx	0.4	0.4	0.4	0.5	0.3	8.4	2.0		0.1	0.7	1.1	
Tonsil	1.0	0.8	1.1	0.8	1.5				0.3	1.3	0.4	
Oropharynx	0.0			0.2	0.1							
Hypopharynx	0.6	0.5	2.3	0.3	0.4							
Pharynx and other buccal cavity	0.2	0.2	0.2	0.3								
Digestive system	74.1	74.8	68.2	75.0	72.6	68.7	67.2	79.9	72.1	85.9	40.7	77.9
Esophagus	4.5	5.0	3.0	3.6	4.2	2.6	0.8	0.9	0.9	3.0	1.4	
Stomach	9.9	9.0	9.1	13.3	10.0	10.7	9.4	30.6	19.9	23.9	7.3	13.2
Small intestine	0.8	1.0	1.1	0.7	0.9		0.7		0.8	4.0		1.0
Colon excluding rectum	30.6	31.5	29.2	30.9	28.1	27.5	28.2	32.5	24.4	17.5	13.2	9.6
Cecum	6.6	7.0	6.6	4.1	7.5	5.2	4.5	8.4	3.2	1.9	0.4	2.4
Appendix	0.1	0.1	0.2	0.4	0.1	0.5		1.7				
Ascending colon	3.1	2.5	3.3	4.9	3.1	1.8	2.4	1.4	3.4	3.6		1.6
Hepatic flexure	1.1	1.2	1.2	1.2	0.7	0.5	0.8	0.9	1.2	0.7		
Transverse colon	4.1	4.3	3.6	2.6	4.5	3.0	4.7	3.0	2.9	1.5	1.9	
Splenic flexure	1.1	1.4	1.3	2.2	0.1	1.0	2.9	1.4	0.9	3.0		
Descending colon	3.5	3.6	3.5	4.4	2.9	4.0	1.8	3.1	2.2	0.9	2.2	1.0
Sigmoid colon	8.8	8.8	7.5	9.1	8.0	11.1	10.3	12.5	10.1	4.8	8.4	3.9
Large intestine, NOS	2.2	2.7	2.1	2.1	1.2	0.6	0.8		0.7	1.2	0.2	0.8
Rectum and rectosigmoid	10.5	11.0	10.2	9.3	11.1	12.0	11.0	5.8	11.0	10.9	10.0	7.6
Rectosigmoid junction	3.4	3.8	5.5	1.9	2.7	0.9	6.4		5.6	6.0	3.3	1.0
Rectum	7.0	7.2	4.7	7.4	8.4	11.1	4.7	5.8	5.4	4.9	6.7	6.6
Anus, anal canal, and anorectum	0.9	0.7	0.7	1.8	0.7	0.4			0.4	1.1	1.7	
Liver	2.1	2.3	1.6	2.6	1.9	4.2	3.6	0.8	2.8	9.7	2.1	3.3
Gallbladder	1.3	0.9	0.7	2.2	1.2		2.2	1.9	2.2	1.5	1.0	22.3
Other biliary	0.7	0.6	0.7	0.5	1.0	3.4	3.0		3.4	4.1	2.3	6.1
Pancreas	11.9	11.8	10.1	8.9	13.0	8.0	7.6	6.2	6.1	9.2	1.8	13.9
Retroperitoneum	0.5	0.6	1.0	0.2	0.6			1.2		1.1		
Peritoneum	0.1	0.1		0.4			0.7					
Other digestive organs	0.4	0.3	0.8	0.6					0.2			0.8
Respiratory system	26.9	28.4	13.0	29.7	29.4	34.9	30.6	9.0	16.7	52.8	27.6	5.6
Nasal cavity, sinuses, and ear	0.4	0.5	0.2	0.2	0.7	1.3	0.8	0.9	1.2	0.4	1.3	1.8
Larynx	1.9	2.2	0.7	2.1	1.9	0.5			0.5	1.7	1.0	
Lung and bronchus	24.3	25.4	11.9	27.5	26.6	33.1	29.9	8.2	15.0	50.7	25.3	3.9
Trachea, pleura, mediastinum, and other	0.3	0.3	0.2		0.2							
Bones and joints	0.6	0.6	0.8	0.7	0.5	0.8			0.4	0.7		0.4
Soft tissues (including heart)	1.8	1.4	2.3	1.9	2.5	3.3	2.1		1.0	0.9	1.9	1.2
Skin (excluding basal and squamous carcinoma)	1.5	1.6	1.3	1.5	1.8	0.3	1.4	1.2	0.7	2.8	0.7	0.4
Melanomas of the skin	0.7	0.7	0.6	0.2	1.2	0.3		1.2	0.1	1.5	0.7	0.4
Other skin cancers	0.8	0.9	0.6	1.3	0.6		1.4		0.6	1.3		
Breast	72.0	71.9	71.6	67.5	74.0	62.8	64.1	63.0	51.3	104.3	29.2	21.2
Female genital system	54.9	58.3	60.2	46.8	51.1	50.6	52.3	37.0	39.0	72.7	31.5	39.0
Cervix uteri	25.7	27.8	29.5	24.4	21.7	14.9	9.0	4.9	7.5	20.0	7.9	19.9
Corpus uteri	14.6	14.3	17.0	13.3	14.3	21.2	33.4	17.7	22.4	40.4	17.3	3.5
Uterus, NOS	1.2	1.6	1.5	0.5								
Ovary	9.3	10.9	7.5	6.3	10.0	11.5	8.1	13.8	8.0	11.8	5.4	11.9
Vagina	1.4	1.2	2.1	0.8	1.4	0.7	1.8		0.3		0.7	1.4
Vulva	1.9	1.6	2.2	1.2	2.3	1.3			0.6			
Other female genital organs	0.9	0.9	0.4	0.3	1.4	1.1		0.6	0.2	0.5	0.3	2.3

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/31

Urinary system	**10.5**	**11.7**	**8.1**	**8.4**	**10.2**	**5.2**	**6.1**	**4.7**	**7.4**	**15.9**	**9.4**	**6.1**
Urinary bladder	5.5	5.8	5.4	5.1	5.8	2.6	1.5	3.7	4.8	8.3	5.6	....
Kidney and renal pelvis	4.4	5.2	2.2	3.2	4.0	1.8	4.6	0.9	2.5	5.5	3.8	6.1
Ureter	0.2	0.4	....	....	0.1	0.8	....	....	0.1	....	....	....
Other urinary organs	0.5	0.3	0.5	0.2	0.3	....	....	....	....	....	....	....
Eye	**0.3**	**0.4**	**0.1**	**0.6**	**0.2**	....	....	....	....	**0.3**	**0.3**	**1.0**
Brain and other nervous system	**2.7**	**2.2**	**2.2**	**3.7**	**3.4**	**3.8**	**4.7**	**1.7**	**1.6**	**5.9**	....	**0.8**
Brain	2.5	2.1	2.0	3.4	3.1	3.4	4.7	1.7	1.5	5.9	....	0.8
Other nervous system	0.2	0.1	0.2	0.4	0.3	0.5	....	....	0.1	....	....	....
Endocrine system	**4.3**	**4.3**	**5.4**	**3.3**	**4.9**	**10.9**	**13.8**	**8.2**	**7.3**	**19.2**	**17.1**	**4.4**
Thyroid gland	4.0	4.2	5.3	3.1	4.2	10.5	13.8	8.2	7.0	19.2	17.1	4.4
Other endocrine (including thymus)	0.3	0.1	0.2	0.2	0.7	0.5	....	....	0.3	....	....	....
Lymphomas	**5.8**	**6.0**	**3.3**	**5.3**	**6.8**	**6.7**	**7.1**	**2.6**	**6.0**	**9.1**	**9.0**	**3.9**
Hodgkin's disease	1.1	1.4	0.5	0.5	1.6	1.1	0.6	....	0.4	1.7	1.6	....
Non-Hodgkin's lymphomas	4.7	4.7	2.8	4.6	5.2	5.5	6.5	2.6	5.6	7.4	7.3	3.9
Multiple myeloma	**6.7**	**6.3**	**5.5**	**7.2**	**7.5**	**3.5**	**1.7**	....	**1.4**	**8.0**	**3.6**	**3.6**
Leukemias	**6.8**	**7.1**	**6.5**	**6.6**	**7.1**	**5.5**	**4.3**	**2.7**	**6.1**	**4.9**	**9.9**	**6.7**
Lymphocytic	2.5	2.6	2.7	2.1	2.8	0.6	2.0	0.6	1.9	0.4	2.4	2.3
Acute lymphocytic	0.6	0.3	0.5	0.5	1.1	0.6	1.2	0.6	1.3	0.4	1.8	0.8
Chronic lymphocytic	1.7	2.1	1.9	1.4	1.6	....	0.8	....	0.3	....	0.6	0.8
Other lymphocytic	0.2	0.2	0.2	0.2	0.1	....	....	....	0.3	....	....	0.8
Granulocytic	3.2	3.0	3.1	4.0	3.2	4.5	2.3	1.6	3.1	3.2	6.8	3.1
Acute granulocytic	1.8	1.3	1.6	2.4	2.2	3.1	1.3	1.6	1.9	2.2	4.0	1.3
Chronic granulocytic	1.2	1.4	1.5	1.5	0.8	1.0	1.0	....	0.7	0.3	1.9	1.8
Other granulocytic	0.2	0.3	....	....	0.3	0.4	....	....	0.4	0.7	0.9	....
Monocytic	0.2	0.4	....	0.4	....	....	....	0.5	0.2	0.6	0.7	1.3
Acute monocytic	0.1	0.2	....	....	....	....	....	0.5	0.1	0.6	0.7	1.3
Chronic monocytic	0.0	0.0	....	....	....	....	....	....	....	....	....	....
Other monocytic	0.1	0.1	....	0.4	....	....	....	....	0.1	....	....	....
Other	0.8	1.1	0.7	0.1	1.1	0.4	....	....	0.9	0.7	....	....
Other acute	0.4	0.4	0.7	0.1	0.5	0.4	....	....	0.6	....	....	....
Other chronic	0.0	0.0	....	....	....	....	....	....	....	....	....	....
Aleukemic, subleukemic, and NOS	0.4	0.7	....	....	0.6	....	....	....	0.3	0.7	....	....
Other, ill-defined, and unknown sites	**12.8**	**11.0**	**14.0**	**16.1**	**11.7**	**15.1**	**4.0**	**10.6**	**6.8**	**17.1**	**4.1**	**19.2**
IN SITU												
All sites	**68.2**	**74.7**	**103.9**	**33.6**	**61.7**	**27.3**	**24.5**	**23.7**	**26.5**	**30.9**	**9.9**	**62.1**
Buccal cavity and pharynx	**0.2**	**0.1**	**0.2**	**0.2**	**0.1**	....	....	....	**0.2**	....	....	....
Digestive system	**1.7**	**1.4**	**3.0**	**2.7**	**1.4**	**0.8**	**1.6**	**1.4**	**2.7**	**1.3**	....	**2.0**
Stomach	0.0	....	0.2	....	....	....	....	....	0.6	....	....	....
Colon excluding rectum	1.1	0.9	2.3	1.4	0.9	0.3	....	0.9	0.6	....	....	....
Rectum and rectosigmoid	0.4	0.3	0.2	1.0	0.3	0.5	0.8	0.5	1.0	1.3	....	....
Anus, anal canal, and anorectum	0.1	0.1	0.2	....	0.1	....	0.8	....	0.3	....	....	....
Respiratory system	**0.2**	**0.1**	**0.2**	**0.5**	**0.1**	....	....	....	....	....	....	....
Larynx	0.1	0.1	....	0.5	0.1	....	....	....	....	....	....	....
Lung and bronchus	0.0	....	0.2	....	....	....	....	....	....	....	....	....
Melanomas of the skin	....	....	....	....	....	**0.4**	....	**0.9**	**0.1**	....	....	....
Breast	**3.0**	**2.5**	**3.9**	**2.7**	**3.7**	**2.8**	**8.6**	**1.4**	**9.6**	**5.8**	**2.0**	**0.5**
Female genital system	**63.0**	**70.5**	**96.5**	**27.6**	**56.1**	**23.4**	**14.3**	**20.0**	**13.8**	**23.8**	**7.9**	**59.6**
Cervix uteri	60.3	67.4	93.3	25.4	53.1	19.1	10.2	11.6	9.5	19.9	6.0	58.5
Corpus uteri	0.7	0.6	0.5	0.7	0.8	1.7	4.1	7.7	3.8	3.2	1.6	....
Vagina	0.5	0.7	0.4	0.7	0.3	1.9	....	....	....	0.5	....	0.6
Vulva	1.4	1.6	1.7	0.6	1.7	0.7	....	0.7	0.6	0.2	0.3	0.5
Urinary system	**0.1**	**0.1**	....	....	**0.3**	....	....	....	**0.1**	....	....	....
Urinary bladder	0.1	0.1	....	....	0.3	....	....	....	0.1	....	....	....

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/32

TABLE 3A. *Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for all races, both sexes*

Primary site	United States 1973–77	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Puerto Rico 1973–77
All sites	**166.5**	**168.5**	**178.7**	**179.0**	**156.1**	**165.6**	**201.1**	**153.6**	**123.6**	**167.3**	**173.9**	**149.7**	**127.0**
Buccal cavity and pharynx	**3.7**	**3.8**	**4.3**	**3.8**	**2.7**	**4.3**	**6.1**	**2.4**	**1.9**	**3.6**	**4.8**	**4.9**	**7.2**
Lip	0.1	0.1	0.1	0.0	0.1	0.0	0.1	—	—	0.1	0.1	0.0	0.1
Tongue	0.9	0.9	1.1	0.9	0.5	1.1	1.4	0.8	0.5	0.8	1.2	0.8	2.1
Major salivary gland	0.3	0.2	0.3	0.2	0.3	0.1	0.1	0.2	0.2	0.3	0.2	0.3	0.1
Floor of mouth	0.2	0.2	0.4	0.3	0.1	0.2	0.4	0.1	0.2	0.2	0.3	0.4	0.2
Gum and other mouth	0.6	0.6	0.7	0.6	0.5	0.7	1.0	0.2	0.2	0.5	0.7	0.5	0.8
Nasopharynx	0.3	0.3	0.2	0.3	0.2	0.4	0.2	0.2	0.1	0.3	0.5	1.1	0.1
Tonsil	0.3	0.3	0.3	0.3	0.2	0.5	0.5	0.3	0.1	0.3	0.5	0.4	0.5
Oropharynx	0.1	0.2	0.2	0.2	0.1	0.1	0.2	0.0	0.1	0.1	0.2	0.2	0.3
Hypopharynx	0.3	0.3	0.3	0.3	0.2	0.4	0.5	0.2	0.1	0.3	0.3	0.6	0.4
Pharynx and other buccal cavity	0.6	0.6	0.7	0.6	0.4	0.7	1.7	0.4	0.4	0.7	0.7	0.5	2.7
Digestive system	**46.1**	**48.0**	**53.6**	**50.5**	**44.3**	**41.2**	**51.7**	**45.2**	**34.2**	**44.0**	**50.1**	**55.2**	**52.1**
Esophagus	3.1	3.4	3.7	4.5	2.4	3.7	4.0	1.9	1.7	2.9	3.8	3.8	11.6
Stomach	6.7	7.3	8.1	7.7	5.1	4.8	8.0	8.3	5.5	6.1	8.0	16.2	17.5
Small intestine	0.3	0.3	0.4	0.4	0.4	0.2	0.3	0.3	0.2	0.3	0.4	0.4	0.4
Colon excluding rectum	18.0	18.4	21.2	19.0	19.6	16.0	19.0	15.5	13.1	17.1	18.4	13.6	6.6
Rectum and rectosigmoid	4.3	4.3	5.4	4.3	4.1	3.0	5.4	2.8	2.5	4.0	4.5	4.3	2.2
Anal canal and anorectum	0.0	0.0	0.0	0.0	0.0	0.0	—	0.0	0.0	0.0	0.0	0.0	0.0
Liver	2.2	2.1	1.8	2.4	1.7	2.3	2.9	2.3	1.1	1.9	2.3	4.7	6.0
Gallbladder	1.1	1.1	1.2	1.3	1.2	0.8	1.0	2.6	1.0	0.9	0.8	1.2	0.9
Other biliary	0.9	1.0	1.1	1.0	0.9	0.9	0.6	1.2	0.8	1.0	1.2	2.3	0.7
Pancreas	8.8	9.3	10.1	9.3	8.3	8.8	9.8	9.6	7.7	8.9	10.2	8.2	5.2
Retroperitoneum	0.2	0.2	0.2	0.3	0.2	0.1	0.2	0.2	0.1	0.3	0.2	0.2	0.1
Peritoneum	0.1	0.1	0.1	0.1	0.1	—	0.3	0.2	0.2	0.1	0.2	0.0	0.2
Other digestive organs	0.3	0.3	0.2	0.3	0.3	0.4	0.3	0.3	0.3	0.5	0.2	0.3	0.8
Respiratory system	**39.7**	**38.9**	**38.7**	**44.2**	**34.2**	**42.1**	**50.8**	**32.1**	**19.9**	**41.8**	**41.0**	**33.1**	**17.3**
Nasal cavity, sinuses, and ear	0.3	0.2	0.1	0.2	0.2	0.5	0.2	0.2	0.2	0.2	0.2	0.4	0.3
Larynx	1.5	1.4	1.4	1.9	1.2	1.8	1.7	1.2	0.9	1.3	1.5	0.9	3.4
Lung and bronchus	37.5	36.8	36.9	41.8	32.3	39.6	48.5	30.3	18.5	39.6	38.8	31.5	13.1
Trachea, pleura, mediastinum, and other	0.4	0.4	0.3	0.4	0.4	0.3	0.4	0.4	0.3	0.6	0.5	0.3	0.5
Bones and joints	**0.8**	**0.7**	**0.7**	**0.7**	**0.9**	**0.9**	**1.1**	**0.6**	**0.5**	**0.7**	**0.6**	**0.5**	**1.3**
Soft tissues (including heart)	**0.9**	**1.0**	**1.0**	**1.0**	**1.0**	**0.9**	**1.0**	**1.1**	**1.0**	**1.1**	**1.0**	**1.0**	**0.4**
Skin	**2.4**	**2.2**	**2.4**	**1.7**	**2.2**	**2.0**	**1.9**	**2.6**	**2.3**	**2.1**	**2.5**	**1.4**	**0.8**
Melanomas of the skin	1.8	1.6	1.9	1.2	1.6	1.6	1.3	1.8	2.1	1.6	1.8	1.1	0.2
Other skin cancers	0.7	0.6	0.5	0.5	0.6	0.4	0.6	0.8	0.2	0.6	0.7	0.3	0.6
Breast	**15.1**	**15.4**	**18.0**	**16.1**	**14.4**	**14.0**	**16.7**	**11.6**	**12.4**	**15.5**	**16.4**	**8.8**	**5.8**
Female genital system	**10.4**	**10.0**	**10.2**	**10.7**	**10.2**	**10.0**	**9.4**	**9.8**	**7.8**	**9.8**	**10.3**	**6.6**	**8.7**
Cervix uteri	2.6	2.2	1.7	3.0	2.2	2.8	2.7	3.0	1.2	1.9	2.0	1.7	2.6
Corpus uteri	1.1	1.1	1.2	1.0	1.1	1.1	1.1	1.0	1.2	1.2	1.2	0.9	0.4
Uterus, NOS	1.4	1.3	1.5	1.4	1.3	1.2	1.7	1.1	1.3	1.2	1.3	1.0	3.6
Ovary	4.7	4.8	5.3	4.8	5.0	4.2	3.4	4.2	3.8	5.0	5.3	2.7	1.4
Vagina	0.2	0.2	0.1	0.2	0.2	0.3	0.2	0.1	0.1	0.2	0.1	0.1	0.3
Vulva	0.2	0.2	0.3	0.2	0.3	0.1	0.2	0.3	0.1	0.2	0.3	0.0	0.3
Other female genital organs	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.0	0.2	0.1	0.2	0.11

Male genital system	**9.2**	**9.4**	**9.3**	**10.3**	**9.5**	**9.6**	**9.8**	**9.6**	**9.5**	**9.3**	**8.6**	**6.3**	**9.6**
Prostate gland	8.7	8.9	8.9	9.8	9.0	9.3	9.5	9.3	9.0	8.9	8.2	5.8	9.1
Testis	0.3	0.4	0.4	0.4	0.5	0.2	0.3	0.3	0.5	0.4	0.3	0.3	0.1
Penis	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	.....	0.1	0.0	0.1	0.4
Other male genital organs	0.0	0.0	0.0	0.0	0.0	0.0	.....	.....	0.0	0.0	.....	0.0	0.0
Urinary system	**7.5**	**7.6**	**8.2**	**8.2**	**7.4**	**6.8**	**8.6**	**6.8**	**5.6**	**7.8**	**7.2**	**6.4**	**3.7**
Urinary bladder	4.2	4.3	4.9	4.6	4.0	4.3	4.8	3.4	3.1	4.5	4.4	3.7	2.6
Kidney and renal pelvis	3.1	3.0	3.2	3.4	3.2	2.4	3.5	3.2	2.3	3.0	2.6	2.7	1.0
Ureter	0.1	0.1	0.1	0.1	0.1	0.1	.....	0.1	0.2	0.1	0.1	0.0	.....
Other urinary organs	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	0.0	0.1
Eye	**0.1**	**0.1**	**0.1**	**0.1**	**0.2**	**0.2**	**0.2**	**0.1**	**0.2**	**0.2**	**0.1**	**0.1**	**0.1**
Brain and other nervous system	**3.9**	**3.9**	**3.8**	**4.0**	**4.0**	**4.0**	**3.8**	**3.4**	**3.3**	**5.3**	**3.9**	**2.8**	**1.6**
Brain	3.1	3.2	2.8	3.6	3.7	2.9	2.8	2.7	2.6	4.7	3.0	2.1	1.0
Other nervous system	0.8	0.7	1.0	0.4	0.4	1.1	1.0	0.7	0.7	0.6	0.9	0.7	0.6
Endocrine system	**0.6**	**0.7**	**0.7**	**0.6**	**0.6**	**0.5**	**0.9**	**0.8**	**0.5**	**0.7**	**0.6**	**1.2**	**0.4**
Thyroid gland	0.4	0.4	0.5	0.4	0.4	0.3	0.7	0.7	0.4	0.5	0.4	0.8	0.3
Other endocrine (including thymus)	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.4	0.1
Lymphomas	**6.0**	**6.1**	**6.0**	**6.1**	**6.8**	**4.9**	**6.1**	**5.1**	**5.7**	**5.9**	**6.4**	**5.6**	**2.8**
Hodgkin's disease	1.1	1.1	1.2	1.3	1.3	0.7	1.2	1.2	1.0	1.2	1.0	0.7	0.5
Non-Hodgkin's lymphomas	4.8	5.0	4.8	4.8	5.6	4.1	4.9	3.9	4.7	4.7	5.4	4.8	2.3
Multiple myeloma	**2.5**	**2.6**	**2.6**	**2.7**	**2.6**	**3.0**	**3.2**	**2.1**	**2.2**	**2.8**	**2.7**	**2.0**	**1.9**
Leukemias	**6.7**	**6.8**	**7.2**	**6.6**	**7.3**	**6.9**	**7.2**	**6.0**	**6.0**	**7.0**	**6.5**	**5.6**	**5.1**
Lymphocytic	2.1	2.0	2.1	1.6	2.9	1.9	1.7	1.8	1.8	2.1	1.7	1.4	1.1
Acute lymphocytic	0.7	0.7	0.8	0.4	1.2	0.7	0.6	0.6	0.7	0.7	0.6	0.8	0.6
Chronic lymphocytic	1.1	1.0	1.1	1.0	1.3	1.1	0.9	0.9	0.8	1.1	0.8	0.5	0.3
Other lymphocytic	0.3	0.3	0.2	0.3	0.4	0.1	0.2	0.3	0.3	0.3	0.2	0.1	0.2
Granulocytic	3.0	3.1	3.1	2.9	3.5	3.2	3.1	2.3	3.1	3.1	3.2	2.8	2.2
Acute granulocytic	2.0	2.1	2.0	1.9	2.3	2.2	2.0	1.3	2.2	2.2	2.2	1.8	1.2
Chronic granulocytic	0.8	0.8	0.9	0.8	0.8	0.8	0.8	0.7	0.8	0.9	0.8	0.8	0.8
Other granulocytic	0.2	0.2	0.2	0.1	0.3	0.3	0.3	0.2	0.1	0.1	0.2	0.2	0.2
Monocytic	0.2	0.2	0.3	0.2	0.3	0.1	0.6	0.3	0.2	0.2	0.2	0.4	0.0
Acute monocytic	0.1	0.2	0.2	0.1	0.2	0.1	0.5	0.2	0.1	0.1	0.1	0.3	0.0
Chronic monocytic	0.0	0.0	0.0	.....	.....	.....	.....	0.0	.....	.....	0.0	0.0	.....
Other monocytic	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0
Other	1.4	1.5	1.7	2.0	0.7	1.6	1.9	1.7	1.0	1.6	1.5	1.0	1.8
Other acute	0.8	0.9	1.0	1.4	0.3	1.0	0.8	0.8	0.5	1.0	1.1	0.6	0.7
Other chronic	0.1	0.0	0.1	0.0	0.0	.....	0.2	.....	0.0	0.1	0.0	0.0	0.1
Aleukemic, subleukemic, and NOS	0.5	0.5	0.6	0.5	0.3	0.6	0.9	0.8	0.5	0.5	0.4	0.3	1.1
Other, ill-defined, and unknown sites	**11.0**	**11.2**	**11.9**	**11.6**	**7.8**	**14.4**	**22.6**	**14.4**	**10.7**	**9.7**	**11.0**	**9.1**	**8.1**

TABLE 5H.—*Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for all races, males*

Primary site	United States 1973–77	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Puerto Rico 1973–77
All sites	211.5	212.7	223.5	231.6	199.5	225.1	275.3	175.5	150.9	209.5	215.5	187.8	155.8
Buccal cavity and pharynx	5.9	6.0	7.3	6.5	4.2	6.8	11.7	3.4	2.6	5.2	6.9	7.0	12.0
Lip	0.2	0.1	0.1	0.1	0.2	0.1	0.2	.....	.....	0.2	0.1	0.1	0.1
Tongue	1.4	1.4	1.9	1.7	0.7	1.7	2.6	1.0	0.7	1.1	1.7	1.1	3.5
Major salivary gland	0.4	0.3	0.5	0.3	0.4	0.2	0.3	0.3	0.3	0.4	0.2	0.4	0.1
Floor of mouth	0.4	0.4	0.7	0.4	0.2	0.2	0.8	0.2	0.2	0.3	0.4	0.6	0.3
Gum and other mouth	0.9	0.9	1.2	1.0	0.8	0.7	1.7	0.3	0.4	0.6	1.1	0.6	1.1
Nasopharynx	0.4	0.5	0.3	0.5	0.2	0.6	0.5	0.2	0.1	0.4	0.8	1.8	0.2
Tonsil	0.5	0.5	0.6	0.6	0.3	0.9	1.0	0.4	0.3	0.4	0.7	0.5	0.7
Oropharynx	0.2	0.3	0.3	0.3	0.2	0.3	0.5	0.1	0.1	0.2	0.4	0.3	0.6
Hypopharynx	0.5	0.5	0.5	0.5	0.4	0.6	0.9	0.2	0.2	0.5	0.6	1.0	0.8
Pharynx and other buccal cavity	1.0	1.0	1.2	1.1	0.7	1.4	3.2	0.6	0.4	1.0	1.0	0.7	4.7
Digestive system	57.7	60.5	67.1	65.0	54.8	54.0	69.2	50.0	41.3	55.5	63.7	71.7	67.2
Esophagus	5.3	5.7	6.4	7.2	4.1	6.4	7.4	2.6	3.1	4.8	6.0	6.5	17.3
Stomach	9.6	10.5	11.6	11.5	7.6	6.6	10.8	11.0	7.2	8.8	11.4	22.1	24.4
Small intestine	0.4	0.4	0.4	0.5	0.4	0.3	0.3	0.4	0.3	0.3	0.5	0.5	0.4
Colon excluding rectum	20.0	20.9	23.6	22.1	21.8	18.1	23.3	15.3	14.2	19.7	21.3	15.4	7.0
Rectum and rectosigmoid	5.7	5.7	7.1	5.9	5.6	4.3	8.1	3.5	3.0	5.2	5.9	5.8	2.4
Anal canal and anorectum	0.0	0.0	0.0	0.0	0.0	.....	.....	.....	.....	.....	0.0	0.1	0.0
Liver	3.1	3.0	2.6	3.3	2.2	3.8	4.5	2.7	1.4	2.5	3.5	6.9	7.2
Gallbladder	0.7	0.8	0.8	0.9	0.7	0.6	0.6	1.3	0.7	0.6	0.6	1.0	0.5
Other biliary	1.1	1.2	1.2	1.1	1.0	1.0	0.7	1.5	0.8	1.1	1.4	2.9	0.6
Pancreas	11.1	11.6	12.6	11.7	10.7	12.3	12.3	11.2	9.9	11.4	12.3	9.6	6.1
Retroperitoneum	0.3	0.3	0.3	0.3	0.3	0.1	0.4	0.3	0.2	0.3	0.4	0.4	0.1
Peritoneum	0.1	0.1	0.2	0.1	0.1	.....	0.2	0.1	0.1	0.0	0.2	.....	0.2
Other digestive organs	0.4	0.3	0.2	0.4	0.3	0.4	0.6	0.1	0.4	0.6	0.2	0.4	0.9
Respiratory system	69.9	67.2	68.0	77.8	63.2	78.5	94.0	49.4	36.1	69.8	66.9	50.4	25.5
Nasal cavity, sinuses, and ear	0.4	0.3	0.2	0.3	0.3	0.6	0.5	0.2	0.3	0.3	0.3	0.7	0.4
Larynx	2.9	2.8	2.8	3.7	2.4	3.8	3.5	2.1	1.8	2.3	2.6	1.4	5.8
Lung and bronchus	66.0	63.5	64.6	73.2	59.9	73.6	89.3	46.7	33.6	66.2	63.1	47.9	18.8
Trachea, pleura, mediastinum, and other	0.6	0.6	0.4	0.6	0.7	0.5	0.6	0.5	0.4	0.9	0.9	0.4	0.5
Bones and joints	1.0	0.9	0.8	0.9	1.1	1.1	1.5	0.7	0.7	0.9	0.8	0.6	1.4
Soft tissues (including heart)	1.0	1.2	1.2	1.3	1.1	1.0	1.3	1.3	0.9	1.3	1.1	1.0	0.4
Skin	3.2	2.8	3.2	2.1	2.8	2.4	2.8	3.6	2.8	2.5	3.2	2.3	0.8
Melanomas of the skin	2.3	2.0	2.4	1.5	1.9	2.0	1.7	2.4	2.5	1.7	2.3	1.7	0.2
Other skin cancers	1.0	0.8	0.8	0.6	0.9	0.4	1.1	1.3	0.3	0.8	0.9	0.6	0.6
Breast	0.3	0.3	0.4	0.3	0.1	0.5	0.2	0.2	0.1	0.3	0.3	0.1	0.1

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/35

Male genital system	**23.0**	**23.6**	**23.8**	**25.4**	**24.1**	**27.5**	**26.7**	**21.3**	**23.0**	**23.5**	**22.3**	**13.9**	**20.3**
Prostatic gland	22.0	22.6	22.8	24.4	22.8	26.9	26.0	20.5	21.9	22.6	21.5	13.1	19.2
Testis	0.7	0.8	0.8	0.8	1.0	0.4	0.6	0.6	1.0	0.8	0.7	0.6	0.2
Penis	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	—	0.2	0.1	0.2	0.8
Other male genital organs	0.0	0.0	0.1	0.0	0.0	0.1	—	—	0.1	0.0	—	0.1	0.1
Urinary system	**11.9**	**12.0**	**13.1**	**12.5**	**12.0**	**10.2**	**13.8**	**9.7**	**8.9**	**12.4**	**11.8**	**8.9**	**5.0**
Urinary bladder	7.2	7.4	8.3	7.6	7.4	6.9	8.0	5.2	5.4	7.6	7.5	5.0	3.7
Kidney and renal pelvis	4.4	4.4	4.6	4.7	4.4	3.2	5.6	4.4	3.1	4.5	4.0	3.8	1.1
Ureter	0.1	0.2	0.1	0.1	0.2	—	—	0.1	0.3	0.2	0.2	0.1	—
Other urinary organs	0.1	0.1	0.0	0.1	0.0	0.2	0.2	0.0	0.1	0.1	0.1	—	0.1
Eye	**0.2**	**0.1**	**0.0**	**0.2**	**0.1**	**0.2**	**0.2**	**0.0**	**0.1**	**0.2**	**0.2**	**0.1**	**0.1**
Brain and other nervous system	**4.7**	**4.9**	**4.6**	**4.9**	**5.2**	**4.8**	**4.9**	**4.8**	**3.6**	**6.5**	**4.8**	**3.4**	**1.9**
Brain	3.7	4.0	3.3	4.4	4.8	3.6	3.4	4.0	2.7	5.5	3.7	2.7	1.1
Other nervous system	1.0	0.8	1.4	0.5	0.4	1.2	1.5	0.8	0.9	0.9	1.1	0.6	0.8
Endocrine system	**0.6**	**0.6**	**0.7**	**0.6**	**0.6**	**0.5**	**0.9**	**0.8**	**0.5**	**0.6**	**0.5**	**1.5**	**0.4**
Thyroid gland	0.4	0.4	0.4	0.4	0.3	0.2	0.6	0.6	0.3	0.3	0.3	0.8	0.3
Other endocrine (including thymus)	0.2	0.3	0.3	0.2	0.3	0.3	0.3	0.2	0.2	0.3	0.2	0.7	0.1
Lymphomas	**7.3**	**7.5**	**7.4**	**7.5**	**8.1**	**6.0**	**7.3**	**5.9**	**7.2**	**7.2**	**8.2**	**6.7**	**3.6**
Hodgkin's disease	1.5	1.5	1.6	1.8	1.6	1.2	1.4	1.4	1.5	1.5	1.3	0.8	0.8
Non-Hodgkin's lymphomas	5.8	6.0	5.8	5.7	6.5	4.7	6.0	4.5	5.7	5.7	6.9	5.9	2.9
Multiple myeloma	**3.0**	**3.1**	**2.9**	**3.4**	**3.1**	**3.5**	**3.7**	**2.4**	**2.8**	**3.4**	**3.3**	**2.2**	**2.0**
Leukemias	**8.8**	**9.1**	**9.1**	**9.2**	**9.9**	**9.9**	**9.5**	**7.9**	**8.1**	**9.2**	**8.5**	**6.8**	**5.9**
Lymphocytic	2.9	2.9	3.0	2.6	3.9	3.3	2.4	2.4	2.7	3.1	2.3	1.8	1.3
Acute lymphocytic	0.9	1.0	1.0	0.6	1.6	1.2	1.0	0.9	0.8	1.0	0.7	1.0	0.7
Chronic lymphocytic	1.6	1.5	1.7	1.6	1.8	1.9	1.0	1.0	1.4	1.8	1.2	0.8	0.4
Other lymphocytic	0.4	0.4	0.3	0.5	0.5	0.2	0.3	0.4	0.5	0.3	0.4	—	0.3
Granulocytic	3.8	3.9	3.7	3.6	4.6	4.3	3.8	3.0	3.8	3.9	4.0	3.3	2.4
Acute granulocytic	2.5	2.5	2.4	2.3	2.9	2.8	2.6	1.7	2.6	2.5	2.7	2.1	1.1
Chronic granulocytic	1.1	1.1	1.2	1.2	1.2	1.1	0.7	1.0	1.0	1.3	1.0	1.1	1.0
Other granulocytic	0.3	0.3	0.2	0.2	0.5	0.3	0.5	0.3	0.2	0.1	0.2	0.1	0.3
Monocytic	0.3	0.3	0.3	0.2	0.3	0.2	0.7	0.4	0.2	0.3	0.3	0.4	0.0
Acute monocytic	0.2	0.2	0.2	0.1	0.2	0.1	0.5	0.4	0.1	0.1	0.1	0.3	0.0
Chronic monocytic	0.0	0.0	0.0	—	—	—	—	—	—	—	0.0	0.1	—
Other monocytic	0.1	0.1	0.1	0.1	0.2	0.1	0.2	—	0.1	0.2	0.1	—	—
Other	1.9	2.0	2.1	2.7	1.1	2.1	2.6	2.3	1.4	1.9	2.0	1.3	2.2
Other acute	1.0	1.2	1.2	1.9	0.5	1.2	1.2	1.0	0.6	1.2	1.4	0.8	0.8
Other chronic	0.1	0.0	0.1	0.1	0.0	—	0.2	—	—	0.1	0.1	—	0.1
Aleukemic, subleukemic, and NOS	0.7	0.7	0.9	0.7	0.6	0.9	1.2	1.2	0.8	0.7	0.5	0.5	1.3
Other, ill-defined, and unknown sites	**13.0**	**13.1**	**14.0**	**14.0**	**9.0**	**18.2**	**27.5**	**14.1**	**12.1**	**11.0**	**13.0**	**11.4**	**9.0**

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/36

TABLE 30 *Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for all races, females*

Primary site	United States 1973-77	All areas ex. Puerto Rico 1973-77	Connecticut 1973-77	Detroit 1973-77	Iowa 1973-77	Atlanta 1975-77	New Orleans 1974-77	New Mexico 1973-77	Utah 1973-77	Seattle-Puget Sound 1974-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	Puerto Rico 1973-77
All sites	**134.6**	**137.7**	**148.2**	**141.5**	**125.4**	**128.8**	**152.3**	**135.1**	**104.1**	**138.6**	**147.2**	**119.8**	**100.3**
Buccal cavity and pharynx	**1.9**	**2.1**	**2.0**	**1.6**	**1.5**	**2.4**	**2.1**	**1.4**	**1.3**	**2.4**	**3.2**	**2.9**	**2.7**
Lip	0.0	0.0	0.0	.....	0.0	.....	.....	.....	.....	0.0	0.0	.....	0.0
Tongue	0.5	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.4	0.6	0.9	0.5	0.7
Major salivary gland	0.2	0.2	0.1	0.2	0.2	0.1	0.0	0.1	0.2	0.2	0.2	0.2	0.1
Floor of mouth	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1
Gum and other mouth	0.4	0.4	0.4	0.3	0.3	0.6	0.5	0.1	0.1	0.4	0.5	0.5	0.4
Nasopharynx	0.2	0.2	0.1	0.1	0.2	0.3	.....	0.1	0.1	0.2	0.3	0.6	0.1
Tonsil	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.3	0.3	0.2
Oropharynx	0.1	0.1	0.1	0.1	0.0	.....	.....	.....	.....	0.1	0.1	0.2	0.1
Hypopharynx	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.0	0.1	0.2	0.1	0.1
Pharynx and other buccal cavity	0.3	0.3	0.3	0.1	0.2	0.2	0.7	0.3	0.3	0.5	0.5	0.4	0.9
Digestive system	**37.4**	**38.8**	**43.8**	**39.7**	**36.5**	**32.8**	**39.8**	**41.9**	**28.6**	**35.7**	**40.4**	**41.0**	**37.9**
Esophagus	1.5	1.6	1.8	2.3	1.0	1.6	1.4	1.3	0.5	1.3	2.1	1.4	6.1
Stomach	4.6	5.0	5.6	4.9	3.2	3.7	6.1	6.1	4.2	4.2	5.6	11.1	11.2
Small intestine	0.3	0.3	0.4	0.4	0.3	0.1	0.2	0.1	0.1	0.3	0.3	0.2	0.3
Colon excluding rectum	16.5	16.8	19.4	16.9	18.1	14.9	16.1	15.5	12.3	15.4	16.4	11.7	6.2
Rectum and rectosigmoid	3.3	3.3	4.2	3.2	3.1	2.3	3.7	2.2	2.0	3.1	3.6	3.0	2.0
Anal canal and anorectum	0.0	0.0	.....	0.0	0.0	0.0	.....	0.0	0.0	0.1	0.0	.....	0.0
Liver	1.6	1.4	1.2	1.6	1.3	1.3	1.6	2.1	0.8	1.4	1.4	2.8	4.8
Gallbladder	1.4	1.4	1.4	1.7	1.5	0.9	1.2	3.8	1.3	1.2	0.9	1.5	1.2
Other biliary	0.8	0.9	1.1	0.9	0.8	0.9	0.6	1.1	0.8	0.9	1.0	1.8	0.8
Pancreas	6.9	7.5	8.2	7.4	6.6	6.5	8.3	8.2	6.0	7.0	8.6	7.0	4.4
Retroperitoneum	0.2	0.2	0.1	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.0
Peritoneum	0.1	0.1	0.1	0.1	0.2	.....	0.3	0.2	0.2	0.2	0.2	0.1	0.3
Other digestive organs	0.3	0.3	0.3	0.2	0.3	0.4	0.2	0.4	0.1	0.5	0.2	0.2	0.6
Respiratory system	**16.4**	**17.0**	**17.0**	**18.0**	**11.5**	**16.7**	**20.0**	**16.8**	**6.7**	**20.1**	**21.9**	**17.6**	**9.5**
Nasal cavity, sinuses, and ear	0.2	0.1	0.1	0.1	0.2	0.3	0.0	0.1	0.2	0.2	0.1	0.2	0.1
Larynx	0.4	0.4	0.3	0.5	0.3	0.4	0.4	0.4	0.1	0.5	0.6	0.5	1.2
Lung and bronchus	15.5	16.2	16.3	17.2	10.8	15.8	19.3	16.0	6.2	19.1	21.1	16.8	7.8
Trachea, pleura, mediastinum, and other	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.3	0.2	0.4	0.2	0.1	0.4
Bones and joints	**0.6**	**0.6**	**0.6**	**0.5**	**0.7**	**0.8**	**0.8**	**0.5**	**0.4**	**0.6**	**0.4**	**0.5**	**1.1**
Soft tissues (including heart)	**0.8**	**0.9**	**0.8**	**0.8**	**0.9**	**0.8**	**0.7**	**0.9**	**1.0**	**0.9**	**1.0**	**1.1**	**0.4**
Skin	**1.8**	**1.7**	**1.8**	**1.4**	**1.8**	**1.6**	**1.4**	**1.7**	**1.9**	**1.8**	**2.0**	**0.7**	**0.7**
Melanomas of the skin	1.4	1.3	1.5	1.0	1.4	1.2	1.1	1.4	1.7	1.4	1.4	0.5	0.2
Other skin cancers	0.4	0.4	0.3	0.4	0.4	0.3	0.3	0.3	0.2	0.4	0.5	0.1	0.6
Breast	**27.0**	**27.9**	**32.0**	**29.2**	**26.1**	**24.1**	**29.2**	**21.8**	**22.9**	**28.4**	**29.6**	**16.2**	**11.2**
Female genital system	**18.6**	**18.1**	**18.1**	**19.4**	**18.4**	**17.2**	**16.3**	**18.5**	**14.4**	**17.9**	**18.4**	**13.1**	**16.9**
Cervix uteri	4.7	4.1	3.1	5.5	4.0	5.0	4.8	5.7	2.3	3.6	3.7	3.3	5.0
Corpus uteri	1.9	2.0	2.1	1.9	1.9	2.0	1.7	1.8	2.2	2.1	2.1	1.7	0.7
Uterus, NOS	2.5	2.3	2.6	2.4	2.3	2.0	2.8	2.0	2.4	2.2	2.3	2.0	7.0
Ovary	8.5	8.7	9.5	8.7	9.1	7.4	5.9	7.9	7.1	9.2	9.5	5.4	2.7
Vagina	0.3	0.3	0.2	0.3	0.4	0.5	0.4	0.1	0.1	0.3	0.2	0.1	0.6
Vulva	0.4	0.4	0.4	0.4	0.4	0.2	0.4	0.5	0.2	0.3	0.5	0.0	0.6
Other female genital organs	0.2	0.3	0.2	0.2	0.3	0.3	0.3	0.4	0.1	0.4	0.3	0.3	0.2

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/37

Urinary system	**4.3**	**4.4**	**4.8**	**5.1**	**4.1**	**4.7**	**5.1**	**4.3**	**5.1**	**4.5**	**5.7**	**4.3**	**4.6**
Urinary bladder	2.1	2.3	2.5	2.5	1.7	2.8	2.9	2.0	1.4	2.5	2.3	2.5	1.6
Kidney and renal pelvis	2.0	2.0	2.1	2.4	2.3	1.7	2.1	2.2	1.6	1.8	1.6	1.7	0.9
Ureter	0.1	0.1	0.1	0.1	0.1	0.1	.....	0.0	0.1	0.1	0.0	.....	.....
Other urinary organs	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1
Eye	**0.1**	**0.1**	**0.1**	**0.1**	**0.2**	**0.3**	**0.2**	**0.1**	**0.2**	**0.2**	**0.1**	.....	**0.2**
Brain and other nervous system	**3.2**	**3.2**	**3.2**	**3.3**	**3.0**	**3.4**	**3.0**	**2.2**	**2.9**	**4.3**	**3.1**	**2.1**	**1.3**
Brain	2.5	2.6	2.4	2.9	2.7	2.3	2.3	1.6	2.5	4.0	2.4	1.4	0.9
Other nervous system	0.6	0.5	0.8	0.3	0.3	1.1	0.7	0.6	0.4	0.3	0.7	0.8	0.4
Endocrine system	**0.7**	**0.7**	**0.7**	**0.6**	**0.6**	**0.5**	**0.8**	**0.9**	**0.6**	**0.7**	**0.8**	**1.1**	**0.4**
Thyroid gland	0.5	0.5	0.5	0.5	0.4	0.4	0.7	0.8	0.5	0.6	0.5	0.9	0.3
Other endocrine (including thymus)	0.2	0.2	0.2	0.1	0.2	0.0	0.1	0.1	0.1	0.2	0.3	0.1	0.1
Lymphomas	**4.9**	**5.0**	**4.9**	**5.0**	**5.8**	**4.2**	**5.0**	**4.4**	**4.5**	**4.7**	**5.0**	**4.5**	**2.0**
Hodgkin's disease	0.9	0.8	0.8	0.9	1.0	0.4	1.0	1.0	0.6	0.8	0.8	0.7	0.3
Non-Hodgkin's lymphomas	4.0	4.2	4.1	4.1	4.8	3.8	4.0	3.4	3.8	3.9	4.3	3.8	1.7
Multiple myeloma	**2.0**	**2.3**	**2.4**	**2.2**	**2.2**	**2.7**	**2.9**	**1.9**	**1.7**	**2.4**	**2.4**	**1.9**	**1.8**
Leukemias	**5.2**	**5.2**	**5.7**	**4.8**	**5.5**	**4.7**	**5.7**	**4.3**	**4.4**	**5.3**	**5.2**	**4.5**	**4.4**
Lymphocytic	1.5	1.3	1.5	1.0	2.1	1.1	1.1	1.3	1.0	1.3	1.2	1.0	1.0
Acute lymphocytic	0.6	0.5	0.6	0.3	0.8	0.3	0.2	0.3	0.5	0.4	0.6	0.6	0.5
Chronic lymphocytic	0.7	0.7	0.7	0.5	0.9	0.6	0.8	0.8	0.4	0.6	0.5	0.3	0.3
Other lymphocytic	0.2	0.2	0.2	0.1	0.4	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.2
Granulocytic	2.5	2.5	2.7	2.2	2.8	2.4	2.6	1.7	2.5	2.5	2.7	2.4	2.0
Acute granulocytic	1.7	1.8	1.8	1.6	1.9	1.8	1.6	1.0	1.8	1.9	1.9	1.7	1.3
Chronic granulocytic	0.6	0.6	0.7	0.5	0.6	0.4	0.9	0.5	0.7	0.5	0.6	0.5	0.6
Other granulocytic	0.2	0.2	0.1	0.1	0.3	0.2	0.2	0.2	.....	0.1	0.2	0.3	0.1
Monocytic	0.2	0.2	0.2	0.1	0.2	0.1	0.4	0.2	0.2	0.1	0.2	0.4	0.0
Acute monocytic	0.1	0.1	0.1	0.1	0.2	0.1	0.4	0.0	0.1	0.1	0.1	0.4	.....
Chronic monocytic	0.0	0.0	0.0	.....	.....	.....	.....	0.0	.....	.....	.....	.....	.....
Other monocytic	0.0	0.0	0.1	0.0	0.0	.....	.....	0.1	0.0	0.0	0.0	0.1	0.0
Other	1.1	1.1	1.3	1.5	0.4	1.2	1.5	1.2	0.7	1.5	1.1	0.6	1.5
Other acute	0.6	0.7	0.9	1.1	0.2	0.8	0.5	0.7	0.4	0.9	0.9	0.4	0.5
Other chronic	0.0	0.0	0.1	0.0	0.0	.....	0.1	.....	0.0	0.1	0.0	0.1	0.1
Aleukemic, subleukemic, and NOS	0.4	0.3	0.4	0.4	0.2	0.4	0.8	0.5	0.3	0.4	0.2	0.1	0.8
Other, ill-defined, and unknown sites	**9.6**	**9.8**	**10.3**	**9.8**	**6.7**	**11.9**	**19.5**	**14.5**	**9.5**	**8.8**	**9.6**	**7.3**	**7.3**

TABLE 3D.—*Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for whites, both sexes*

Primary site	United States 1973–77	All areas ex. Puerto Rico 1973–77	Connecticut 1973–77	Detroit 1973–77	Iowa 1973–77	Atlanta 1975–77	New Orleans 1974–77	New Mexico 1973–77	Utah 1973–77	Seattle-Puget Sound 1974–77	San Francisco-Oakland 1973–77	Hawaii 1973–77
All sites	163.5	166.1	176.6	172.7	156.0	158.2	186.4	156.1	123.9	167.1	174.0	168.6
Buccal cavity and pharynx	3.5	3.7	4.1	3.6	2.7	3.9	5.6	2.5	1.9	3.6	4.7	7.0
Lip	0.1	0.1	0.1	0.1	0.1	0.0	0.1			0.1	0.1	0.2
Tongue	0.8	0.9	1.1	0.9	0.5	1.0	1.4	0.8	0.5	0.8	1.3	1.0
Major salivary gland	0.3	0.2	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.3	0.2	0.5
Floor of mouth	0.2	0.2	0.3	0.2	0.1	0.2	0.5	0.1	0.2	0.2	0.3	0.2
Gum and other mouth	0.6	0.6	0.7	0.6	0.5	0.8	0.7	0.2	0.2	0.5	0.7	1.1
Nasopharynx	0.3	0.3	0.2	0.3	0.2	0.4	0.3	0.2	0.1	0.2	0.4	0.6
Tonsil	0.3	0.3	0.3	0.3	0.2	0.4	0.5	0.3	0.1	0.3	0.4	0.9
Oropharynx	0.1	0.2	0.2	0.2	0.1	0.1	0.2	0.0	0.1	0.1	0.3	0.6
Hypopharynx	0.3	0.3	0.3	0.3	0.2	0.2	0.4	0.2	0.1	0.3	0.3	1.1
Pharynx and other buccal cavity	0.6	0.6	0.7	0.6	0.4	0.6	1.4	0.4	0.4	0.7	0.7	0.8
Digestive system	44.7	46.6	52.9	48.2	44.3	37.6	48.0	45.3	34.1	43.5	48.8	47.9
Esophagus	2.6	2.9	3.4	3.6	2.3	2.1	2.9	1.9	1.7	2.8	3.3	3.5
Stomach	6.2	6.6	8.0	7.1	5.0	3.9	5.4	8.1	5.3	5.9	7.6	10.0
Small intestine	0.3	0.3	0.4	0.4	0.4	0.2	0.2	0.3	0.2	0.3	0.4	0.5
Colon excluding rectum	18.1	18.7	21.2	18.9	19.6	15.2	19.5	16.1	13.3	17.1	18.7	15.7
Rectum and rectosigmoid	4.3	4.3	5.4	4.3	4.1	2.9	4.9	2.9	2.5	4.0	4.6	2.8
Anal canal and anorectum	0.0	0.0	0.0	0.0	0.0	.....	.....	0.0	0.0	0.0	0.0	.....
Liver	2.0	1.9	1.8	2.2	1.6	1.8	2.8	2.3	1.0	1.8	2.0	2.8
Gallbladder	1.1	1.1	1.1	1.4	1.2	0.8	0.9	2.3	1.0	0.9	0.8	0.6
Other biliary	1.0	1.0	1.2	1.0	0.9	1.1	0.8	1.2	0.9	1.0	1.1	2.2
Pancreas	8.6	9.1	9.9	8.7	8.3	9.1	9.6	9.6	7.7	8.8	9.8	9.3
Retroperitoneum	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.3	0.2	0.2
Peritoneum	0.1	0.1	0.1	0.1	0.2	.....	0.3	0.1	0.2	0.1	0.2	.....
Other digestive organs	0.3	0.3	0.2	0.2	0.3	0.3	0.4	0.2	0.2	0.5	0.2	0.4
Respiratory system	39.0	38.1	38.0	41.9	34.0	42.7	48.3	33.2	19.9	41.8	40.9	38.6
Nasal cavity, sinuses, and ear	0.3	0.2	0.1	0.2	0.2	0.4	0.3	0.2	0.2	0.2	0.2	0.2
Larynx	1.4	1.4	1.3	1.8	1.2	1.8	1.7	1.2	0.8	1.3	1.4	1.1
Lung and bronchus	36.9	36.1	36.3	39.6	32.2	40.2	46.1	31.4	18.6	39.6	38.7	37.0
Trachea, pleura, mediastinum, and other	0.4	0.4	0.2	0.3	0.4	0.2	0.3	0.4	0.3	0.6	0.5	0.3
Bones and joints	0.8	0.7	0.7	0.7	0.9	0.9	0.9	0.6	0.6	0.8	0.6	0.2
Soft tissues (including heart)	0.9	1.0	1.0	1.0	1.0	0.9	0.9	1.1	1.0	1.1	1.0	1.7
Skin	2.6	2.4	2.5	1.9	2.3	2.3	2.3	2.8	2.3	2.2	2.8	3.3
Melanomas of the skin	1.9	1.8	2.0	1.4	1.6	1.9	1.7	2.0	2.1	1.6	2.1	2.6
Other skin cancers	0.7	0.6	0.5	0.5	0.6	0.4	0.6	0.8	0.2	0.6	0.7	0.8
Breast	15.2	15.8	18.0	16.3	14.5	13.9	16.5	11.9	12.6	15.7	17.1	11.1
Female genital system	9.9	9.9	10.1	10.0	10.2	8.6	8.4	10.0	7.9	9.7	10.4	7.8
Cervix uteri	2.2	1.9	1.6	2.3	2.1	1.9	1.7	3.0	1.2	1.8	1.8	1.4
Corpus uteri	1.1	1.1	1.2	0.9	1.1	0.7	0.8	1.0	1.2	1.2	1.2	0.9
Uterus, NOS	1.4	1.3	1.4	1.4	1.3	1.0	1.4	1.1	1.4	1.2	1.3	1.3
Ovary	4.8	5.0	5.3	4.9	5.0	4.4	4.0	4.3	3.9	5.0	5.5	3.6
Vagina	0.2	0.1	0.1	0.2	0.2	0.3	0.2	0.1	0.1	0.2	0.1	0.2
Vulva	0.2	0.2	0.3	0.2	0.3	0.1	0.3	0.3	0.1	0.2	0.3	0.1
Other female genital organs	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.0	0.2	0.1	0.4

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/39

Male genital system	**8.5**	**9.0**	**9.1**	**8.9**	**9.6**	**8.2**	**7.7**	**9.6**	**9.4**	**9.3**	**8.4**	**10.1**
Prostatic gland	8.0	8.5	8.6	8.4	9.0	7.9	7.4	9.2	8.9	8.8	7.9	9.3
Testis	0.4	0.4	0.4	0.4	0.5	0.2	0.3	0.3	0.5	0.4	0.4	0.4
Penis	0.1	0.1	0.1	0.1	0.1	0.0	.....	0.1	.....	0.1	0.0	0.2
Other male genital organs	0.0	0.0	0.0	0.0	0.0	0.0	.....	.....	0.0	0.0	.....	0.2
Urinary system	**7.6**	**7.7**	**8.2**	**8.3**	**7.4**	**7.0**	**9.3**	**6.9**	**5.6**	**7.8**	**7.4**	**7.9**
Urinary bladder	4.2	4.4	4.8	4.6	4.0	4.4	5.3	3.6	3.1	4.6	4.5	4.4
Kidney and renal pelvis	3.1	3.1	3.2	3.5	3.2	2.4	3.9	3.2	2.4	3.0	2.6	3.4
Ureter	0.1	0.1	0.1	0.1	0.1	0.1	.....	0.1	0.2	0.2	0.1	.....
Other urinary organs	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1
Eye	**0.2**	**0.1**	**0.1**	**0.1**	**0.2**	**0.3**	**0.2**	**0.1**	**0.2**	**0.2**	**0.2**	.....
Brain and other nervous system	**4.0**	**4.2**	**3.9**	**4.3**	**4.1**	**4.5**	**4.0**	**3.7**	**3.3**	**5.4**	**4.2**	**4.9**
Brain	3.2	3.5	2.8	3.9	3.7	3.4	2.8	2.9	2.6	4.8	3.2	3.8
Other nervous system	0.8	0.7	1.0	0.4	0.4	1.1	1.2	0.8	0.7	0.6	0.9	1.2
Endocrine system	**0.6**	**0.6**	**0.7**	**0.6**	**0.6**	**0.5**	**0.9**	**0.8**	**0.5**	**0.7**	**0.6**	**0.8**
Thyroid gland	0.4	0.4	0.4	0.4	0.4	0.4	0.7	0.7	0.4	0.5	0.4	0.2
Other endocrine (including thymus)	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.3	0.6
Lymphomas	**6.2**	**6.3**	**6.1**	**6.5**	**6.8**	**5.3**	**6.7**	**5.1**	**5.7**	**5.9**	**6.8**	**5.9**
Hodgkin's disease	1.2	1.2	1.2	1.3	1.3	0.8	1.4	1.2	1.0	1.2	1.1	1.2
Non Hodgkin's lymphomas	5.0	5.1	4.9	5.1	5.6	4.6	5.3	3.9	4.7	4.8	5.7	4.6
Multiple myeloma	**2.3**	**2.4**	**2.5**	**2.3**	**2.6**	**2.6**	**2.6**	**2.0**	**2.1**	**2.7**	**2.4**	**2.1**
Leukemias	**6.9**	**6.9**	**7.2**	**6.8**	**7.4**	**7.1**	**7.0**	**6.2**	**6.1**	**7.0**	**6.7**	**7.1**
Lymphocytic	2.1	2.1	2.1	1.7	2.9	1.9	1.8	1.9	1.8	2.1	1.8	2.5
Acute lymphocytic	*0.8*	*0.8*	*0.8*	*0.4*	*1.2*	*0.8*	0.7	0.6	0.7	0.7	0.7	1.4
Chronic lymphocytic	1.1	1.0	1.1	1.0	1.3	1.0	0.9	1.0	0.9	1.1	0.9	1.0
Other lymphocytic	0.3	0.3	0.2	0.3	0.4	0.1	0.2	0.3	0.3	0.3	0.3	0.2
Granulocytic	3.1	3.2	3.1	2.9	3.5	3.4	3.1	2.3	3.1	3.1	3.2	3.2
Acute granulocytic	2.1	2.1	2.1	2.0	2.3	2.3	2.0	1.3	2.2	2.1	2.2	1.9
Chronic granulocytic	0.8	0.8	0.9	0.8	0.8	0.8	0.9	0.7	0.8	0.9	0.8	1.0
Other granulocytic	0.2	0.2	0.2	0.1	0.3	0.3	0.3	0.3	0.1	0.1	0.2	0.3
Monocytic	0.2	0.2	0.3	0.2	0.3	0.1	0.6	0.3	0.2	0.2	0.2	0.4
Acute monocytic	0.1	0.1	0.2	0.1	0.2	0.1	0.5	0.2	0.1	0.1	0.1	0.4
Chronic monocytic	0.0	0.0	0.0	.....	.....	.....	.....	0.0	.....	.....	0.0	.....
Other monocytic	0.1	0.1	0.1	0.1	0.1	.....	0.1	0.0	0.1	0.1	0.1	.....
Other	1.4	1.5	1.7	2.0	0.7	1.7	1.4	1.7	1.0	1.6	1.5	1.0
Other acute	0.8	0.9	1.0	1.4	0.3	1.0	0.8	0.9	0.5	1.0	1.1	0.3
Other chronic	0.1	0.0	0.1	0.0	0.0	.....	0.1	.....	0.0	0.0	0.0	0.2
Aleukemic, subleukemic, and NOS	0.5	0.5	0.6	0.5	0.3	0.7	0.6	0.9	0.5	0.5	0.4	0.5
Other, ill-defined, and unknown sites	**10.5**	**10.7**	**11.7**	**11.2**	**7.7**	**12.0**	**17.0**	**14.3**	**10.7**	**9.7**	**10.9**	**12.3**

TABLE 31.—*Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for white males*

Primary site	United States 1973-77	All areas ex. Puerto Rico 1973-77	Connecticut 1973-77	Detroit 1973-77	Iowa 1973-77	Atlanta 1975-77	New Orleans 1974-77	New Mexico 1973-77	Utah 1973-77	Seattle-Puget Sound 1974-77	San Francisco-Oakland 1973-77	Hawaii 1973-77
All sites	207.1	209.5	220.6	222.2	199.4	212.3	258.7	179.5	151.5	209.6	216.1	216.4
Buccal cavity and pharynx	5.6	5.8	7.0	6.3	4.1	6.1	11.3	3.5	2.6	5.2	6.8	9.9
Lip	0.2	0.2	0.2	0.1	0.2	0.1	0.3	.....	.....	0.2	0.1	0.4
Tongue	1.3	1.4	1.8	1.6	0.7	1.5	2.8	1.0	0.7	1.1	1.8	0.7
Major salivary gland	0.4	0.4	0.5	0.2	0.4	0.2	0.3	0.4	0.2	0.4	0.3	1.2
Floor of mouth	0.4	0.4	0.6	0.4	0.2	0.3	1.0	0.2	0.2	0.3	0.4	0.5
Gum and other mouth	0.8	0.9	1.2	1.0	0.8	0.7	1.1	0.3	0.4	0.6	1.1	1.2
Nasopharynx	0.4	0.4	0.2	0.4	0.2	0.6	0.6	0.2	0.2	0.3	0.6	0.8
Tonsil	0.5	0.5	0.6	0.5	0.3	0.9	1.0	0.5	0.1	0.4	0.6	1.0
Oropharynx	0.2	0.3	0.3	0.3	0.2	0.2	0.5	0.1	0.1	0.2	0.4	0.6
Hypopharynx	0.5	0.5	0.5	0.5	0.4	0.3	0.7	0.2	0.2	0.5	0.6	1.8
Pharynx and other buccal cavity	1.0	1.0	1.2	1.1	0.6	1.3	2.8	0.6	0.4	1.1	0.9	1.5
Digestive system	55.8	58.4	66.0	62.0	54.8	48.3	64.8	50.3	41.5	55.0	62.1	56.2
Esophagus	4.4	4.9	5.8	5.8	4.0	3.4	5.8	2.7	3.2	4.8	5.2	5.0
Stomach	8.9	9.5	11.3	10.7	7.5	5.3	6.9	10.2	7.1	8.7	10.9	13.7
Small intestine	0.3	0.4	0.4	0.4	0.5	0.3	0.2	0.5	0.3	0.3	0.5	1.2
Colon excluding rectum	20.2	21.3	23.6	22.3	21.9	16.6	25.4	16.0	14.4	19.7	22.0	17.1
Rectum and rectosigmoid	5.7	5.7	7.2	5.8	5.6	4.0	7.6	3.7	3.1	5.3	6.1	2.9
Anal canal and anorectum	0.0	0.0	0.0	0.0	0.0	.....	.....	.....	.....	.....	0.0	.....
Liver	2.8	2.6	2.6	3.0	2.2	3.6	4.6	2.6	1.3	2.2	2.9	2.9
Gallbladder	0.7	0.7	0.8	0.9	0.7	0.7	0.6	1.1	0.7	0.6	0.6	.....
Other biliary	1.1	1.2	1.3	1.1	1.0	1.1	0.8	1.5	0.9	1.2	1.4	2.7
Pancreas	11.0	11.4	12.5	11.2	10.7	13.0	11.7	11.5	9.9	11.3	11.7	10.5
Retroperitoneum	0.3	0.3	0.3	0.3	0.3	0.1	0.4	0.2	0.2	0.4	0.3	0.2
Peritoneum	0.1	0.1	0.2	0.1	0.1	.....	0.1	0.2	0.1	0.0	0.2	.....
Other digestive organs	0.3	0.3	0.2	0.3	0.3	0.2	0.6	0.1	0.4	0.6	0.3	0.2
Respiratory system	68.6	66.1	66.8	73.8	63.0	77.2	89.5	51.2	36.2	69.8	67.2	64.4
Nasal cavity, sinuses, and ear	0.4	0.3	0.2	0.3	0.3	0.6	0.5	0.2	0.2	0.3	0.3	0.3
Larynx	2.7	2.7	2.7	3.5	2.4	3.9	3.6	2.2	1.7	2.4	2.6	1.8
Lung and bronchus	64.9	62.5	61.5	69.4	59.8	72.4	84.8	48.3	33.8	66.1	63.3	62.0
Trachea, pleura, mediastinum, and other	0.6	0.6	0.3	0.6	0.7	0.3	0.5	0.5	0.4	0.9	1.0	0.2
Bones and joints	1.0	0.9	0.8	0.9	1.1	1.4	1.4	0.8	0.7	1.0	0.9	0.2
Soft tissues (including heart)	1.0	1.2	1.2	1.3	1.1	1.1	1.3	1.4	1.0	1.3	1.2	1.4
Skin	3.5	3.0	3.3	2.4	2.8	2.8	3.3	3.9	2.9	2.6	3.6	5.0
Melanomas of the skin	2.5	2.2	2.5	1.8	1.9	2.3	2.2	2.6	2.6	1.8	2.7	4.2
Other skin cancers	1.0	0.8	0.8	0.6	0.9	0.4	1.1	1.4	0.3	0.8	1.0	0.8
Breast	0.3	0.2	0.4	0.3	0.2	0.3	0.2	0.2	0.1	0.3	0.2	0.3

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/41

Prostate gland	20.6	22.0	22.3	21.2								
Testis	0.7	0.8	0.8	0.9	1.0	0.4	0.6	0.6	1.0	0.8	0.8	
Penis	0.2	0.2	0.2	0.2	0.2	0.1	.....	0.2	.....	0.2	0.1	0.4
Other male genital organs	0.0	0.0	0.1	0.0	0.0	0.1	.....	.....	0.1	0.0	.....	0.5
Urinary system	12.2	12.4	13.2	13.2	12.0	10.6	15.4	10.2	8.9	12.5	12.6	11.3
Urinary bladder	7.4	7.7	8.4	8.1	7.4	7.3	9.2	5.6	5.5	7.7	8.2	7.2
Kidney and renal pelvis	4.5	4.4	4.6	4.9	4.4	3.1	6.0	4.5	3.2	4.5	4.1	4.1
Ureter	0.2	0.2	0.2	0.1	0.2	.....	.....	0.1	0.2	0.2	0.3	.....
Other urinary organs	0.1	0.1	0.0	0.1	0.0	0.2	0.2	0.0	0.1	0.1	0.1	.....
Eye	0.2	0.1	0.0	0.2	0.1	0.2	0.2	.....	0.1	0.2	0.2	.....
Brain and other nervous system	4.9	5.1	4.7	5.2	5.2	5.5	5.1	5.1	3.7	6.7	5.2	6.4
Brain	3.9	4.2	3.3	4.8	4.8	4.2	3.3	4.3	2.8	5.7	4.0	5.3
Other nervous system	1.0	0.9	1.4	0.5	0.4	1.3	1.8	0.9	0.9	1.0	1.2	1.1
Endocrine system	0.6	0.6	0.7	0.6	0.6	0.5	0.9	0.8	0.5	0.6	0.5	1.6
Thyroid gland	0.4	0.4	0.4	0.4	0.3	0.3	0.5	0.6	0.4	0.3	0.3	0.2
Other endocrine (including thymus)	0.2	0.2	0.3	0.2	0.3	0.2	0.4	0.2	0.1	0.3	0.2	1.4
Lymphomas	7.5	7.7	7.4	7.8	8.1	6.3	8.2	6.0	7.3	7.3	8.8	7.2
Hodgkin's disease	1.5	1.6	1.6	1.9	1.6	1.2	1.4	1.4	1.5	1.6	1.4	1.6
Non Hodgkin's lymphomas	6.0	6.1	5.8	6.0	6.5	5.0	6.8	4.5	5.8	5.7	7.4	5.5
Multiple myeloma	2.8	2.9	2.8	2.9	3.1	2.9	2.9	2.2	2.8	3.3	3.9	2.2
Leukemias	9.1	9.3	9.3	9.4	10.0	10.0	9.9	8.3	8.2	9.4	8.8	8.2
Lymphocytic	3.0	3.0	3.0	2.6	3.9	3.2	2.6	2.5	2.7	3.2	2.6	3.1
Acute lymphocytic	0.9	1.0	1.0	0.6	1.6	1.3	1.3	0.9	0.8	1.0	0.8	1.5
Chronic lymphocytic	1.6	1.6	1.7	1.5	1.8	1.9	1.0	1.1	1.4	1.9	1.3	1.6
Other lymphocytic	0.4	0.4	0.3	0.5	0.5	.....	0.4	0.5	0.5	0.3	0.4	.....
Granulocytic	3.9	4.0	3.7	3.8	4.6	4.3	4.0	3.0	3.8	4.0	4.1	3.8
Acute granulocytic	2.6	2.6	2.4	2.5	3.0	2.8	2.6	1.7	2.7	2.5	2.8	1.8
Chronic granulocytic	1.1	1.1	1.2	1.2	1.2	1.1	0.8	1.0	0.9	1.3	1.0	2.0
Other granulocytic	0.3	0.3	0.2	0.2	0.5	0.4	0.6	0.3	0.2	0.1	0.3	.....
Monocytic	0.3	0.3	0.4	0.3	0.3	0.2	0.8	0.4	0.2	0.3	0.2	0.2
Acute monocytic	0.2	0.2	0.2	0.2	0.2	0.2	0.5	0.4	0.1	0.1	0.1	0.2
Chronic monocytic	0.0	0.0	0.0	.....	.....	.....	.....	.....	.....	.....	0.0	.....
Other monocytic	0.1	0.1	0.1	0.1	0.2	.....	0.3	.....	0.1	0.2	0.1	.....
Other	1.9	2.0	2.2	2.7	1.1	2.3	2.5	2.4	1.4	1.9	2.0	1.1
Other acute	1.1	1.2	1.2	2.0	0.5	1.2	1.3	1.1	0.6	1.2	1.4	0.5
Other chronic	0.1	0.1	0.1	0.1	0.0	.....	0.2	.....	.....	0.1	0.1	.....
Aleukemic, subleukemic, and NOS	0.7	0.7	0.9	0.7	0.6	1.0	1.0	1.3	0.8	0.7	0.5	0.5
Other, ill-defined, and unknown sites	12.5	12.5	13.7	13.6	9.1	14.9	22.5	14.2	12.2	10.9	12.9	16.0

TABLE 3F. *Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for white females*

Primary site	United States 1973-77	All areas ex. Puerto Rico 1973-77	Connecticut 1973-77	Detroit 1973-77	Iowa 1973-77	Atlanta 1975-77	New Orleans 1974-77	New Mexico 1973-77	Utah 1973-77	Seattle-Puget Sound 1974-77	San Francisco-Oakland 1973-77	Hawaii 1973-77
All sites	133.1	136.9	147.0	138.7	125.4	125.8	141.5	136.8	104.2	138.5	148.8	137.1
Buccal cavity and pharynx	1.9	2.0	1.9	1.5	1.5	2.3	1.6	1.5	1.3	2.3	3.3	5.1
Lip	0.0	0.0	0.0		0.0					0.0	0.0	.....
Tongue	0.4	0.5	0.5	0.3	0.4	0.7	0.5	0.5	0.4	0.6	0.9	1.3
Major salivary gland	0.2	0.2	0.1	0.2	0.2	0.2	0.1	0.1	0.2	0.2	0.2	.....
Floor of mouth	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.2	.....
Gum and other mouth	0.4	0.4	0.4	0.3	0.3	0.7	0.4	0.1	0.1	0.4	0.5	1.3
Nasopharynx	0.2	0.2	0.1	0.1	0.2	0.3		0.1	0.1	0.2	0.2	0.4
Tonsil	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.9
Oropharynx	0.1	0.1	0.1	0.1	0.0					0.1	0.2	0.5
Hypopharynx	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.0	0.1	0.2	0.4
Pharynx and other buccal cavity	0.3	0.3	0.3	0.1	0.2	0.1	0.4	0.3	0.3	0.5	0.6	0.4
Digestive system	36.6	38.1	43.4	38.2	36.5	30.8	37.3	40.9	28.3	35.2	40.0	40.9
Esophagus	1.2	1.5	1.6	1.8	1.0	1.2	1.0	1.3	0.4	1.3	1.9	2.2
Stomach	4.2	4.5	5.5	4.5	3.2	3.2	4.5	6.3	4.0	3.9	5.3	6.6
Small intestine	0.2	0.3	0.4	0.3	0.3	0.1	0.2	0.1	0.1	0.3	0.3	.....
Colon excluding rectum	16.5	16.9	19.5	16.7	18.2	14.3	15.9	16.1	12.4	15.4	16.7	14.5
Rectum and rectosigmoid	3.3	3.3	4.2	3.2	3.1	2.4	3.3	2.2	2.0	3.0	3.7	3.0
Anal canal and anorectum	0.0	0.0	.....	0.0	0.0	.....	.....	0.0	0.0	0.1	0.0	.....
Liver	1.5	1.3	1.2	1.5	1.3	0.7	1.4	2.0	0.8	1.4	1.3	2.7
Gallbladder	1.4	1.4	1.4	1.8	1.5	0.9	1.1	3.4	1.2	1.2	1.0	0.9
Other biliary	0.8	0.9	1.1	0.9	0.8	1.0	0.8	0.9	0.8	0.9	0.9	2.0
Pancreas	6.8	7.3	8.1	6.8	6.6	6.4	8.5	8.0	6.0	7.0	8.4	8.3
Retroperitoneum	0.2	0.2	0.1	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.2
Peritoneum	0.1	0.1	0.1	0.1	0.2	.....	0.3	0.1	0.2	0.2	0.2	.....
Other digestive organs	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.1	0.5	0.2	0.5
Respiratory system	16.4	16.9	16.8	17.6	11.4	18.9	20.1	17.6	6.7	20.4	22.5	19.6
Nasal cavity, sinuses, and ear	0.2	0.1	0.1	0.1	0.2	0.3	0.1	0.1	0.2	0.2	0.1	0.2
Larynx	0.4	0.4	0.3	0.4	0.3	0.4	0.4	0.4	0.1	0.5	0.6	0.6
Lung and bronchus	15.6	16.2	16.1	16.9	10.7	18.0	19.6	16.8	6.2	19.4	21.6	18.5
Trachea, pleura, mediastinum, and other	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.3	0.2	0.4	0.2	0.4
Bones and joints	0.6	0.6	0.6	0.6	0.7	0.6	0.6	0.6	0.4	0.6	0.4	0.2
Soft tissues (including heart)	0.8	0.9	0.8	0.8	0.9	0.8	0.6	0.9	1.0	0.9	0.9	1.9
Skin	1.9	1.8	1.8	1.6	1.9	1.8	1.7	1.8	1.9	1.9	2.2	1.7
Melanomas of the skin	1.5	1.5	1.5	1.1	1.4	1.6	1.4	1.5	1.7	1.4	1.7	1.2
Other skin cancers	0.4	0.4	0.3	0.4	0.4	0.3	0.3	0.3	0.2	0.4	0.6	0.5
Breast	27.2	28.4	32.0	29.5	26.1	24.0	28.7	22.2	23.1	28.6	30.7	21.3
Female genital system	17.9	17.7	17.9	18.1	18.4	14.8	14.5	18.8	14.5	17.6	18.4	14.5
Cervix uteri	4.0	3.5	2.9	4.2	3.9	3.3	2.9	5.6	2.2	3.2	3.2	2.6
Corpus uteri	1.9	1.9	2.1	1.7	1.9	1.3	1.3	1.9	2.2	2.1	2.1	1.6
Uterus, NOS	2.4	2.3	2.5	2.4	2.3	1.6	2.4	2.1	2.5	2.1	2.2	2.3
Ovary	8.7	9.0	9.5	9.0	9.2	7.6	6.9	8.1	7.2	9.3	9.9	6.8
Vagina	0.3	0.2	0.2	0.3	0.4	0.6	0.3	0.1	0.1	0.3	0.2	0.3
Vulva	0.4	0.4	0.5	0.4	0.4	0.1	0.5	0.5	0.2	0.3	0.5	0.2
Other female genital organs	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.4	0.1	0.3	0.2	0.8

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/43

Urinary system	4.3	4.4	4.7	4.9	4.1	4.8	5.6	4.2	3.1	4.5	3.9	5.1
Urinary bladder	2.1	2.2	2.5	2.3	1.7	2.7	3.1	2.0	1.4	2.5	2.2	2.0
Kidney and renal pelvis	2.1	2.0	2.1	2.4	2.3	1.9	2.5	2.1	1.6	1.7	1.6	2.9
Ureter	0.1	0.1	0.1	0.1	0.1	0.1	—	0.1	0.1	0.1	0.0	—
Other urinary organs	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2
Eye	0.1	0.1	0.1	0.1	0.2	0.3	0.2	0.1	0.2	0.2	0.1	—
Brain and other nervous system	3.3	3.3	3.2	3.5	3.1	3.8	3.2	2.4	2.9	4.4	3.3	3.4
Brain	2.7	2.8	2.4	3.2	2.7	2.7	2.5	1.7	2.5	4.1	2.6	2.3
Other nervous system	0.7	0.6	0.8	0.3	0.3	1.1	0.7	0.7	0.4	0.3	0.8	1.1
Endocrine system	0.7	0.7	0.7	0.6	0.6	0.5	0.8	0.9	0.6	0.8	0.8	0.2
Thyroid gland	0.5	0.5	0.5	0.4	0.4	0.5	0.7	0.8	0.4	0.6	0.5	0.2
Other endocrine (including thymus)	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.3	—
Lymphomas	5.1	5.2	5.0	5.4	5.8	4.8	5.5	4.4	4.5	4.8	5.3	5.0
Hodgkin's disease	0.9	0.9	0.9	0.9	1.0	0.4	1.3	1.0	0.6	0.8	0.9	1.2
Non-Hodgkin's lymphomas	4.1	4.3	4.1	4.5	4.8	4.4	4.2	3.4	3.9	4.0	4.4	3.8
Multiple myeloma	1.9	2.1	2.3	1.8	2.2	2.4	2.3	1.8	1.7	2.3	2.1	2.0
Leukemias	5.3	5.2	5.7	4.9	5.5	5.1	5.2	4.6	4.5	5.2	5.4	6.4
Lymphocytic	1.5	1.4	1.5	1.1	2.1	1.1	1.2	1.3	1.0	1.3	1.4	2.2
Acute lymphocytic	0.6	0.5	0.6	0.3	0.8	0.4	0.3	0.3	0.5	0.4	0.7	1.5
Chronic lymphocytic	0.7	0.7	0.7	0.6	0.9	0.6	0.8	0.8	0.4	0.6	0.6	0.5
Other lymphocytic	0.2	0.2	0.2	0.1	0.4	0.1	0.1	0.2	0.1	0.3	0.1	0.2
Granulocytic	2.5	2.6	2.7	2.3	2.8	2.7	2.6	1.7	2.5	2.5	2.7	2.8
Acute granulocytic	1.7	1.8	1.8	1.7	1.9	2.0	1.5	1.0	1.9	1.8	1.9	1.8
Chronic granulocytic	0.6	0.6	0.7	0.5	0.6	0.5	1.0	0.5	0.7	0.5	0.6	0.5
Other granulocytic	0.2	0.2	0.2	0.1	0.3	0.2	0.1	0.3	—	0.1	0.2	0.5
Monocytic	0.2	0.2	0.2	0.1	0.2	0.1	0.4	0.1	0.2	0.1	0.1	0.5
Acute monocytic	0.1	0.1	0.1	0.1	0.2	0.1	0.4	—	0.1	0.1	0.1	0.5
Chronic monocytic	0.0	0.0	0.0	—	—	—	—	0.0	—	—	—	—
Other monocytic	0.0	0.0	0.1	0.0	0.0	—	—	0.1	0.0	0.0	0.1	—
Other	1.1	1.1	1.3	1.4	0.4	1.2	0.9	1.2	0.7	1.4	1.2	0.9
Other acute	0.7	0.7	0.9	1.0	0.2	0.8	0.5	0.7	0.4	0.9	1.0	0.2
Other chronic	0.0	0.0	0.1	0.0	0.0	—	—	—	0.0	0.0	0.0	0.2
Aleukemic, subleukemic, and NOS	0.4	0.3	0.4	0.3	0.2	0.4	0.4	0.5	0.3	0.4	0.2	0.5
Other, ill-defined, and unknown sites	9.2	9.4	10.2	9.6	6.6	10.1	13.6	14.2	9.5	8.8	9.5	9.7

TABLE 3G *Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for races other than white,[1] both sexes*

Primary site	Black						Chinese		Japanese		Hawaiian	Filipino	Am. Indian
	United States 1973-77	All areas ex. Puerto Rico 1973-77	Detroit 1973-77	Atlanta 1975-77	New Orleans 1974-77	San Francisco-Oakland 1973-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	San Francisco-Oakland 1973-77	Hawaii 1973-77	Hawaii 1973-77	Hawaii 1973-77	New Mexico 1973-77
All sites	**205.0**	**217.4**	**215.0**	**196.3**	**243.9**	**206.8**	**162.1**	**127.5**	**103.7**	**129.4**	**257.1**	**120.7**	**100.7**
Buccal cavity and pharynx	5.2	5.5	4.4	6.2	7.7	4.9	7.3	8.5	1.0	1.9	8.9	4.2	0.6
Lip	0.0	0.0				0.1							
Tongue	1.2	1.2	1.1	1.3	1.3	0.9	0.4		0.7	0.5	1.5	0.8	0.6
Major salivary gland	0.3	0.2	0.3			0.0		1.0		0.1		0.2	
Floor of mouth	0.4	0.3	0.3	0.1	0.2	0.1				0.1	1.8	0.6	
Gum and other mouth	0.8	0.9	0.7	0.3	1.8	0.8	0.4	0.7	0.3			1.2	
Nasopharynx	0.3	0.4	0.4	0.5	0.2	0.6	5.3	5.8		0.6	2.4	0.2	
Tonsil	0.6	0.6	0.5	0.9	0.6	0.6	0.4			0.2	0.8		
Oropharynx	0.2	0.2	0.1	0.4	0.2	0.1				0.1	0.2	0.2	
Hypopharynx	0.4	0.5	0.3	1.3	0.6	0.4	0.4	0.5		0.2	0.8	0.3	
Pharynx and other buccal cavity	0.9	1.2	0.6	1.4	2.8	1.2	0.5	0.5		0.2	1.3	0.7	
Digestive system	**60.3**	**63.0**	**62.8**	**55.5**	**62.5**	**63.5**	**59.2**	**46.9**	**60.2**	**60.8**	**79.4**	**47.5**	**42.7**
Esophagus	8.8	8.9	9.1	10.2	6.9	8.5	4.9	2.9	4.3	2.3	9.6	6.0	1.4
Stomach	11.6	11.6	10.8	8.0	15.4	11.3	8.8	7.3	24.6	22.5	30.5	8.7	11.9
Small intestine	0.4	0.6	0.6	0.2	0.3	0.7	0.2			0.4	0.8		
Colon excluding rectum	17.9	18.8	19.3	19.2	17.4	17.9	16.6	16.3	10.6	12.6	14.2	11.8	4.2
Rectum and rectosigmoid	4.4	4.7	4.6	3.5	6.9	3.5	5.7	2.5	3.6	6.0	1.9	4.5	1.8
Anal canal and anorectum	0.0	0.0		0.1						0.1			
Liver	3.8	3.2	3.6	4.0	2.9	2.5	11.2	4.2	6.0	4.4	9.8	7.4	2.8
Gallbladder	0.8	0.8	0.7	0.7	1.1	0.5	0.6	1.6	1.0	1.5	0.8	1.8	8.7
Other biliary	0.7	0.9	0.9	0.4	0.2	1.6	2.7	2.6	0.9	2.5	2.4	1.8	2.8
Pancreas	11.0	12.6	12.5	8.0	10.5	16.1	8.4	9.4	9.1	8.0	9.1	4.6	7.7
Retroperitoneum	0.2	0.3	0.2		0.3	0.5				0.3	0.1	0.2	
Peritoneum	0.1	0.1	0.1		0.4	0.2				0.1			0.5
Other digestive organs	0.5	0.4	0.4	1.1	0.2	0.1	0.2			0.2	0.2	0.8	1.0
Respiratory system	**48.2**	**54.2**	**57.1**	**41.1**	**58.5**	**48.9**	**41.7**	**27.9**	**15.0**	**25.5**	**68.3**	**24.6**	**5.5**
Nasal cavity, sinuses, and ear	0.4	0.3	0.3	0.5	0.2	0.4	0.4	1.2		0.4	0.2	0.5	0.4
Larynx	2.4	2.4	2.7	1.9	1.8	2.1	0.9	0.9	0.7	0.7	1.6	0.5	
Lung and bronchus	45.0	51.0	53.8	37.9	55.7	45.9	39.9	25.8	14.3	24.1	65.8	23.6	4.4
Trachea, pleura, mediastinum, and other	0.4	0.5	0.4	0.7	0.7	0.5	0.5			0.3	0.6		0.6
Bones and joints	**0.9**	**0.8**	**0.6**	**1.0**	**1.5**	**0.7**	**0.7**	**0.5**		**0.3**	**1.8**	**0.1**	**0.2**
Soft tissues (including heart)	**1.0**	**1.1**	**1.1**	**0.8**	**1.1**	**1.0**	**1.1**	**0.7**	**0.4**	**0.9**	**1.2**	**0.3**	**0.2**
Skin	**0.9**	**0.9**	**0.8**	**0.8**	**0.9**	**1.1**	**0.2**	**1.1**	**0.5**	**0.3**	**2.7**	**0.6**	
Melanomas of the skin	0.4	0.4	0.3	0.2	0.4	0.7		0.8		0.2	2.0	0.4	
Other skin cancers	0.5	0.5	0.5	0.5	0.6	0.3	0.2	0.3	0.5	0.1	0.7	0.1	
Breast	**15.1**	**15.6**	**15.2**	**14.5**	**17.3**	**15.5**	**9.1**	**7.6**	**5.3**	**6.1**	**17.7**	**1.6**	**5.5**
Female genital system	**15.1**	**13.9**	**14.8**	**15.5**	**12.2**	**12.4**	**6.8**	**6.8**	**5.6**	**4.7**	**15.1**	**3.0**	**5.9**
Cervix uteri	6.4	5.8	6.9	6.6	5.6	3.9	2.7	2.3	1.0	1.0	6.1	0.6	3.6
Corpus uteri	1.6	1.7	1.6	2.6	1.8	1.6	0.2	0.3	0.7	0.6	2.4	0.6	
Uterus, NOS	2.6	1.9	1.5	2.1	2.3	1.9	0.6	1.5		0.8	1.9	0.6	
Ovary	3.8	3.7	4.0	3.7	1.8	4.2	3.3	2.2	3.9	2.1	4.7	1.2	2.1
Vagina	0.3	0.3	0.3	0.1	0.4	0.4				0.1			0.1
Vulva	0.2	0.2	0.2	0.4		0.3							
Other female genital organs	0.2	0.3	0.3		0.3	0.2		0.5		0.1			

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/45

Male genital system	**17.6**	**17.2**	**18.6**	**14.8**	**16.1**	**16.2**	**4.5**	**3.8**	**2.4**	**4.1**	**10.3**	**5.2**	**4.7**
Prostatic gland	17.2	17.0	18.4	14.6	15.6	16.0	4.2	3.8	2.0	3.7	9.9	5.2	8.7
Testis	0.1	0.1	0.1	0.1	0.3	0.1	0.2	—	0.4	0.3	0.4	—	—
Penis	0.2	0.1	0.1	0.1	0.1	0.1	0.2	—	—	0.1	—	—	—
Other male genital organs	0.0	—	—	—	—	—	—	—	—	—	—	—	—
Urinary system	**6.9**	**7.4**	**7.4**	**6.2**	**6.4**	**7.7**	**4.2**	**3.1**	**1.0**	**5.3**	**8.7**	**7.1**	**6.0**
Urinary bladder	4.2	4.2	4.3	4.1	3.6	4.2	2.2	1.8	0.7	3.3	3.6	4.1	0.5
Kidney and renal pelvis	2.4	2.9	3.0	2.1	2.6	3.3	1.8	1.2	0.3	1.9	5.1	2.9	5.5
Ureter	0.0	0.0	0.1	—	—	—	—	—	—	0.1	—	—	—
Other urinary organs	0.2	0.2	0.1	—	0.3	0.2	0.2	—	—	—	—	—	—
Eye	**0.1**	**0.1**	**0.1**	**0.1**	**0.2**	—	—	—	—	**0.3**	—	—	**0.1**
Brain and other nervous system	**2.4**	**2.6**	**2.6**	**2.0**	**3.0**	**3.1**	**1.6**	**3.7**	**0.4**	**1.0**	**4.2**	**1.7**	**0.3**
Brain	1.8	2.0	2.1	1.0	2.4	2.3	1.2	2.8	0.4	0.9	2.6	1.5	0.3
Other nervous system	0.6	0.6	0.4	1.0	0.7	0.8	0.4	0.9	—	0.1	1.6	0.2	—
Endocrine system	**0.6**	**0.7**	**0.6**	**0.3**	**0.9**	**0.7**	**0.4**	**1.7**	**0.6**	**6.9**	**2.7**	**1.7**	**0.8**
Thyroid gland	0.5	0.6	0.4	0.2	0.8	0.6	0.4	1.1	0.6	0.6	2.2	1.7	0.8
Other endocrine (including thymus)	0.2	0.1	0.2	0.1	0.1	0.1	—	0.7	—	0.2	0.6	—	—
Lymphomas	**4.2**	**4.3**	**4.3**	**3.0**	**4.0**	**4.7**	**4.7**	**3.4**	**2.8**	**4.8**	**6.8**	**7.4**	**3.3**
Hodgkin's disease	0.9	0.9	1.1	0.6	0.6	0.7	0.2	0.4	0.4	0.2	0.7	1.6	0.6
Non-Hodgkin's lymphomas	3.3	3.4	3.2	2.4	3.4	4.0	4.5	3.0	2.4	4.6	6.1	5.8	2.7
Multiple myeloma	**4.6**	**5.4**	**4.9**	**4.5**	**5.0**	**6.7**	**2.1**	**0.4**	**1.1**	**1.1**	**4.9**	**3.5**	**2.9**
Leukemias	**5.8**	**6.1**	**5.8**	**6.2**	**7.9**	**5.9**	**7.8**	**4.6**	**3.5**	**4.5**	**7.6**	**6.2**	**3.7**
Lymphocytic	1.8	1.4	1.3	2.2	1.5	1.0	1.3	1.7	0.3	0.9	0.7	1.2	0.8
Acute lymphocytic	0.5	0.4	0.2	0.6	0.3	0.5	0.7	1.4	0.3	0.5	0.5	1.0	0.8
Chronic lymphocytic	1.0	0.9	0.9	1.3	1.1	0.5	0.6	0.3	—	0.5	0.2	—	—
Other lymphocytic	0.2	0.1	0.1	0.3	0.1	0.1	—	—	—	—	—	0.2	—
Granulocytic	2.5	2.7	2.4	2.6	2.9	3.5	4.2	1.5	1.6	2.5	5.2	3.1	1.8
Acute granulocytic	1.5	1.7	1.4	2.1	1.9	2.3	2.4	0.7	1.6	1.3	4.5	2.5	1.3
Chronic granulocytic	0.8	0.8	0.9	0.5	0.6	0.9	1.7	0.8	—	1.0	0.7	0.5	0.6
Other granulocytic	0.1	0.2	0.2	—	0.3	0.2	—	—	—	0.2	—	0.2	—
Monocytic	0.2	0.1	0.1	0.2	0.4	0.1	1.0	—	—	0.4	1.0	0.2	0.5
Acute monocytic	0.1	0.1	0.1	—	0.4	0.1	0.4	—	—	0.3	0.6	0.2	0.5
Chronic monocytic	0.0	—	—	—	—	—	—	—	—	—	0.4	—	—
Other monocytic	0.0	0.0	—	0.2	—	—	0.6	—	—	0.1	—	—	—
Other	1.4	1.9	2.0	1.2	3.1	1.3	1.3	1.3	1.6	0.7	0.7	1.6	0.6
Other acute	0.7	1.1	1.5	0.8	0.9	1.0	1.1	1.3	1.6	0.7	0.4	0.9	0.5
Other chronic	0.1	0.1	0.0	—	0.3	—	—	—	—	—	—	—	—
Aleukemic, subleukemic, and NOS	0.6	0.7	0.5	0.4	1.9	0.3	0.2	—	—	—	0.3	0.7	0.1
Other, ill-defined, and unknown sites	**16.3**	**18.7**	**13.8**	**23.9**	**38.9**	**13.9**	**10.6**	**6.8**	**4.0**	**6.8**	**16.8**	**5.9**	**14.3**

TABLE 311 — *Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for races other than white, males*

Primary site	Black						Chinese		Japanese		Hawaiian	Filipino	Am. Indian
	United States 1971–77	All areas ex. Puerto Rico 1973–77	Detroit 1973–77	Atlanta 1975–77	New Orleans 1974–77	San Francisco-Oakland 1973–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Hawaii 1973–77	Hawaii 1973–77	New Mexico 1973–77
All sites	**270.9**	**292.1**	**285.6**	**284.8**	**329.3**	**278.3**	**193.5**	**141.5**	**130.7**	**180.9**	**330.3**	**141.2**	**97.6**
Buccal cavity and pharynx	**8.7**	**9.0**	**7.2**	**10.6**	**13.4**	**7.8**	**12.0**	**11.6**	**0.9**	**3.1**	**17.3**	**4.3**	**1.2**
Lip	0.0	0.0	.....	.....	.....	0.1	.....	.....	.....	.....	.....	.....	.....
Tongue	2.0	2.0	2.0	2.9	2.2	0.9	0.7	.....	0.9	1.0	3.3	1.1	1.2
Major salivary gland	0.4	0.3	0.5	.....	.....	.....	.....	1.2	.....	.....	.....	.....	.....
Floor of mouth	0.7	0.5	0.5	.....	0.2	0.2	.....	.....	.....	0.1	2.5	0.9	.....
Gum and other mouth	1.3	1.4	1.0	0.6	3.0	1.4	0.8	0.6	.....	.....	.....	1.6	.....
Nasopharynx	0.5	0.6	0.6	0.6	0.4	0.7	8.1	7.5	.....	1.1	5.6	.....	.....
Tonsil	1.0	0.9	0.8	1.2	1.1	1.2	0.7	.....	.....	0.2	1.8	.....	.....
Oropharynx	0.4	0.3	0.2	1.0	0.5	0.4	.....	.....	.....	.....	0.5	0.3	.....
Hypopharynx	0.8	0.9	0.4	1.9	1.4	0.8	0.8	1.0	.....	0.5	1.8	0.5	.....
Pharynx and other buccal cavity	1.6	1.9	1.2	2.4	4.6	2.0	0.9	1.3	.....	0.1	1.9	.....	.....
Digestive system	**78.4**	**83.2**	**81.1**	**79.0**	**83.3**	**85.0**	**78.2**	**58.2**	**80.6**	**86.6**	**107.7**	**60.7**	**43.1**
Esophagus	15.9	15.0	14.4	20.0	12.4	14.9	8.0	5.6	10.7	4.8	19.0	7.1	2.8
Stomach	17.0	17.1	16.1	12.1	21.4	17.9	10.9	8.2	28.0	34.7	42.5	10.1	20.4
Small intestine	0.5	0.7	0.7	0.6	0.6	0.5	0.4	.....	.....	0.4	1.1	.....	.....
Colon excluding rectum	18.7	20.9	21.3	23.8	18.3	17.4	20.4	19.1	15.6	14.2	16.5	14.8	5.5
Rectum and rectosigmoid	5.5	6.3	6.3	5.8	9.6	4.4	7.6	1.9	5.5	9.8	1.9	5.6	1.0
Anal canal and anorectum	0.0	.....	.....	.....	.....	.....	.....	.....	.....	0.2	.....	.....	.....
Liver	5.7	4.5	5.1	4.9	4.1	3.7	18.5	5.5	8.6	7.3	11.2	11.2	3.0
Gallbladder	0.5	0.7	0.7	0.3	0.9	0.3	1.2	1.9	.....	0.9	.....	2.2	5.0
Other biliary	0.9	1.2	1.1	0.3	0.3	2.5	2.2	4.5	.....	3.7	2.9	1.9	1.6
Pancreas	13.7	15.7	14.4	10.1	14.4	22.0	9.1	11.4	12.3	9.6	12.0	6.1	3.9
Retroperitoneum	0.3	0.4	0.3	.....	0.2	0.9	.....	.....	.....	0.6	0.2	0.3	.....
Peritoneum	0.1	0.1	0.0	.....	0.5	0.2	.....	.....	.....	.....	.....	.....	.....
Other digestive organs	0.6	0.6	0.7	1.2	0.4	0.2	.....	.....	.....	0.2	0.5	1.2	.....
Respiratory system	**87.4**	**98.4**	**100.6**	**87.9**	**109.9**	**86.8**	**53.7**	**36.4**	**26.6**	**45.1**	**102.2**	**28.8**	**7.4**
Nasal cavity, sinuses, and ear	0.6	0.6	0.3	0.9	0.6	0.8	0.4	2.1	.....	0.7	.....	0.6	.....
Larynx	4.5	4.5	5.0	4.1	3.3	3.9	0.7	1.9	1.7	1.2	2.5	0.3	.....
Lung and bronchus	81.7	92.6	94.8	81.4	105.2	81.2	51.6	32.4	25.0	42.7	98.3	27.9	7.4
Trachea, pleura, mediastinum, and other	0.6	0.7	0.4	1.4	0.9	0.9	1.1	.....	.....	0.6	1.3	.....	.....
Bones and joints	**1.1**	**1.0**	**1.0**	**0.2**	**1.7**	**0.6**	**0.8**	**1.3**	.....	**0.4**	**1.4**	**0.2**	.....
Soft tissues (including heart)	**1.0**	**1.1**	**1.3**	**0.7**	**1.4**	**0.7**	**1.2**	.....	**0.9**	**1.2**	**1.1**	**0.3**	**0.4**
Skin	**1.1**	**1.0**	**0.8**	**1.1**	**1.3**	**1.4**	.....	**2.1**	.....	**0.3**	**7.7**	**0.9**	.....
Melanomas of the skin	0.5	0.3	0.2	0.5	0.4	0.9	.....	1.5	.....	.....	5.6	0.8	.....
Other skin cancers	0.6	0.7	0.6	0.6	0.9	0.5	.....	0.6	.....	0.3	2.1	0.2	.....
Breast	**0.4**	**0.6**	**0.7**	**1.0**	**0.5**	**0.8**	**0.8**	.....	.....	.....	.....	.....	.....

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/47

Male genital system	41.8	41.6	43.4	40.1	40.3	40.5	8.4	7.6	4.9	10.1	27.2	7.8	15.9
Prostatic gland	40.9	41.1	42.9	39.6	39.3	40.0	7.8	7.6	3.9	9.2	26.3	7.8	15.9
Testis	0.2	0.3	0.2	0.2	0.8	0.3	0.3		1.0	0.7	0.9		
Penis	0.6	0.2	0.3	0.3	0.2	0.1	0.4			0.2			
Other male genital organs	0.1												
Urinary system	9.5	9.7	9.0	9.1	10.6	10.6	5.9	3.1	0.9	8.0	13.9	7.7	5.2
Urinary bladder	5.8	5.3	4.9	5.5	5.4	5.0	3.0	2.5		4.5	4.4	4.3	
Kidney and renal pelvis	3.4	4.2	3.9	3.6	4.9	5.2	2.6	0.6	0.9	3.3	9.5	3.4	5.2
Ureter	0.1	0.1	0.1							0.2			
Other urinary organs	0.2	0.2	0.1		0.3	0.4	0.4						
Eye	0.1	0.1	0.1		0.2					0.6			0.3
Brain and other nervous system	2.9	3.4	3.2	2.1	4.5	4.4	1.9	3.3		1.5	5.7	2.7	0.5
Brain	2.2	2.7	2.7	1.3	3.6	3.3	1.5	3.3		1.3	4.4	2.3	0.5
Other nervous system	0.7	0.8	0.5	0.8	0.9	1.0	0.4			0.3	1.3	0.4	
Endocrine system	0.6	0.6	0.6	0.3	1.1	0.4		2.1		1.1	1.7	1.9	0.9
Thyroid gland	0.4	0.4	0.2		0.8	0.4		1.3		0.6	0.5	1.9	0.9
Other endocrine (including thymus)	0.2	0.3	0.4	0.3	0.2			0.8		0.5	1.2		
Lymphomas	5.5	5.6	6.2	4.7	4.9	5.1	5.4	3.5	5.7	6.3	7.8	7.8	4.3
Hodgkin's disease	1.2	1.3	1.4	1.2	1.2	1.0	0.4		1.0	0.2	0.5	1.6	1.2
Non-Hodgkin's lymphomas	4.2	4.4	4.8	3.5	3.7	4.0	5.1	3.5	4.8	6.1	7.3	6.2	3.1
Multiple myeloma	5.6	6.6	5.9	5.5	5.8	8.3	1.9		0.9	1.0	6.6	3.7	3.0
Leukemias	7.3	8.0	8.0	10.4	8.9	7.7	9.9	4.8	4.0	5.9	11.6	7.8	3.7
Lymphocytic	2.4	2.3	2.5	3.7	2.1	1.5	1.7	1.4		1.5	1.2	1.7	1.1
Acute lymphocytic	0.6	0.4	0.2	1.1	0.6	0.3	0.5	0.6		0.7	0.7	1.7	1.1
Chronic lymphocytic	1.5	1.6	2.1	1.8	1.3	1.1	1.1	0.6		0.8	0.5		
Other lymphocytic	0.3	0.3	0.2	0.8	0.2	0.2							
Granulocytic	3.0	3.3	3.0	4.5	3.3	4.0	4.4	0.8	2.3	3.3	8.5	2.6	2.2
Acute granulocytic	1.9	2.0	1.5	3.4	2.2	2.9	3.1		2.3	1.8	7.9	1.5	0.9
Chronic granulocytic	0.9	1.1	1.2	1.0	0.7	1.0	1.3	0.8		1.5	0.6	0.9	1.2
Other granulocytic	0.2	0.2	0.3		0.4	0.1						0.2	
Monocytic	0.2	0.1	0.1	0.5	0.3		1.6			0.3	1.5	0.3	
Acute monocytic	0.1	0.1	0.1		0.3		0.4			0.3	0.6	0.3	
Chronic monocytic	0.0										0.9		
Other monocytic	0.1	0.0		0.5			1.2						
Other	1.7	2.2	2.5	1.7	3.1	2.1	2.1	2.7	1.8	0.8	0.5	2.4	0.5
Other acute	0.8	1.4	1.9	1.1	1.2	1.4	1.8	2.7	1.8	0.8		1.5	0.5
Other chronic	0.1	0.1	0.1		0.2						0.5	0.9	
Aleukemic, subleukemic, and NOS	0.9	0.8	0.6	0.6	1.7	0.8	0.4						
Other, ill-defined, and unknown sites	19.4	22.2	16.6	32.1	41.6	18.4	13.3	7.4	5.3	9.5	18.5	7.4	11.7

TABLE 31.—*Average annual age-adjusted (1970 standard) mortality rates per 100,000 population by primary site, geographic area, and period for races other than white, females*

Primary site	Black						Chinese		Japanese		Hawaiian	Filipino	Am Indian
	United States 1973–77	All areas ex. Puerto Rico 1973–77	Detroit 1973–77	Atlanta 1975–77	New Orleans 1974–77	San Francisco-Oakland 1973–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	San Francisco-Oakland 1973–77	Hawaii 1973–77	Hawaii 1973–77	Hawaii 1973–77	New Mexico 1973–77
All sites	**154.5**	**160.6**	**158.1**	**139.0**	**181.8**	**155.3**	**127.5**	**116.7**	**86.8**	**93.9**	**207.3**	**78.1**	**104.2**
Buccal cavity and pharynx	**2.3**	**2.5**	**2.0**	**2.8**	**3.3**	**2.5**	**2.3**	**5.9**	**1.1**	**0.9**	**1.8**	**3.0**	.....
Lip	0.0	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....
Tongue	0.5	0.5	0.4	.....	0.5	0.9	.....	.....	0.5	.....	.....	.....	.....
Major salivary gland	0.2	0.0	0.1	.....	.....	0.1	.....	0.6	.....	0.2	.....	0.4	.....
Floor of mouth	0.1	0.1	0.2	0.2	0.2	.....	.....	.....	.....	.....	1.1	.....	.....
Gum and other mouth	0.4	0.5	0.5	.....	0.9	0.2	.....	0.8	0.5	.....	.....	0.6	.....
Nasopharynx	0.2	0.2	0.2	0.5	.....	0.5	2.3	4.5	.....	0.3	.....	0.3	.....
Tonsil	0.3	0.3	0.3	0.7	0.2	0.1	.....	.....	.....	0.1	.....	.....	.....
Oropharynx	0.1	0.1	0.1	.....	.....	.....	.....	.....	.....	0.2	.....	.....	.....
Hypopharynx	0.2	0.2	0.1	0.6	.....	0.1	.....	.....	.....	.....	.....	.....	.....
Pharynx and other buccal cavity	0.4	0.6	0.2	0.7	1.6	0.6	.....	.....	.....	0.2	0.7	1.7	.....
Digestive system	**46.1**	**47.2**	**47.9**	**39.4**	**46.7**	**47.1**	**38.8**	**37.5**	**48.3**	**41.9**	**58.9**	**21.3**	**42.8**
Esophagus	3.8	3.9	4.5	3.2	2.7	3.7	1.2	0.8	.....	0.4	2.7	2.5	.....
Stomach	7.5	7.4	6.5	5.4	10.9	6.5	6.6	6.7	23.4	13.2	22.6	5.7	3.5
Small intestine	0.3	0.5	0.6	.....	0.2	0.7	.....	.....	.....	0.3	0.6	.....	.....
Colon excluding rectum	17.4	17.4	18.1	16.6	16.4	17.9	12.2	13.5	7.5	11.3	11.6	5.2	2.5
Rectum and rectosigmoid	3.5	3.6	3.4	2.0	5.0	2.8	3.8	3.0	2.2	3.4	1.9	2.4	2.7
Anal canal and anorectum	0.0	0.0	.....	0.2	.....	.....	.....	.....	.....	.....	.....	.....	.....
Liver	2.2	2.0	2.2	3.2	1.9	1.5	3.4	3.0	4.7	2.2	8.7	1.0	2.3
Gallbladder	1.0	0.9	0.6	1.0	1.2	0.7	.....	1.6	1.8	2.0	1.5	1.0	12.6
Other biliary	0.6	0.6	0.7	0.5	0.2	0.8	3.4	1.3	1.9	1.9	2.3	1.4	4.1
Pancreas	8.9	10.2	10.8	6.5	7.8	11.8	7.8	7.7	6.8	7.0	7.1	2.0	11.8
Retroperitoneum	0.2	0.2	0.2	.....	0.4	0.3	.....	.....	.....	.....	.....	.....	.....
Peritoneum	0.1	0.1	0.1	.....	0.2	0.3	.....	.....	.....	0.1	.....	.....	1.0
Other digestive organs	0.5	0.3	0.2	0.8	.....	0.1	0.4	.....	.....	0.2	.....	.....	2.1
Respiratory system	**16.8**	**18.8**	**19.9**	**8.5**	**19.6**	**19.4**	**27.8**	**19.8**	**6.3**	**11.4**	**38.5**	**16.2**	**3.4**
Nasal cavity, sinuses, and ear	0.2	0.2	0.2	0.2	.....	.....	0.5	.....	.....	0.3	0.4	.....	0.8
Larynx	0.6	0.6	0.7	0.2	0.5	0.6	1.0	.....	.....	0.4	0.7	0.7	.....
Lung and bronchus	15.7	17.6	18.7	7.8	18.4	18.6	26.4	19.8	6.3	10.7	37.5	15.6	1.3
Trachea, pleura, mediastinum, and other	0.3	0.4	0.3	0.2	0.7	0.2	.....	.....	.....	.....	.....	.....	1.3
Bones and joints	**0.7**	**0.7**	**0.3**	**1.5**	**1.3**	**0.7**	**0.5**	.....	.....	**0.3**	**2.3**	.....	**0.4**
Soft tissues (including heart)	**1.0**	**1.1**	**1.0**	**0.9**	**0.8**	**1.3**	**0.9**	**1.5**	.....	**0.8**	**1.2**	**0.3**	.....
Skin	**0.7**	**0.8**	**0.8**	**0.5**	**0.7**	**0.8**	**0.5**	.....	**0.9**	**0.4**	.....	.....	.....
Melanomas of the skin	0.3	0.4	0.4	.....	0.3	0.6	.....	.....	.....	0.4	.....	.....	.....
Other skin cancers	0.4	0.4	0.4	0.5	0.3	0.2	0.5	.....	0.9	.....	.....	.....	.....
Breast	**26.8**	**27.8**	**27.7**	**24.4**	**30.3**	**27.4**	**18.3**	**15.5**	**9.7**	**11.5**	**33.3**	**3.5**	**11.0**
Female genital system	**27.1**	**24.9**	**27.2**	**26.4**	**21.3**	**22.2**	**14.5**	**13.3**	**9.7**	**8.7**	**28.4**	**8.7**	**11.9**
Cervix uteri	11.6	10.5	12.6	11.4	9.9	7.2	5.6	4.3	1.5	1.7	11.2	1.4	7.3
Corpus uteri	2.8	3.1	3.0	4.4	3.1	2.7	0.5	0.6	1.3	1.1	4.1	2.2	.....
Uterus, NOS	4.5	3.3	2.7	3.4	3.9	3.4	1.3	3.1	.....	1.5	3.8	1.5	.....
Ovary	6.9	6.6	7.4	6.3	3.2	7.4	7.2	4.3	6.8	3.9	9.3	3.7	4.3
Vagina	0.5	0.6	0.6	0.2	0.7	0.7	.....	.....	.....	0.2	.....	.....	0.3
Vulva	0.4	0.4	0.4	0.7	.....	0.5	.....	.....	.....	.....	.....	.....	.....
Other female genital organs	0.4	0.5	0.5	.....	0.6	0.3	.....	1.0	.....	0.3	.....	.....	.....

Published by AsbestosClaims.Law
asbestosclaims.law/library/25458/49

Urinary system	**4.8**	**5.5**	**6.1**	**4.2**	**3.4**	**5.5**	**2.5**	**2.5**	**1.5**	**3.3**	**5.6**	**5.9**	**6.8**
Urinary bladder	3.0	3.4	3.8	3.1	2.2	3.5	1.2	0.9	1.3	2.4	3.8	4.6	4.0
Kidney and renal pelvis	1.6	1.8	2.1	1.1	0.8	1.9	1.0	1.6	—	0.9	1.8	1.3	2.8
Ureter	0.0	0.0	0.1	—	—	—	—	—	—	—	—	—	—
Other urinary organs	0.2	0.2	0.1	—	0.4	0.1	—	—	—	—	—	—	—
Eye	**0.1**	**0.1**	**0.1**	**0.1**	**0.1**	—	—	—	—	—	—	—	—
Brain and other nervous system	**1.9**	**1.9**	**2.0**	**2.1**	**1.9**	**2.0**	**1.3**	**4.0**	**0.9**	**0.5**	**3.6**	**0.4**	—
Brain	1.5	1.4	1.6	0.9	1.4	1.4	0.9	2.1	0.9	0.5	1.6	0.4	—
Other nervous system	0.4	0.5	0.4	1.3	0.4	0.6	0.3	1.9	—	—	2.1	—	—
Endocrine system	**0.7**	**0.7**	**0.6**	**0.2**	**0.7**	**1.0**	**1.0**	**1.5**	**0.9**	**0.7**	**3.8**	**1.5**	**0.8**
Thyroid gland	0.5	0.7	0.6	0.2	0.7	0.8	1.0	0.9	0.9	0.6	3.8	1.5	0.8
Other endocrine (including thymus)	0.1	0.0	—	—	—	0.2	—	0.6	—	0.1	—	—	—
Lymphomas	**3.1**	**3.2**	**2.9**	**1.8**	**3.2**	**4.3**	**3.8**	**3.7**	**0.9**	**3.8**	**5.6**	**6.3**	**2.5**
Hodgkin's disease	0.6	0.5	0.9	0.2	0.2	0.3	—	0.7	—	0.1	0.9	1.5	—
Non-Hodgkin's lymphomas	2.5	2.7	2.0	1.6	3.0	3.9	3.8	3.0	0.9	3.7	4.7	4.8	2.5
Multiple myeloma	**3.8**	**4.6**	**4.1**	**3.8**	**4.6**	**5.6**	**2.3**	**0.8**	**1.2**	**1.2**	**3.8**	**3.8**	**2.7**
Leukemias	**4.6**	**4.7**	**4.1**	**3.4**	**7.0**	**4.5**	**5.7**	**4.4**	**2.5**	**3.3**	**5.1**	**3.9**	**3.9**
Lymphocytic	1.3	0.7	0.4	1.1	0.9	0.7	0.9	2.1	0.5	0.5	0.2	0.4	0.5
Acute lymphocytic	0.4	0.3	0.3	0.1	—	0.5	0.9	2.1	0.5	0.2	0.2	—	0.5
Chronic lymphocytic	0.7	0.4	0.1	0.9	0.9	0.1	—	—	—	0.3	—	—	—
Other lymphocytic	0.2	0.1	0.1	—	—	—	—	—	—	—	—	0.4	—
Granulocytic	2.1	2.2	2.0	1.3	2.5	3.1	4.0	2.3	0.9	1.9	3.5	3.5	1.7
Acute granulocytic	1.3	1.4	1.2	1.1	1.7	2.0	1.8	1.5	0.9	1.0	2.5	3.5	1.7
Chronic granulocytic	0.7	0.7	0.7	0.1	0.5	0.8	2.1	0.8	—	0.6	0.9	—	—
Other granulocytic	0.1	0.1	0.1	—	0.3	0.3	—	—	—	0.4	—	—	—
Monocytic	0.1	0.1	0.1	—	0.4	0.1	0.5	—	—	0.4	0.8	—	1.0
Acute monocytic	0.1	0.1	0.1	—	0.4	0.1	0.5	—	—	0.2	0.8	—	1.0
Chronic monocytic	0.0	—	—	—	—	—	—	—	—	—	—	—	—
Other monocytic	0.0	—	—	—	—	—	—	—	—	0.2	—	—	—
Other	1.1	1.6	1.6	1.0	3.2	0.6	0.4	—	1.1	0.6	0.7	—	0.7
Other acute	0.5	0.9	1.2	0.5	0.6	0.6	0.4	—	1.1	0.6	0.7	—	0.5
Other chronic	0.1	0.1	—	—	0.4	—	—	—	—	—	—	—	—
Aleukemic, subleukemic, and NOS	0.5	0.6	0.4	0.5	2.2	—	—	—	—	—	—	—	0.3
Other, ill-defined, and unknown sites	**16.0**	**16.0**	**11.5**	**18.8**	**36.8**	**11.0**	**7.6**	**6.3**	**3.1**	**5.2**	**15.2**	**3.2**	**18.0**